Document:

exv10w1

 

Exhibit 10.1

Confidential materials omitted and filed separately with the Securities and Exchange Commission.
Asterisks denote omissions.

      

NOVATED AND RESTATED

TECHNOLOGY LICENSE AGREEMENT

dated as of June 15, 2007

among

LEXICON PHARMACEUTICALS, INC.,

SYMPHONY ICON, INC.

and

SYMPHONY ICON HOLDINGS LLC

 

 

 

TABLE OF CONTENTS

	 	 	 	 	 
	 	 	Page	 
	ARTICLE 1 DEFINITIONS
	 	 	1	 
	 
	 	 	 	 
	ARTICLE 2 GRANT OF RIGHTS
	 	 	1	 
	 
	 	 	 	 
	2.1 Assignment
	 	 	1	 
	2.2 License Grant
	 	 	2	 
	2.3 Sublicense to Licensor
	 	 	2	 
	2.4 Right to Sublicense
	 	 	2	 
	2.5 Partial Reversion of License upon Licensor’s Exercise of Discontinuation Option
	 	 	3	 
	2.6 Reservation of Rights
	 	 	3	 
	2.7 Regulatory Files After Expiration or Termination of Term or Discontinuation Option
	 	 	4	 
	2.8 Delivery of Materials After Expiration or Termination of Term
	 	 	5	 
	2.9 License Opportunities
	 	 	5	 
	2.10 Separate Third Party License for Discontinued Program
	 	 	6	 
	2.11 Supply of Product After Expiration or Termination of Term
	 	 	6	 
	 
	 	 	 	 
	ARTICLE 3 SUBLICENSE TO CERTAIN THIRD PARTY INTELLECTUAL PROPERTY
	 	 	6	 
	 
	 	 	 	 
	3.1 Third Party Sublicense Payments
	 	 	7	 
	3.2 Sublicensed Intellectual Property
	 	 	7	 
	 
	 	 	 	 
	ARTICLE 4 INTELLECTUAL PROPERTY
	 	 	7	 
	 
	 	 	 	 
	4.1 Ownership
	 	 	7	 
	4.2 Marking
	 	 	7	 
	4.3 Prosecution and Maintenance
	 	 	8	 
	4.4 Abandonment
	 	 	9	 
	4.5 Infringement
	 	 	9	 
	4.6 Enforcement Right During Term
	 	 	9	 
	4.7 Post-Term Enforcement
	 	 	10	 
	4.8 Withdrawal of Enforcement
	 	 	12	 
	4.9 Recoveries
	 	 	12	 
	 
	 	 	 	 
	ARTICLE 5 REPRESENTATIONS AND WARRANTIES
	 	 	13	 
	 
	 	 	 	 
	5.1 Representations and Warranties of Licensor
	 	 	13	 

-i-

 

TABLE OF CONTENTS
(continued)

	 	 	 	 	 
	 	 	Page	 
	5.2 Disclaimer and Acknowledgement
	 	 	14	 
	 
	 	 	 	 
	ARTICLE 6 INDEMNIFICATION AND LIMITATION OF LIABILITY
	 	 	14	 
	 
	 	 	 	 
	6.1 Indemnity
	 	 	14	 
	6.2 Notice of Claims
	 	 	15	 
	6.3 Defense of Proceedings
	 	 	16	 
	6.4 Settlement
	 	 	17	 
	6.5 Limitation of Liability
	 	 	17	 
	6.6 Insurance
	 	 	18	 
	 
	 	 	 	 
	ARTICLE 7 TERM AND TERMINATION
	 	 	18	 
	 
	 	 	 	 
	7.1 Term
	 	 	18	 
	7.2 Termination
	 	 	18	 
	7.3 Survival
	 	 	18	 
	7.4 Bankruptcy
	 	 	19	 
	 
	 	 	 	 
	ARTICLE 8 MISCELLANEOUS
	 	 	19	 
	 
	 	 	 	 
	8.1 Notices
	 	 	19	 
	8.2 Entire Agreement
	 	 	20	 
	8.3 Assignment
	 	 	20	 
	8.4 Headings
	 	 	21	 
	8.5 Independent Contractor
	 	 	21	 
	8.6 Severability
	 	 	21	 
	8.7 No Third-Party Beneficiaries
	 	 	21	 
	8.8 Compliance with Laws
	 	 	21	 
	8.9 Amendment
	 	 	21	 
	8.10 Governing Law; Consent to Jurisdiction and Service of Process
	 	 	21	 
	8.11 Waiver of Jury Trial
	 	 	22	 

-ii-

 

TABLE OF CONTENTS
(continued)

	 	 	 	 	 
	 	 	Page	 
	8.12 Counterparts
	 	 	22	 
	8.13 No Waiver
	 	 	22	 
	 
	 	 	 	 
	ANNEX A DEFINITIONS
	 	 	 	 
	ANNEX B CERTAIN ROYALTY AND MILESTONE PAYMENTS
	 	 	 	 
	ANNEX C CERTAIN LICENSED PATENTS
	 	 	 	 
	SCHEDULE 2.2 CERTAIN RESTRICTIONS RELATING TO LICENSED INTELLECTUAL PROPERTY
LICENSED TO LICENSOR BY A THIRD PARTY
	 	 	 	 

-iii-

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

NOVATED AND RESTATED

TECHNOLOGY LICENSE AGREEMENT

     This NOVATED AND RESTATED TECHNOLOGY LICENSE AGREEMENT (this “Agreement”) is made and
effective as of June 15, 2007 by and among, Lexicon Pharmaceuticals, Inc., a Delaware corporation
(f/k/a Lexicon Genetics Incorporated) (the “Licensor”), Symphony Icon, Inc., a Delaware
corporation (“Symphony Icon”) (each of Licensor and Symphony Icon being a “Party,”
and collectively, the “Parties”), and Symphony Icon Holdings LLC, a Delaware limited
liability company (“Holdings”).

     WHEREAS, Licensor and Holdings have entered into that certain Technology License Agreement,
dated June 15, 2007 (the “Original Agreement”);

     WHEREAS, Holdings desires to assign its right, title and interest in, and delegate and novate
its obligations under the Original Agreement to Symphony Icon, and Licensor and Symphony Icon
desire to novate and restate the terms and conditions of the Original Agreement to effect such
novation;

     WHEREAS, Licensor owns or has rights in certain technology, know-how, patents and other
intellectual property rights related to the design, development, manufacture and/or use of the
Products;

     WHEREAS, Licensor desires to grant to Symphony Icon, and Symphony Icon desires to acquire, the
exclusive (or nonexclusive, as the case may be) right to use such technology, know-how, patents and
other intellectual property rights to develop and commercialize Products on the terms and
conditions of this Agreement; and

     WHEREAS, Licensor desires to receive, and Symphony Icon desires to grant to Licensor, the
exclusive right to use such technology, know-how, patents and other intellectual property rights to
develop Products on behalf of Symphony Icon on the terms and            conditions of this Agreement.

     NOW THEREFORE, in consideration of the mutual promises and agreements set forth herein, and
for other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the Parties agree as follows:

ARTICLE 1

DEFINITIONS

     Capitalized terms used herein and not defined shall have the meanings assigned to such terms
in Annex A attached hereto.

ARTICLE 2

GRANT OF RIGHTS

 

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

     2.1 Assignment. Holdings hereby assigns to Symphony Icon all of its right, title and
interest in and to the Original Agreement. The Parties agree that from and after the Closing Date,
all of the right, title, interest and obligations of Holdings under the Original Agreement will be
assigned, novated and transferred to, and assumed by, Symphony Icon, as amended and restated by
this Agreement.

     2.2 License Grant.

          (a) Subject to Sections 2.3, 2.4, 2.5 and 2.6 below, the
limitations and restrictions set forth on Schedule 2.2 and the terms and conditions of this
Agreement, Licensor hereby grants to Symphony Icon a fully paid, worldwide, exclusive license under
the Licensed Intellectual Property, solely to develop, make, have made, use, offer for sale, sell,
and import Products.

     2.3 Sublicense to Licensor. Symphony Icon hereby grants to Licensor a fully paid,
worldwide, exclusive (even as to Symphony Icon) sublicense under the Licensed Intellectual
Property, with the right to grant further sublicense(s), to develop, make, have made, use and
import Products, or otherwise as necessary or useful to carry out Licensor’s obligations or
exercise Licensor’s rights under the Operative Documents. Notwithstanding the foregoing, Licensor
shall only exercise its rights as sublicensee hereunder in connection with and for the purpose of
carrying out Licensor’s obligations or exercising Licensor’s rights under the Operative Documents.
In the event of the expiration of a Discontinuation Option without exercise by Licensor, the
sublicense set forth in this Section 2.3 shall expire with respect to the Products relating
to the Program to which such Discontinuation Option pertained. Upon the unexercised expiration or
termination of the Purchase Option without Licensor’s exercise of the Purchase Option, the
sublicense set forth in this Section 2.3 shall expire with respect to all Products relating
to the Program(s) for which Licensor has not exercised the Discontinuation Option.

     2.4 Right to Sublicense. Subject to the limitations and restrictions set forth on
Schedule 2.2 , the license granted hereunder includes the right of Symphony Icon to grant
sublicenses under the Licensed Intellectual Property, provided, that,

          (a) subject to Sections 2.3 and 2.4(b), Symphony Icon shall not sublicense any
of the rights granted pursuant to Section 2.2 to any third party (including without
limitation any Affiliates) during the Term;

          (b) notwithstanding (a), in the event of the expiration of a Discontinuation Option without
exercise by Licensor, Symphony Icon may grant to third parties (including without limitation
Affiliates) sublicenses of the rights granted pursuant to Section 2.2 with respect to the
Products relating to the Program to which such Discontinuation Option pertained;

          (c) each sublicense granted (i) is pursuant to a written contract, (ii) is consistent with the
terms of this Agreement, (iii) does not grant any rights beyond

2

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

the scope of the license rights granted herein, and (iv) is as protective of Licensor’s rights
as set forth in this Agreement; and

          (d) upon Licensor’s written request, Symphony Icon shall provide to Licensor copies of any
sublicense agreements, provided that (i) Symphony Icon may redact any financial or other
proprietary information contained therein which does not affect Licensor’s rights and (ii) Licensor
shall treat its copy of the sublicense agreements as Confidential Information of Symphony Icon.

     2.5 Partial Reversion of License upon Licensor’s Exercise of Discontinuation Option.
Licensor and Symphony Icon acknowledge that Licensor may exercise its Discontinuation Option
pursuant to Section 11 of the Amended and Restated Research and Development Agreement.
Upon the Discontinuation Option Closing Date, as applicable, (i) the license set forth in
Section 2.2 (and the corresponding sublicense under Section 2.3) shall expire with
respect to the Products relating to the Program for which Licensor exercised its Discontinuation
Option, as applicable, (ii) those patents, patent applications, Know-How and Symphony Icon
Enhancements that were part of the Licensed Intellectual Property as of the applicable
Discontinuation Option Closing Date and relate exclusively to such Program (including its Products)
but not to the other Program, shall be deleted from the relevant intellectual property definitions,
and accordingly, Symphony Icon shall no longer be responsible for any obligations or costs
(including royalties or fees to third parties, prosecution costs, maintenance costs and enforcement
costs) accruing after such Discontinuation Option Closing Date with respect to such patents, patent
applications, Know-How and Symphony Icon Enhancements; and (iii) Symphony Icon shall (a) at
Licensor’s request and option, promptly return to Licensor or destroy all Tangible Materials
relating solely to such Program; and (b) upon Licensor’s request, provide Licensor a copy of all
Tangible Materials which relate to such Program (but not solely to such Program). The Parties
shall, as necessary, promptly amend this Agreement, in connection with the exercise and
consummation of the Discontinuation Option pursuant to Section 11 of the Amended and
Restated Research and Development Agreement, to give Licensor all rights it needs to pursue the
Program for which such option was exercised without any obligation to or dependency on Symphony
Icon and to limit this Agreement to the other Program.

     2.6 Reservation of Rights. All rights not expressly granted to a Party hereunder
shall remain the exclusive property of the other Party. Symphony Icon covenants and agrees not to
use or exploit the Licensed Intellectual Property outside of the scope of the licenses granted
herein. Licensor covenants and agrees that Licensor will not, and will cause its Affiliates not
to, use or exploit the Licensed Intellectual Property in connection with the development,
manufacture, use, sale, or importation of Products after the expiration of all sublicenses granted
pursuant to Section 2.3; provided, however, that such covenant by Licensor shall not apply
to any Program for which Licensor exercises a Discontinuation Option or to any Products relating to
such Program. For the avoidance of doubt, Licensor and its Affiliates shall not be restricted from
using

3

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

or otherwise exploiting any intellectual property relating to their respective drug discovery
programs outside the fields of the Products and/or the Programs.

     2.7 Regulatory Files After Expiration or Termination of Term or Discontinuation
Option.

          (a) As soon as reasonably practical after the expiration or termination of the Purchase Option
without exercise by Licensor and as of a date to be agreed upon by Licensor and Symphony Icon,
Licensor and Symphony Icon shall, at Symphony Icon’s expense, take all actions necessary to effect
the assignment to Symphony Icon or its designee of the sponsorship to the Regulatory Files with
respect to the Programs for which Licensor has not exercised its Discontinuation Option. After
such Regulatory Files are assigned to Symphony Icon, Licensor shall have no further rights therein
or obligations thereunder; provided, however, that during the [**] following such assignment of
Regulatory Files, at Symphony Icon’s reasonable request and expense, Licensor shall use
commercially reasonable efforts to provide Symphony Icon or its designee with assistance in respect
of such Regulatory Files. Licensor shall, at the reasonable request of Symphony Icon and at
Symphony Icon’s expense, perform any acts that Symphony Icon may reasonably deem necessary or
desirable to evidence or confirm Symphony Icon’s ownership interest in such Regulatory Files,
including, but not limited to, making further written assignments in a form determined by Symphony
Icon. Without limiting the license rights granted under this ARTICLE 2, the Parties understand and
agree that the assignment of such Regulatory Files does not include an assignment of any Licensed
Intellectual Property.

          (b) As soon as reasonably practical after the expiration of a Discontinuation Option without
exercise by Licensor and as of a date to be agreed upon by Licensor and Symphony Icon, Licensor and
Symphony Icon shall, at Symphony Icon’s expense, take all actions necessary to effect the
assignment to Symphony Icon or its designee of the sponsorship to the Regulatory Files with respect
to the Programs for which Licensor has not exercised its Discontinuation Option. After such
Regulatory Files are assigned to Symphony Icon, Licensor shall have no further rights therein or
obligations thereunder; provided, however, that during the [**] following such assignment of
Regulatory Files, at Symphony Icon’s reasonable request and expense, Licensor shall use
commercially reasonable efforts to provide Symphony Icon or its designee with assistance in respect
of such Regulatory Files. Licensor shall, at the reasonable request of Symphony Icon and at
Symphony Icon’s expense, perform any acts that Symphony Icon may reasonably deem necessary or
desirable to evidence or confirm Symphony Icon’s ownership interest in such Regulatory Files,
including, but not limited to, making further written assignments in a form determined by Symphony
Icon. Without limiting the license rights granted under this ARTICLE 2, the Parties understand and
agree that the assignment of such Regulatory Files does not include an assignment of any Licensed
Intellectual Property.

     2.8 Delivery of Materials After Expiration or Termination of Term.

4

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

          (a) Upon the expiration or termination of the Purchase Option without exercise by Licensor,
Licensor shall, at Symphony Icon’s expense, promptly deliver to Symphony Icon all copies of
Tangible Materials existing as of the date of such unexercised expiration or termination that
relate to the Programs for which Licensor has not exercised its Discontinuation Option; provided,
however, that Licensor may also retain copies of (and the right to use) those Tangible Materials
that are required to be delivered to Symphony Icon hereunder but which also relate to (i) any
Program for which Licensor has exercised its Discontinuation Option or (ii) any other product of
Licensor.

          (b) In the event of the expiration of a Discontinuation Option without exercise by Licensor,
Licensor shall, at Symphony Icon’s expense, promptly deliver to Symphony Icon all copies of
Tangible Materials existing as of the date of such expiration that relate to the Program to which
the Discontinuation Option pertained; provided, however, that Licensor may also retain copies of
(and the right to use) those Tangible Materials that are required to be delivered to Symphony Icon
hereunder but which also relate to any other Program or any other product of Licensor.

     2.9 License Opportunities. In the event that, during the Term, Licensor reasonably
determines that it is necessary to license from any third party any intellectual property relating
to the composition of matter, use, manufacture, formulation or exploitation of the Products
(“Third Party IP”) and Licensor desires to license such Third Party IP during the Term,
then (i) if Licensor desires Symphony Icon to pay any or all of the financial obligations under
such license, Licensor shall obtain Symphony Icon’s written consent, which shall not be
unreasonably withheld or delayed, before acquiring such license; and (ii) if Symphony Icon provides
such consent, then unless otherwise agreed to by the Parties in writing, Licensor shall use
commercially reasonable efforts to obtain, at the time such license is granted, the right to
sublicense such Third Party IP to Symphony Icon consistent with the terms of this Agreement as if
such Third Party IP were Licensed Intellectual Property. Unless otherwise agreed to by the Parties
in writing, the financial obligations under any license to Third Party IP obtained by Licensor with
Symphony Icon’s consent shall (1)[**]; or (2) [**]; or (3) [**]. Notwithstanding the foregoing,
Licensor shall have no obligation to obtain any such third party licenses under this Agreement or,
in the event that Symphony Icon does not give such consent, to grant any sublicenses to Symphony
Icon. Upon obtaining a license to such Third Party IP and the right to sublicense to Symphony
Icon, the Parties will, as necessary, promptly amend this Agreement to include such sublicensed
intellectual property within the license granted hereunder, incorporate any other limitations,
royalties or other provisions required by such third party with respect to such sublicense, and
address Symphony Icon’s rights (if any) with respect to patent prosecution, maintenance and
enforcement of patents and patent applications within such Third Party IP.

     2.10 Separate Third Party License for Discontinued Program. In the event of the
expiration of a Discontinuation Option without exercise by Licensor, Symphony Icon has the right to
transfer to a third party Symphony Icon’s rights to the Products relating to the Program to which
such Discontinuation Option pertained (the

5

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

“Discontinued Program”). If Symphony Icon identifies a third party that wishes to
obtain such rights, then upon Symphony Icon’s request, (i) Licensor and Symphony Icon shall amend
this Agreement to terminate all of Symphony Icon’s rights and obligations to the extent applicable
to the Discontinued Program and (ii) Licensor shall enter into a separate license agreement with
such third party in which all of such terminated rights and obligations shall be conferred upon and
undertaken by such third party. The terms and conditions of such license agreement shall be
identical to those contained herein, to the extent that such terms are applicable to the
Discontinued Program and not dependent on any Operative Document other than this Agreement. Such
terms shall include but not be limited to (1) provisions allowing for termination of such license
agreement upon a material, uncured breach of such license agreement by the third party on similar
terms as provided herein with respect to Symphony Icon and (2) a confidentiality provision that is
not dependent on any of the Operative Documents. Termination of this Agreement shall not effect
such license agreement and Licensor’s obligation to enter into such a license agreement shall
survive termination of this Agreement.

     2.11 Supply of Product After Expiration or Termination of Term. In the event of
expiration or termination of the Purchase Option without exercise by Licensor, without limiting
Licensor’s other obligations pursuant to the Operative Documents, during the [**] period following
any such expiration or termination, Licensor agrees to cooperate in good faith and provide
reasonable assistance to Symphony Icon (or its partners or transferees hereunder) in connection
with the transition of the continued development (including clinical development), manufacture and
commercialization of Products by Symphony Icon (or its partners or transferees hereunder), in each
case at the expense of Symphony Icon (or its partners or transferees hereunder).

     2.12 Right of First Offer for LG617 Program. In the event of the expiration or
termination of the Purchase Option or expiration of a Discontinuation Option with respect to the
LG617 Program, in each case without exercise by Licensor and absent any other re-acquisition by
Licensor of rights to the LG617 Program, Symphony Icon agrees that BMS shall have the following
right of first offer. Symphony Icon shall not grant any license or otherwise transfer rights to
any third party for the development or commercialization of any LG617 Product (any such arrangement
being referred to herein as a “LG617 License”) [**] without first notifying BMS of its
desire to enter into an LG617 License, and if requested by BMS within [**] of such notice, entering
into good faith negotiations with BMS with respect to an LG617 License for a period of [**]
following such notice (the “LG617 Negotiation Period”). In the event that Symphony Icon
and BMS do not enter into a LG617 License within such LG617 Negotiation Period, Symphony Icon will
be free, at any time thereafter to enter into negotiations with respect to an LG617 License with
any third party. In the event (but only in the event) that (a) the obligations of Licensor under
Section 4.4 of Licensor’s Collaboration and License Agreement with BMS, dated December 17, 2003,
were not terminated before the expiration of the relevant option of Licensor described above, and
(b) the expiration of such LG617 Negotiation Period occurs prior to the later of (i) December 31,
2008 or (ii) the commencement of a Phase 1 clinical trial in the U.S. for

6

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

an LG617 Compound, [**]. Any notice issued by Symphony Icon to BMS pursuant to this Section
2.13 shall be made pursuant to Section 8.1 hereof to BMS at the following address Bristol-Myers
Squibb Company, P.O. Box 4000, Route 206 & Province Line Road, Princeton, New Jersey 08543-4000,
Attention: Vice President, External Science, Technology & Licensing, Telephone: 609-252-4712,
Facsimile: 609-252-7212; with a copy to: Bristol-Myers Squibb Company, P.O. Box 4000, Route 206 &
Province Line Road, Princeton, New Jersey 08543-4000, Attention: Vice President & Senior Counsel,
Corporate Development, Telephone: 609-252-4311, Facsimile: 609-252-4232.

ARTICLE 3

SUBLICENSE TO CERTAIN THIRD PARTY INTELLECTUAL PROPERTY

     3.1 Third Party Sublicense Payments. Unless otherwise agreed to by the Parties in
writing, to the extent that (a) any Licensed Intellectual Property is licensed to Licensor by a
third party and sublicensed to Symphony Icon by Licensor hereunder and the development,
manufacture, use, sale or other commercialization of any Product by Symphony Icon shall require the
Licensor to make a royalty payment, milestone or any other payment obligation to the third party
licensor of such Licensed Intellectual Property, (i) Symphony Icon shall be responsible for the
satisfaction of such royalty payment, milestone or any other obligation to such licensor if such
payment is triggered by the development, manufacture, use, sale or other commercialization of any
Product by Symphony Icon; or (ii) such royalty payment shall be shared by the Parties in amounts
and/or percentages to be agreed upon by the Parties if such payment relates (but does not relate
solely) to the manufacture, use, sale or other commercialization of any Product by Symphony Icon.
Notwithstanding the foregoing, with respect to agreements between Licensor or its Affiliates and
any third party existing as of the Closing Date, Symphony Icon’s obligations under this Section 3.1
for Products will be limited solely to those royalties and milestones set forth on Annex B.

     3.2 Sublicensed Intellectual Property. Symphony Icon acknowledges (i) that certain
Licensed Intellectual Property is licensed to Licensor or its Affiliates by third parties and will
be sublicensed to Symphony Icon hereunder (the “Sublicensed Intellectual Property”) and (ii) that
such sublicense is subject to certain restrictions and obligations set forth in the applicable
written agreements between Licensor and such third parties (the “Sublicense Obligations”),
including but not limited to those restrictions and obligations set forth on Schedule 2.2.
Symphony Icon agrees to either be bound by the Sublicense Obligations or forfeit the applicable
sublicense of such Intellectual Property under Section 2.2; provided, however, that Symphony Icon
cannot use this Section 3.2 to avoid any Sublicense Obligation that has accrued prior to the date
Symphony Icon elects to forfeit the applicable sublicense.

ARTICLE 4

INTELLECTUAL PROPERTY

7

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

     4.1 Ownership. The Parties acknowledge and agree that, as between Licensor and
Symphony Icon, and subject to Schedule 2.2, Licensor or its licensors are the owners of all
right, title and interest in and to the Licensed Intellectual Property, including without
limitation Symphony Icon Enhancements. Symphony Icon hereby assigns to Licensor all of Symphony
Icon’s rights and interests in any Symphony Icon Enhancements, including any rights in inventions
made jointly by Licensor and Symphony Icon. Symphony Icon shall promptly disclose any Symphony
Icon Enhancement to Licensor, and shall use reasonable efforts, at Licensor’s request and at no
cost to Licensor, to cooperate fully with Licensor to transfer such Symphony Icon Enhancements to
Licensor.

     4.2 Marking. Symphony Icon shall mark, and shall cause all of its sublicensees to
mark, all Products, or the packaging thereof or materials related thereto, with the number of the
applicable patents licensed hereunder in accordance with applicable U.S. patent law.

     4.3 Prosecution and Maintenance.

          (a) Unless otherwise set forth in this Section 4.3, (i) Licensor shall prepare, file,
prosecute and maintain those patents and patent applications in Licensed Patent Rights for which
Licensor has patent prosecution and maintenance rights; and (ii) Licensor shall provide Symphony
Icon with (1) quarterly reports regarding the status of the prosecution and maintenance of Licensed
Patent Rights, (2) copies of and/or access to any patent documents related to the Licensed Patent
Rights as reasonably requested by Symphony Icon, (3) copies of patent applications and other
substantive patent prosecution documents pertaining to the Program-Specific Patents prior to filing
in the United States so as to afford Symphony Icon and its patent counsel, at Symphony Icon’s
expense, a reasonable opportunity to review and comment on such documents and (4) timely answers to
Symphony Icon’s questions regarding the status of patents and patent applications in Licensed
Patent Rights.

          (b) Licensor will use commercially reasonable efforts to seek the allowance of broad generic
claims that read on Products, consistent with Licensor’s determination of enforceability, business
considerations and other factors.

          (c) Subject to a reasonable allocation of costs in the event that any Program-Specific Patent
relate to Licensor’s business other than the Programs, the cost of the prosecution and maintenance
of Program-Specific Patents shall be paid by Symphony Icon. Upon the scope of any Licensed Patent
Rights being amended so that the patent or patent application’s claims no longer relate to, or are
exploitable in connection with, any Product and/or any Program, for which Licensor has not
exercised a Discontinuation Option, such patent or patent application shall cease to be a Licensed
Patent Right and all rights and obligations with respect to such patent or patent application
(including costs, fees, prosecution, maintenance and enforcement) shall revert to Licensor.

8

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

          (d) Symphony Icon shall not be responsible for the costs of any interference or reexamination
initiated by Licensor with respect to the Program Specific Patents (except to the extent allocated
in the Development Budget), unless the Parties mutually agree in writing (i) that it is reasonably
necessary or useful to file and prosecute such interference or re-examination in connection with
such Program Specific Patents to protect their interests in such Program Specific Patents and (ii)
to a reasonable allocation of costs in the event that any Program Specific Patents relate to
Licensor’s business other than the Programs, which agreement will not be unreasonably withheld or
delayed. In the event, however, that (i) Symphony Icon does not agree to pay such costs (or its
share of costs as reasonably allocated as set forth above) of such interference or reexamination
and (ii) Licensor successfully files and prosecutes or settles such interference or reexamination
at its sole cost, then the licenses granted by Licensor to Symphony Icon in Section 2.2
herein shall immediately terminate with respect to specific Program Specific Patent subject to such
interference or reexamination.

          (e) Symphony Icon shall not be responsible for the costs of any opposition, protest or
reexamination initiated by Licensor with respect to any Third Party IP (except to the extent
allocated in the Development Budget), unless the Parties mutually agree in writing (i) that it is
reasonably necessary or useful to file and prosecute such opposition, protest or reexamination in
connection with such Third Party IP to protect their interests in the Programs and (ii) to a
reasonable allocation of costs in the event that such Third Party IP relates to Licensor’s business
other than the Programs, which agreement will not be unreasonably withheld or delayed.

          (f) Each Party shall provide the prosecuting Party with reasonable cooperation under this
Section 4.3.

     4.4 Abandonment. Subject to the limitations and restrictions set forth on
Schedule 2.2, Licensor shall not cancel a Program-Specific Claim or abandon a
Program-Specific Patent without (a) expressly reserving the right to pursue the relevant
Program-Specific Claim in a separate patent application or (b) requesting and obtaining the consent
of Symphony Icon, which consent shall not be unreasonably withheld or delayed. If Symphony Icon
does not provide such consent promptly upon Licensor’s request, then Licensor may (i) continue to
prosecute such Program-Specific Claim in the patent application in which it is currently pending,
or (ii) cancel such Program-Specific Claim in a manner that allows future prosecution of such claim
and then propose such claim in a newly filed divisional or continuation application that Symphony
Icon may prosecute at its expense (including reimbursing Licensor for the costs associated with
filing such divisional or continuation application), in the name of Licensor, and in Symphony
Icon’s discretion.

     4.5 Infringement. Each Party agrees to immediately notify the other Party upon
becoming aware of any infringement, misappropriation, illegal use or misuse of the Licensed
Intellectual Property in connection with Products and provide to the other Party all available
evidence of such infringement.

9

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

     4.6 Enforcement Right During Term.

          (a) Except as provided in Section 4.6(b), during the Term, Licensor has the first
right, but not the obligation, to take action against others in the courts, administrative agencies
or otherwise to prevent, terminate or seek damages on account of infringement, misappropriation,
illegal use or misuse of the Licensed Patent Rights or other Licensed Intellectual Property;
including such actions against others to prevent, terminate or seek damages on account of an Icon
Relevant Infringement. The costs and expenses of any such action shall be borne by Symphony Icon
to the extent the action relates to an Icon Relevant Infringement; provided, that Symphony Icon’s
written consent was obtained prior to the initiation of such action, such consent not to be
unreasonably withheld or delayed. Symphony Icon shall, at its expense, cooperate with and
reasonably assist Licensor in any such action if so requested by Licensor, and, upon Licensor’s
request, execute, file and deliver all documents and proof necessary for such purpose, including
being named as a party to such litigation if requested by Licensor or if required by Law. Symphony
Icon shall have the right to participate and be represented by its own counsel at its own expense
in any such action, suit or proceeding with respect to Licensed Patent Rights solely relating to
Products for which Licensor has not exercised the relevant Discontinuation Option; provided that
Symphony Icon shall not enter into any settlement or compromise of such action, suit or proceeding
that affects or concerns the validity, enforceability, or ownership of any Licensed Patent Rights
or other Licensed Intellectual Property without the prior written consent of Licensor, which
consent shall not be unreasonably withheld or delayed. Licensor shall not enter into any
settlement or compromise of such action, suit or proceeding that affects or concerns the validity,
enforceability, or ownership of any Licensed Patent Rights or other Licensed Intellectual Property
without the prior, written consent of Symphony Icon, which consent shall not be unreasonably
withheld or delayed.

          (b) Subject to the limitations and restrictions set forth on Schedule 2.2, if, (1)
during the Term, Symphony Icon requests Licensor to take action pursuant to Section 4.6(a)
with respect to an Icon Relevant Infringement that either (i) solely involves the enforcement of a
Program Specific Patent or (ii) involves the enforcement of other Licensed Intellectual Property
relating exclusively to the Programs and there is not a claim of an issued Program Specific Patent,
and (2) Licensor does not within [**] of Symphony Icon’s written request take such action or
provide Symphony Icon with a reasonable basis for not taking such action; then Symphony Icon shall
have the option to commence any such action under its own direction and control, and at Symphony
Icon’s cost and expense; provided, that Licensor agrees that neither (x) the potential
disturbance of an actual or potential commercial relationship between Licensor and a third party
nor (y) concerns regarding potential risks to the Licensed Intellectual Property or other
intellectual property owned or controlled by Licensor is a reasonable basis for Licensor not taking
such action. Licensor shall, at Symphony Icon’s expense, cooperate with and reasonably assist
Symphony Icon in any such action if so requested by Symphony Icon, and, upon Symphony Icon’s
request, execute, file and deliver all documents and proof necessary for such purpose, including
being named as a party to

10

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

such litigation if requested by Symphony Icon or if required by Law. Licensor shall have the
right to participate and be represented by its own counsel at its own expense in any such action,
suit or proceeding with respect to Licensed Patent Rights provided that Licensor shall not enter
into any settlement or compromise of such action, suit or proceeding that affects or concerns the
validity, enforceability, or ownership of any Licensed Patent Rights or other Licensed Intellectual
Property without the prior written consent of Symphony Icon, which consent shall not be
unreasonably withheld or delayed. Symphony Icon shall not enter into any settlement or compromise
of such action, suit or proceeding that affects or concerns the validity, enforceability, or
ownership of any Licensed Patent Rights or other Licensed Intellectual Property without the prior,
written consent of Licensor, which consent shall not be unreasonably withheld or delayed.

     4.7 Post-Term Enforcement.

          (a) Program Specific Patents. Following the expiration or termination of the Purchase Option
without Licensor’s exercise of the Purchase Option, as between the Parties, and solely with respect
to Program Specific Patents, Symphony Icon shall have the first right, but not the obligation, to
take action against others, at Symphony Icon’s cost and expense, to prevent, terminate or seek
damages on account of Icon Relevant Infringements. Licensor shall, at Symphony Icon’s expense,
cooperate and reasonably assist Symphony Icon in such action if so requested, and upon Symphony
Icon’s request, execute, file and deliver all documents and proof necessary for such purpose,
including being named as a party to such litigation if requested by Symphony Icon or if required by
Law. Licensor shall have the right to participate and be represented in any such action, suit or
proceeding by its own counsel at its own expense provided that Licensor shall not enter into any
settlement or compromise of such action, suit or proceeding that affects or concerns the validity,
enforceability, or ownership of any Licensed Patent Rights or other Licensed Intellectual Property
without the prior written consent of Symphony Icon, which consent shall not be unreasonably
withheld or delayed. Symphony Icon shall not enter into any settlement or compromise of such
action, suit or proceeding that affects or concerns the validity, enforceability, or ownership of
any Licensed Patent Rights or other Licensed Intellectual Property without the prior written
consent of Licensor, which consent shall not be unreasonably withheld or delayed.

          (b) Following the expiration or termination of the Purchase Option without Licensor’s exercise
of the Purchase Option, if Symphony Icon does not take action under Section 4.7(a) within
[**] of Licensor’s written request that Symphony Icon take such action, then Licensor shall have
the option to commence any such action under its own direction and control, and at Licensor’s cost
and expense. Symphony Icon shall, at Licensor’s expense, cooperate and reasonably assist Licensor
in such action if so requested, and upon Licensor’s request, execute, file and deliver all
documents and proof necessary for such purpose, including being named as a party to such litigation
if requested by Licensor or if required by Law. Symphony Icon shall have the right to participate
and be represented in any such action, suit or proceeding by its own counsel at its own expense
provided that Symphony Icon shall not enter into any settlement or

11

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

compromise of such action, suit or proceeding that affects or concerns the validity,
enforceability, or ownership of any Licensed Patent Rights or other Licensed Intellectual Property
without the prior written consent of Licensor, which consent shall not be unreasonably withheld or
delayed. Licensor shall not enter into any settlement or compromise of such action, suit or
proceeding that affects or concerns the validity, enforceability, or ownership of any Licensed
Patent Rights or other Licensed Intellectual Property without the prior written consent of Symphony
Icon, which consent shall not be unreasonably withheld or delayed.

          (c) Licensed Intellectual Property. Except as set forth in Section 4.7(a) and
4.7(b) above, following the expiration or termination of the Purchase Option without
Licensor’s exercise of the Purchase Option, as between the Parties, Licensor shall have the first
right, but not the obligation, to take action against others in the courts, administrative agencies
or otherwise, under Licensor’s direction and control and at Licensor’s cost and expense, to prevent
or terminate infringement, misappropriation, illegal use or misuse of any Licensed Intellectual
Property, including but not limited to an Icon Relevant Infringement. Symphony Icon shall, at
Licensor’s expense, cooperate and reasonably assist Licensor in such action if so requested, and
upon Licensor’s request, execute, file and deliver all documents and proof necessary for such
purpose, including being named as a party to such litigation if requested by Licensor or if
required by Law. Symphony Icon shall have the right to participate and be represented in any such
action, suit or proceeding by its own counsel at its own expense, to the extent the action relates
to an Icon Relevant Infringement; provided that Symphony Icon shall not enter into any settlement
or compromise of such action, suit or proceeding that affects or concerns the validity,
enforceability, or ownership of any Licensed Patent Rights or other Licensed Intellectual Property
without the prior written consent of Licensor, which consent shall not be unreasonably withheld or
delayed. Licensor shall not enter into any settlement or compromise of such action, suit or
proceeding that affects or concerns the validity, enforceability, or ownership of any Licensed
Patent Rights or other Licensed Intellectual Property without the prior written consent of Symphony
Icon, which consent shall not be unreasonably withheld or delayed.

          (d) Except as set forth in Section 4.7(a) and 4.7(b) above and subject to the
limitations and restrictions set forth on Schedule 2.2, following the expiration or
termination of the Purchase Option without Licensor’s exercise of the Purchase Option, if Licensor
does not take action under Section 4.7(c) with respect to an Icon Relevant Infringement,
within ninety (90) days of Symphony Icon’s written request that Licensor take such action, then
Symphony Icon shall have the option to commence any such action under its own direction and
control, and at Symphony Icon’s cost and expense. Licensor shall, at Symphony Icon’s expense,
cooperate and reasonably assist Symphony Icon in such action if so requested, and upon Symphony
Icon’s request, execute, file and deliver all documents and proof necessary for such purpose,
including being named as a party to such litigation if requested by Symphony Icon or if required by
Law. Licensor shall have the right to participate and be represented in any such action, suit or
proceeding by its own counsel at its own expense provided that Licensor shall not

12

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

enter into any settlement or compromise of such action, suit or proceeding that affects or
concerns the validity, enforceability, or ownership of any Licensed Patent Rights or other Licensed
Intellectual Property without the prior written consent of Symphony Icon, which consent shall not
be unreasonably withheld or delayed. Symphony Icon shall not enter into any settlement or
compromise of such action, suit or proceeding that affects or concerns the validity,
enforceability, or ownership of any Licensed Patent Rights or other Licensed Intellectual Property
without the prior written consent of Licensor, which consent shall not be unreasonably withheld or
delayed.

     4.8 Withdrawal of Enforcement. If either Party brings an action under this ARTICLE 4
with respect to an Icon Relevant Infringement and subsequently ceases to pursue or withdraws from
such action without resolution (which resolution may include the granting of a license by Licensor
to such third party that does not violate Section 2.2 or Section 2.6 of this
Agreement), it shall promptly notify the other Party and the other Party may, to the extent
permitted by Law, substitute itself for the withdrawing party under the terms of this ARTICLE 4.

     4.9 Recoveries. All damages or other compensation of any kind recovered in such
action, suit, or proceeding brought under this ARTICLE 4 or from any related settlement or
compromise shall first be used to reimburse each Party for its expenses in connection with such
action, suit or proceeding, (in proportion to the expenses of each Party if recovery is
insufficient to cover all such expenses) and the remainder of such recovery, shall be allocated
[**].

ARTICLE 5

REPRESENTATIONS AND WARRANTIES

     5.1 Representations and Warranties of Licensor. Licensor hereby represents and
warrants to Symphony Icon, that as of the Closing Date:

          (a) Subject to Section 3.2 and Schedule 2.2, Licensor is the exclusive owner
of all right, title, and interest in and to (i) all Licensed Patent Rights listed on Annex C and
not identified as jointly owned or licensed from a third party and (ii) the Regulatory Files;

          (b) Licensor has sufficient rights to grant the licenses granted hereunder and the grant of
such licenses does not and will not conflict with any agreement to which Licensor is a party or
otherwise governing the Licensed Intellectual Property and Licensor further represents and warrants
that, on an ongoing basis throughout the Term, Licensor shall not enter into any agreement that
will conflict with the rights and licenses granted to Symphony Icon hereunder;

          (c) To the Knowledge of Licensor, no third party is engaging in any activity that infringes or
misappropriates the Licensed Patent Rights or related know-how or trade secrets;

13

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

          (d) No Licensed Intellectual Property owned by Licensor and, to the Knowledge of Licensor, no
Licensed Intellectual Property licensed to Licensor has been adjudged invalid or unenforceable, in
whole or in part, and there is no pending or, to the Knowledge of Licensor, threatened action,
suit, proceeding or claim by others challenging the validity or scope of any Licensed Intellectual
Property, and Licensor is unaware of any facts which would support any such claim;

          (e) To the Knowledge of Licensor, no actions or claims have been asserted, are pending or have
been threatened, against Licensor in writing alleging that the manufacture, use or sale of any
Product misappropriates or infringes the intellectual property rights of any third party;

          (f) Except as set forth on Annex B, Licensor and/or Symphony Icon shall not be liable or
otherwise obligated to pay royalties, milestone payments or other consideration pursuant to any
agreement Licensor may have with a third party existing on the Closing Date in connection with
Symphony Icon’s exploitation of the Licensed Intellectual Property (including Sublicensed
Intellectual Property) in connection with the development, manufacture, use, sale, or importation
of Products hereunder;

          (g) To the Knowledge of Licensor, the manufacture, use or sale of any Product by Symphony Icon
(or its sublicensees) in strict accordance with the licenses herein and other terms of this
Agreement will not misappropriate or infringe the intellectual property rights of any third party,
and Licensor is unaware of any facts which would support any such claim;

          (h) The data and information relating to the Programs, including such data and information
relating to pre-clinical and clinical studies provided in writing to Symphony Icon or its
Affiliates prior to the Closing Date has been accurate in all material respects and Licensor has
made no material misrepresentation or material omission in connection with such data and
information; and

          (i) Except for the LG617 Program, Licensor has not prior to the Closing Date itself or in
conjunction with a third party (via license or otherwise) conducted any activities related to the
development of a pharmaceutical product that Targets, to Licensor’s Knowledge, a [**].

     5.2 Disclaimer and Acknowledgement. EXCEPT AS EXPRESSLY SET FORTH IN THIS ARTICLE 5,
THE LICENSED INTELLECTUAL PROPERTY, PRODUCTS, TANGIBLE MATERIALS AND REGULATORY FILES ARE PROVIDED
“AS IS” WITH NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, AND LICENSOR EXPRESSLY DISCLAIMS ALL
OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO ANY WARRANTIES OF
MERCHANTABILITY, FITNESS FOR PARTICULAR PURPOSE, OR NON-INFRINGEMENT. LICENSOR DOES NOT WARRANT
THE PERFORMANCE OF ANY PRODUCT, INCLUDING THEIR SAFETY, EFFECTIVENESS OR COMMERCIAL VIABILITY. ANY
SYMPHONY ICON ENHANCEMENTS

14

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

PROVIDED TO LICENSOR HEREUNDER ARE PROVIDED “AS IS” WITH NO REPRESENTATIONS OR WARRANTIES OF
ANY KIND AND SYMPHONY ICON EXPRESSLY DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING BUT
NOT LIMITED TO ANY WARRANTIES OF MERCHANTABILITY, FITNESS FOR PARTICULAR PURPOSE, OR
NON-INFRINGEMENT.

ARTICLE 6

INDEMNIFICATION AND LIMITATION OF LIABILITY

     6.1 Indemnity. To the greatest extent permitted by applicable Law, Licensor shall
indemnify and hold harmless Symphony Icon, its Affiliates and each of their respective officers,
directors, employees, agents, members, managers, successors and assigns (each, a “Symphony Icon
Indemnified Party”) and Symphony Icon shall indemnify and hold harmless Licensor, its
Affiliates and each of their respective officers, directors, employees, agents, members, successors
and assigns (each, a “Licensor Indemnified Party” and together with Symphony Icon
Indemnified Party, the “Indemnified Parties”), from and against any and all claims, losses,
costs, interest, awards, judgments, fees (including reasonable fees for attorneys and other
professionals), court costs, liabilities, damages and expenses (as determined by the applicable
Indemnified Parties acting in good faith), incurred by any Indemnified Party (irrespective of
whether any such Indemnified Party is a party to the action for which indemnification hereunder is
sought), (collectively, a “Loss”) to the extent resulting from, arising out of, or relating
to any and all third party suits, claims, actions, proceedings, investigations, litigation or
demands based upon:

	 	(ii)	 	in the case of Licensor being the Indemnifying Party, (A) any
breach of any representation or warranty made by Licensor herein or in any
other Operative Document, (B) any breach of any covenant, agreement or
obligation of Licensor contained herein, or in any other Operative Document,
(C) any gross negligence or willful misconduct by Licensor in performing its
obligations under this Agreement, (D) any action undertaken or performed by or
on behalf of Licensor prior to, and including, the Closing Date that relates
to the Programs or the Products, or (E) in the event Licensor exercises a
Discontinuation Option for a Program, any action undertaken and/or performed
by or on behalf of Licensor after the Discontinuation Option Closing Date and
relating to the Product that was the subject of such Program (including the
development, manufacture, use, handling, storage, sale or other disposition of
such Product); in each case, except (1) with respect to Losses for which
Licensor is entitled to indemnification under this ARTICLE 6 or (2) to the
extent such Loss arises from the

15

 

	Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

	 	 	 	gross negligence or willful misconduct of a Symphony Icon Indemnified
Party, and
	 
	     (ii)    in the case of Symphony Icon being the Indemnifying Party, (A) any breach of any
representation or warranty made by Symphony Icon herein or in any other Operative Document, (B) any
breach of any covenant, agreement or obligation of Symphony Icon contained herein, or in any other
Operative Document, (C) any gross negligence or willful misconduct of Symphony Icon (and not that
of its direct subcontractors) in performing its obligations under this Agreement, or (D) the
development, manufacture, use, handling, storage, sale or other disposition of Products (including
in the course of conducting the Programs) during the Term (except with respect to the development,
manufacture, use, handling storage, sale or other disposition, after Licensor’s exercise of a
Discontinuation Option, of Products covered under Section 6.1(i)(E); in each case, except
(1) with respect to Losses for which Symphony Icon is entitled to indemnification under this
ARTICLE 6 or (2) to the extent such Loss arises from the gross negligence or willful misconduct of
a Licensor Indemnified Party.

     To the extent that the foregoing undertakings by Licensor and/or Symphony Icon may be
unenforceable for any reason, such Party shall make the maximum contribution to the payment and
satisfaction of any Loss that is permissible under applicable Law.

     6.2 Notice of Claims. Any Indemnified Party that proposes to assert a right to be
indemnified under this ARTICLE 6 shall notify Licensor or Symphony Icon, as applicable (the
“Indemnifying Party”), promptly after receipt of notice of commencement of any action, suit
or proceeding against such Indemnified Party (an “Indemnified Proceeding”) in respect of
which a claim is to be made under this ARTICLE 6, or the incurrence or realization of any Loss in
respect of which a claim is to be made under this ARTICLE 6, of the commencement of such
Indemnified Proceeding or of such incurrence or realization, enclosing a copy of all relevant
documents, including all papers served and claims made, but the omission so to notify the
applicable Indemnifying Party promptly of any such Indemnified Proceeding or incurrence or
realization shall not relieve (a) such Indemnifying Party from any liability that it may have to
such Indemnified Party under this ARTICLE 6 or otherwise, except, as to such Indemnifying Party’s
liability under this ARTICLE 6, to the extent, but only to the extent, that such Indemnifying Party
shall have been prejudiced by such omission, or (b) any other indemnitor from liability that it may
have to any Indemnified Party under the Operative Documents.

     6.3 Defense of Proceedings. In case any Indemnified Proceeding shall be brought
against any Indemnified Party, it shall notify the applicable Indemnifying Party of the
commencement thereof and such Indemnifying Party shall be entitled to participate in, and provided
such Indemnified Proceeding involves a claim solely for money damages and does not seek an
injunction or other equitable relief against the Indemnified Party and is not a criminal or
regulatory action, to assume the defense of, such Indemnified Proceeding with counsel reasonably
satisfactory to such Indemnified

16

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

Party. After notice from such Indemnifying Party to such Indemnified Party of such
Indemnifying Party’s election so to assume the defense thereof and the failure by such Indemnified
Party to object to such counsel within ten (10) Business Days following its receipt of such notice,
such Indemnifying Party shall not be liable to such Indemnified Party for legal or other expenses
related to such Indemnified Proceedings incurred after such notice of election to assume such
defense except as provided below and except for the reasonable costs of investigating, monitoring
or cooperating in such defense subsequently incurred by such Indemnified Party reasonably necessary
in connection with the defense thereof. Such Indemnified Party shall have the right to employ its
counsel in any such Indemnified Proceeding, but the fees and expenses of such counsel shall be at
the expense of such Indemnified Party unless:

          (a) the employment of counsel by such Indemnified Party at the expense of the applicable
Indemnifying Party has been authorized in writing by such Indemnifying Party;

          (b) such Indemnified Party shall have reasonably concluded in its good faith (which conclusion
shall be determinative unless a court determines that such conclusion was not reached reasonably
and in good faith) that there is or may be a conflict of interest between the applicable
Indemnifying Party and such Indemnified Party in the conduct of the defense of such Indemnified
Proceeding or that there are or may be one or more different or additional defenses, claims,
counterclaims, or causes of action available to such Indemnified Party (it being agreed that in any
case referred to in this clause (b) such Indemnifying Party shall not have the right to direct the
defense of such Indemnified Proceeding on behalf of the Indemnified Party);

          (c) the applicable Indemnifying Party shall not have employed counsel reasonably acceptable to
the Indemnified Party to assume the defense of such Indemnified Proceeding within a reasonable time
after notice of the commencement thereof; provided, however, that (i) this clause shall not be
deemed to constitute a waiver of any conflict of interest that may arise with respect to any such
counsel, and (ii) an Indemnified Party may not invoke this clause I if such Indemnified Party
failed to timely object to such counsel pursuant to the first paragraph of this Section 6.3
(it being agreed that in any case referred to in this clause I such Indemnifying Party shall not
have the right to direct the defense of such Indemnified Proceeding on behalf of the Indemnified
Party); or

          (d) any counsel employed by the applicable Indemnifying Party shall fail to timely commence or
reasonably conduct the defense of such Indemnified Proceeding and such failure has prejudiced (or
is in immediate danger of prejudicing) the outcome of such Indemnified Proceeding (it being agreed
that in any case referred to in this clause (d) such Indemnifying Party shall not have the right to
direct the defense of such Indemnified Proceeding on behalf of the Indemnified Party);

in each of which cases the fees and expenses of counsel for such Indemnified Party shall be at the
expense of such Indemnifying Party. Only one counsel shall be retained by all

17

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

Indemnified Parties with respect to any Indemnified Proceeding, unless counsel for any Indemnified
Party reasonably concludes in good faith (which conclusion shall be determinative unless a court
determines that such conclusion was not reached reasonably and in good faith) that there is or may
be a conflict of interest between such Indemnified Party and one or more other Indemnified Parties
in the conduct of the defense of such Indemnified Proceeding or that there are or may be one or
more different or additional defenses, claims, counterclaims, or causes of action available to such
Indemnified Party.

     6.4 Settlement. Without the prior written consent of such Indemnified Party, such
Indemnifying Party shall not settle or compromise, or consent to the entry of any judgment in, any
pending or threatened Indemnified Proceeding, unless such settlement, compromise, consent or
related judgment (i) includes an unconditional release of such Indemnified Party from all liability
for Losses arising out of such claim, action, investigation, suit or other legal proceeding, (ii)
provides for the payment of money damages as the sole relief for the claimant (whether at law or in
equity), (iii) involves no admission of fact adverse to the Indemnified Party or finding or
admission of any violation of Law or the rights of any Person by the Indemnified Party, and (iv) is
not in the nature of a criminal or regulatory action. No Indemnified Party shall settle or
compromise, or consent to the entry of any judgment in, any pending or threatened Indemnified
Proceeding (A) in respect of which any payment would result hereunder or under any other Operative
Document, (B) which includes an injunction that will adversely affect any Indemnifying Party, (C)
which involves an admission of fact adverse to the Indemnifying Party or a finding or admission of
any violation of Law or the rights of any Person by the Indemnifying Party, (D) which is in the
nature of a criminal or regulatory action, without the prior written consent of the Indemnifying
Party, such consent not to be unreasonably conditioned, withheld or delayed, or (E) which admits
the invalidity, misuse or unenforceability of a Licensed Patent Right, without the prior written
consent of the Indemnifying Party, such consent not to be unreasonably conditioned, withheld or
delayed.

     6.5 Limitation of Liability. TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW,
NEITHER PARTY NOR ANY OF THEIR RESPECTIVE DIRECTORS, OFFICERS, MEMBERS, MANAGERS, EMPLOYEES,
INDEPENDENT CONTRACTORS OR AGENTS SHALL HAVE ANY LIABILITY OF ANY TYPE (INCLUDING, BUT NOT LIMITED
TO, CLAIMS IN CONTRACT, NEGLIGENCE AND TORT LIABILITY) FOR ANY SPECIAL, INCIDENTAL, INDIRECT,
PUNITIVE OR CONSEQUENTIAL DAMAGES, INCLUDING, BUT NOT LIMITED TO, THE LOSS OF OPPORTUNITY, LOSS OF
USE OR LOSS OF REVENUE OR PROFIT IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR THE
SERVICES PERFORMED HEREUNDER, EVEN IF SUCH DAMAGES MAY HAVE BEEN FORESEEABLE. THE FOREGOING SHALL
NOT LIMIT EITHER PARTY’S INDEMNIFICATION OBLIGATIONS PURSUANT TO SECTION 6.1.

18

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

     6.6 Insurance. The Parties shall maintain insurance as set forth in Section 6.7 of
the Amended and Restated Research and Development Agreement.

ARTICLE 7

TERM AND TERMINATION

     7.1 Term. This Agreement shall commence on the Closing Date and shall remain in force
until terminated as provided herein.

     7.2 Termination.

          (a) Either Party may terminate this Agreement at any time if the other Party is in material
default or breach of this Agreement that has resulted in, or would reasonably be expected to result
in, a material adverse effect on the Programs or the non-breaching Party’s rights under the
Operative Documents, and such material default or breach continues unremedied for a period of [**]
after written notice thereof is delivered to the defaulting or breaching Party.

          (b) Licensor may terminate this Agreement at any time upon written notice to Symphony Icon if
(i) Holdings breaches Section 2 of the Subscription Agreement or (ii) Holdings or Symphony
Icon is in material default or breach of the Purchase Option Agreement that has resulted in, or
would reasonably be expected to result in, a material adverse effect on Licensor’s rights under the
Purchase Option Agreement and such default or breach is not cured within [**] after written notice
of such default or breach under the Purchase Option Agreement is delivered to the defaulting or
breaching party.

          (c) Licensor may terminate Symphony Icon’s sublicense to a specific element of Sublicensed
Intellectual Property if Symphony Icon is in material default or breach of a Sublicense Obligation
relating to such Sublicensed Intellectual Property and such material default or breach continues
unremedied for a period of [**] (or such shorter cure period as may be stipulated in the applicable
Sublicense Obligation) after written notice thereof is delivered to Symphony Icon.

          (d) Upon any termination of this Agreement, all license rights granted herein (except for
those rights granted in or pursuant to Section 2.5) shall immediately terminate.

     7.3 Survival. The following Sections and Articles shall survive any expiration or
termination of this Agreement: Sections 2.11, 4.1, 5.2 and 7.3, and Articles 6 and 8.

     7.4 Bankruptcy. All rights and licenses granted under this Agreement are, and shall
otherwise be deemed to be, for purposes of Section 365(n) of the United States Bankruptcy Code (the
“Code”), licenses to “Intellectual Property” as defined in the

19

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

Code. The Parties agree that each Party shall retain and may fully exercise all of its rights
and elections under the Code.

ARTICLE 8

MISCELLANEOUS

     8.1 Notices. Any notice, request, demand, waiver, consent, approval or other
communication which is required or permitted to be given to any Party shall be in writing addressed
to the Party at its address set forth below and shall be deemed given (i) when delivered to the
Party personally, (ii) if sent to the Party by facsimile transmission (promptly followed by a
hard-copy delivered in accordance with this Section 8.1), when the transmitting Party
obtains written proof of transmission and receipt; provided, however, that notwithstanding the
foregoing, any communication sent by facsimile transmission after 5:00 PM (receiving Party’s time)
or not on a Business Day shall not be deemed received until the next Business Day, (iii) when
delivered by next Business Day delivery by a nationally recognized courier service, or (iv) if sent
by registered or certified mail, when received, provided postage and registration or certification
fees are prepaid and delivery is confirmed by a return receipt:

     Licensor:

Lexicon Pharmaceuticals, Inc.

8800 Technology Forest Place

The Woodlands, TX 77381-1160

Attn: Arthur T. Sands, M.D., Ph.D

Facsimile: (281) 863-8095

     with copies to:

Lexicon Pharmaceuticals, Inc.

8800 Technology Forest Place

The Woodlands, TX 77381-1160

Attn: Jeffrey L. Wade

Facsimile: (281) 863-8010

     and

Lexicon Pharmaceuticals, Inc.

8800 Technology Forest Place

The Woodlands, TX 77381-1160

Attn: Julia P. Gregory

Facsimile: (281) 863-8095

     Symphony Icon:

20

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

Symphony Icon, Inc.

7361 Calhoun Place, Suite 325

Rockville, MD 20855

Attn: Charles W. Finn, Ph.D.

Facsimile: (301) 762-6154

     with copies to:

Symphony Capital Partners, L.P.

875 Third Avenue, 18th Floor

New York, NY 10022

Attn: Mark Kessel

Facsimile: (212) 632-5401

     and

Symphony Strategic Partners, LLC

875 Third Avenue, 18th Floor

New York, NY 10022

Attn: Mark Kessel

Facsimile: (212) 632-5401

or to such other address as such Party may from time to time specify by notice given in the manner
provided herein to each other Party entitled to receive notice hereunder.

     8.2 Entire Agreement. This Agreement (including any Annexes, Schedules, Exhibits or
other attachments hereto) and the agreements referred to herein (including the Operative Documents)
constitute the entire agreement between the Parties with respect to the subject matter hereof, and
no oral or written statement may be used to interpret or vary the meaning of the terms and
conditions hereof. This Agreement supersedes all prior and contemporaneous agreements,
correspondence, discussion and understandings, whether written or oral, between the Parties with
respect to the subject matter hereof, including the Original Agreement but excluding the Operative
Documents.

     8.3 Assignment. Neither Party may assign or otherwise transfer this Agreement without
the prior written consent of the other Party; provided, however, that (i) Licensor may assign this
Agreement or any of its rights and obligations hereunder without the consent of Symphony Icon (A)
to an Affiliate or in connection with a merger or the sale of all or substantially all of the
assets of Licensor to which this Agreement relates, or (B) to the Surviving Entity in the event
Licensor undergoes a Change of Control in compliance with Article 14 of the Amended and Restated
Research and Development Agreement, provided, however, the Licensed Patent Rights and Licensed
Know-How shall not be construed, as a result of such assignment, to include any patent rights,
know-how, trade secret, and other intellectual property that, prior to such Change of Control, were
owned or Controlled by the Person (other than Licensor) involved in such Change of Control; and
(ii) after expiration of the Term without Licensor’s exercise

21

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

of the Purchase Option, Symphony Icon may assign or otherwise transfer this Agreement to any
Person without the prior, written consent of Licensor. Assignment of this Agreement by either
Party shall not relieve the assignor of its obligations hereunder. This Agreement shall be binding
upon and inure to the benefit of the Parties and their respective successors and permitted assigns.

     8.4 Headings. The descriptive headings contained in this Agreement are for
convenience of reference only and shall not affect in any way the meaning or interpretation of the
Agreement.

     8.5 Independent Contractor. Each Party shall be acting as an independent contractor
in performing under this Agreement and shall not be considered or deemed to be an agent, employee,
joint venturer or partner of the other Party.

     8.6 Severability. If any term or other provision of this Agreement is invalid,
illegal or incapable of being enforced by any rule of Law or public policy, all other conditions
and provisions of this Agreement shall nevertheless remain in full force and effect so long as the
economic or legal substance of the transactions contemplated hereby is not affected in any manner
materially adverse to any Party. Upon such determination that any term or other provision is
invalid, illegal or incapable of being enforced, the Parties hereto shall negotiate in good faith
to modify this Agreement so as to effect the original intent of the Parties as closely as possible
in an acceptable manner to the end that the transactions contemplated hereby are fulfilled to the
extent possible.

     8.7 No Third-Party Beneficiaries. Except with respect to (i) certain indemnification
obligations and liability limitations pursuant to ARTICLE 6 and (ii) BMS, solely with respect to
its rights pursuant to Section 2.12, nothing in this Agreement, either express or implied,
is intended to or shall confer upon any third party any legal or equitable right, benefit or remedy
of any nature whatsoever under or by reason of this Agreement.

     8.8 Compliance with Laws. In performing under this Agreement, each Party shall comply
with all applicable Laws, rules and regulations, including without limitation the Federal Food,
Drug, and Cosmetic Act and regulations promulgated pursuant thereto and the United States Export
Administration Regulations.

     8.9 Amendment. The terms of this Agreement shall not be altered, modified, amended,
waived or supplemented in any manner whatsoever except by a written instrument signed by each of
Licensor and Symphony Icon.

     8.10 Governing Law; Consent to Jurisdiction and Service of Process.

          (a) This Agreement shall be governed by, and construed in accordance with, the Laws of the
State of New York; except to the extent that this Agreement pertains to the internal governance of
Symphony Icon or Holdings, and to

22

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

such extent this Agreement shall be governed and construed in accordance with the Laws of the
State of Delaware.

          (b) Each of the Parties hereby irrevocably and unconditionally submits, for itself and its
property, to the nonexclusive jurisdiction of any New York State court or federal court of the
United States of America sitting in The City of New York, Borough of Manhattan, and any appellate
court from any jurisdiction thereof, in any action or proceeding arising out of or relating to this
Agreement, or for recognition or enforcement of any judgment, and each of the Parties hereby
irrevocably and unconditionally agrees that all claims in respect of any such action or proceeding
may be heard and determined in any such New York State court or, to the fullest extent permitted by
Law, in such federal court. Each of the Parties agrees that a final judgment in any such action or
proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment
or in any other manner provided by Law. Nothing in this Agreement shall affect any right that any
Party may otherwise have to bring any action or proceeding relating to this Agreement.

          (c) Each of the Parties irrevocably and unconditionally waives, to the fullest extent it may
legally and effectively do so, any objection that it may now or hereafter have to the laying of
venue of any suit, action or proceeding arising out of or relating to this Agreement in any New
York State or federal court. Each of the Parties hereby irrevocably waives, to the fullest extent
permitted by Law, the defense of an inconvenient forum to the maintenance of such action or
proceeding in any such court.

     8.11 Waiver of Jury Trial. EACH OF THE PARTIES HERETO IRREVOCABLY WAIVES ALL RIGHT TO
TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR
OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT.

     8.12 Counterparts. This Agreement may be executed in one or more counterparts, and by
the respective Parties in separate counterparts, each of which when executed shall be deemed to be
an original but all of which taken together shall constitute one and the same Agreement.

     8.13 No Waiver. The failure of either Party to enforce at any time for any period the
provisions of or any rights deriving from this Agreement shall not be construed to be a waiver of
such provisions or rights or the right of such Party thereafter to enforce such provisions.

SIGNATURES FOLLOW ON NEXT PAGE

23

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

     IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed as of the
date first written above by their respective duly authorized officers.

	 	 	 	 	 
	 	 	SYMPHONY ICON, INC.
	 
	 	 	 	 
	 

	 	By:	 	 
	 

	 	 	 	 
	 

	 	 	 	Name: Mark Kessel
	 

	 	 	 	Title: Chairman of the Board
	 
	 	 	 	 
	 	 	SYMPHONY ICON HOLDINGS LLC
	 
	 	 	 	 
	 

	 	By:
	 	Symphony Capital Partners, L.P.,
	 

	 	 	 	its Manager
	 
	 	 	 	 
	 

	 	By:
	 	Symphony Capital GP, L.P.,
	 

	 	 	 	its general partner
	 
	 	 	 	 
	 

	 	By:
	 	Symphony GP, LLC,
	 

	 	 	 	its general partner
	 
	 	 	 	 
	 

	 	By:	 	 
	 

	 	 	 	 
	 

	 	 	 	Name: Mark Kessel
	 

	 	 	 	Title: Managing Member
	 
	 	 	 	 
	 	 	LEXICON PHARMACEUTICALS, INC.
	 
	 	 	 	 
	 

	 	By:	 	 
	 

	 	 	 	 
	 

	 	 	 	Name: Arthur T. Sands, M.D., Ph.D.
	 

	 	 	 	Title: President and Chief Executive Officer

Signature page to Novated and Restated Technology License Agreement

24

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

SCHEDULE 2.2

CERTAIN RESTRICTIONS RELATING TO LICENSED INTELLECTUAL

PROPERTY LICENSED TO LICENSOR BY A THIRD PARTY

NONE

Sched. 2.2-1

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

ANNEX A

CERTAIN DEFINITIONS

[See attached]

A-1

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

CERTAIN DEFINITIONS

          “$” means United States dollars.

          “Accredited Investor” has the meaning set forth in Rule 501(a) of Regulation D
promulgated under the Securities Act of 1933, as amended.

          “Act” means the Delaware Limited Liability Company Act, 6 Del. C. § 18-101 et seq.

          “Activity” means:

               (a) in the case of goods or services procured from third party vendors, the resources applied
(and the costs incurred therefor) on one clinical study or protocol under a single contract with a
vendor, said contract consisting of either a purchase order or a stand alone contract, if for a
one-time purchase, or a series of work orders under a master contract or master services agreement,
if for multiple purchases of similar goods or services from the same vendor; and

               (b) in the case of internally provided goods or services, the resources applied, allocated or
reallocated (and the costs associated therewith) under a single budgetary line item for any LG103
Program or any LG617 Program.

          “Ad Hoc Meeting” has the meaning set forth in Paragraph 6 of Annex B of the Amended
and Restated Research and Development Agreement.

          “Additional Party” has the meaning set forth in Section 14 of the
Confidentiality Agreement.

          “Additional Regulatory Filings” means such Governmental Approvals as required to be
made under any law applicable to the purchase of the Symphony Icon Equity Securities under the
Purchase Option Agreement.

          “Adjusted Capital Account Deficit” has the meaning set forth in Section 1.01
of the Holdings LLC Agreement.

          “Affected Member” has the meaning set forth in Section 26 of the Investors LLC
Agreement.

          “Affiliate” means, with respect to any Person (i) any Person directly or indirectly
controlling, controlled by or under common control with such Person, (ii) any officer, director,
general partner, member or trustee of such Person, or (iii) any Person who is an officer, director,
general partner, member or trustee of any Person described in clauses (i) or (ii)
of this sentence. For purposes of this definition, the terms “controlling,” “controlled by” or
“under common control with” shall mean the possession, direct or indirect, of the power to direct
or cause the direction of the management and policies of a

 

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

Person or entity, whether through the ownership of voting securities, by contract or
otherwise, or the power to elect at least 50% of the directors, managers, general partners, or
persons exercising similar authority with respect to such Person or entities.

          “Amended and Restated Research and Development Agreement” means the Amended and
Restated Research and Development Agreement dated as of the Closing Date, among Lexicon, Holdings
and Symphony Icon.

          “Annual Price” has the meaning set forth in Section 2(b) of the Purchase
Option Agreement.

          “Asset Value” has the meaning set forth in Section 1.01 of the Holdings LLC
Agreement.

          “Auditors” means an independent certified public accounting firm of recognized
national standing.

          “Balance
Sheet Deficiency” has the meaning set forth in Section 1(c)(iii) of
the Purchase Option Agreement.

          “Balance
Sheet Deficiency Date” has the meaning set forth in Section 1(c)(iii) of the Purchase Option Agreement.

          “Balance Sheet Deficiency Threshold” shall have the meaning set forth in Section 3(b)
of the Research Cost Sharing, Payment and Extension Agreement.

          “Bankruptcy Code” means the United States Bankruptcy Code.

          “Bankruptcy Event” means, with respect to a Person, the occurrence of either of the
following:

               (a) a case or other proceeding shall be commenced, without the application or consent of such
Person, in any court, seeking the liquidation, reorganization, debt arrangement, dissolution,
winding up, or composition or readjustment of debts of such Person, the appointment of a trustee,
receiver, custodian, liquidator, assignee, sequestrator or the like for such Person of all or
substantially all of its assets, or any similar action with respect to such Person under any Law
relating to bankruptcy, insolvency, reorganization, winding up or composition or adjustment of
debts, and such case or proceeding shall continue undismissed, or unstayed and in effect, for a
period of sixty (60) consecutive days; or an order for relief in respect of such Person shall be
entered in an involuntary case under the federal bankruptcy Laws or other similar Laws now or
hereafter in effect; or

               (b) such Person shall generally not pay its debts as such debts become due or shall admit in
writing its inability to pay its debts generally or such Person shall commence a voluntary case or
other proceeding under any applicable bankruptcy,

 

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

insolvency, reorganization, debt arrangement, dissolution or other similar Law now or
hereafter in effect, or shall consent to the appointment of or taking possession by a receiver,
liquidator, assignee, trustee (other than a trustee under a deed of trust, indenture or similar
instrument), custodian, sequestrator (or other similar official) for, such Person or for any
substantial part of its property, or shall make any general assignment for the benefit of
creditors, or shall be adjudicated insolvent, or admit in writing its inability to pay its debts
generally as they become due, or, if a corporation or similar entity, its board of directors shall
vote to implement any of the foregoing.

          “BMS” means Bristol-Myers Squibb Company, a Delaware corporation.

          “Business Day” means any day other than Saturday, Sunday or any other day on which
commercial banks in the City of New York are authorized or required by law to remain closed.

          “Capital Contributions” has the meaning set forth in Section 1.01 of the
Holdings LLC Agreement.

          “Capitalized Leases” means all leases that have been or should be, in accordance with
GAAP, recorded as capitalized leases.

          “Cash Available for Distribution” has the meaning set forth in Section 1.01 of
the Holdings LLC Agreement.

          “Chair” has the meaning set forth in Paragraph 4 of Annex B to the Amended and
Restated Research and Development Agreement.

          “Change of Control” means and includes the occurrence of any of the following events,
but specifically excludes (i) acquisitions of capital stock directly from Lexicon for cash, whether
in a public or private offering, (ii) sales of capital stock by stockholders of Lexicon, and (iii)
acquisitions of capital stock by or from any employee benefit plan or related trust:

          (a) the merger, reorganization or consolidation of Lexicon into or with another corporation or
legal entity in which Lexicon’s stockholders holding the right to vote with respect to matters
generally immediately preceding such merger, reorganization or consolidation, own less than fifty
percent (50%) of the voting securities of the surviving entity; or

          (b) the sale of all or substantially all of Lexicon’s assets or business.

          “Change of Control Put Option” has the meaning set forth in Section 2A of the
Purchase Option Agreement.

          “Change of Control Put Option Exercise Notice” has the meaning set forth in
Section 2A of the Purchase Option Agreement.

 

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

          “Class A Member” means a holder of a Class A Membership Interest.

          “Class A Membership Interest” means a Class A Membership Interest in Holdings.

          “Class B Member” means a holder of a Class B Membership Interest.

          “Class B Membership Interest” means a Class B Membership Interest in Holdings.

          “Class C Member” means a holder of a Class C Membership Interest.

          “Class C Membership Interest” means a Class C Membership Interest in Holdings.

          “Class D Member” means a holder of a Class D Membership Interest.

          “Class D Membership Interest” means a Class D Membership Interest in Holdings.

          “Client Schedules” has the meaning set forth in Section 5(b) of the RRD
Services Agreement.

          “Clinical Trial Material” means Product and placebo for administration to animals for
pre-clinical testing or to humans for clinical testing, and Product for non-clinical testing.

          “Closing Date” means June 15, 2007.

          “CMC” means the chemistry, manufacturing and controls documentation as required for
filings with a Regulatory Authority relating to the manufacturing, production and testing of drug
products.

          “CNS Field” means the field of prevention, palliation, control or treatment in humans
of (a) depression, schizophrenia, bipolar disease, dementia, anxiety, attention deficit
hyperactivity disorder, anorexia nervosa and other affective disorders, (b) Alzheimer’s disease and
other cognitive disorders, (c) Parkinson’s disease, amyotrophic lateral sclerosis and other
neurodegenerative disorders, (d) pain, (e) epilepsy, (f) insomnia, narcolepsy and other sleep
disorders, (g) substance abuse and (h) migraine.

          “Code” means the Internal Revenue Code of 1986, as amended from time to time.

          “Common Stock” means the common stock, par value $0.01 per share, of Symphony Icon.

 

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

          “Company Expenses” has the meaning set forth in Section 5.09 of the Holdings
LLC Agreement.

          “Company Property” has the meaning set forth in Section 1.01 of the Holdings
LLC Agreement.

          “Confidential Information” has the meaning set forth in Section 2 of the
Confidentiality Agreement.

          “Confidentiality Agreement” means the Confidentiality Agreement, dated as of the
Closing Date, among Symphony Icon, Holdings, Lexicon, SCP, SSP, Investors, Symphony Capital and
RRD, as such agreement may be amended or amended and restated from time to time.

          “Conflict Transaction” has the meaning set forth in Article X of the Symphony
Icon Charter.

          “Control” means, with respect to any material, information or intellectual property
right, that a Party owns or has a license to such item or right, and has the ability to grant the
other Party access, a license or a sublicense (as applicable) in or to such item or right as
provided in the Operative Documents without violating the terms of any agreement or other
arrangement with any third party.

          “Cross Program Budget Component” has the meaning set forth in Section 4.1 of
the Amended and Restated Research and Development Agreement.

          “Debt” of any Person means, without duplication:

          (a) all indebtedness of such Person for borrowed money,

          (b) all obligations of such Person for the deferred purchase price of property or services
(other than any portion of any trade payable obligation that shall not have remained unpaid for 91
days or more from the later of (A) the original due date of such portion and (B) the customary
payment date in the industry and relevant market for such portion),

          (c) all obligations of such Person evidenced by bonds, notes, debentures or other similar
instruments,

          (d) all obligations of such Person created or arising under any conditional sale or other
title retention agreement with respect to property acquired by such Person (whether or not the
rights and remedies of the seller or lender under such agreement in an event of default are limited
to repossession or sale of such property),

          (e) all Capitalized Leases to which such Person is a party,

 

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

          (f) all obligations, contingent or otherwise, of such Person under acceptance, letter of
credit or similar facilities,

          (g) all obligations of such Person to purchase, redeem, retire, defease or otherwise acquire
for value any Equity Securities of such Person,

          (h) the net amount of all financial obligations of such Person in respect of Hedge Agreements,

          (i) the net amount of all other financial obligations of such Person under any contract or
other agreement to which such Person is a party,

          (j) all
Debt of other Persons of the type described in clauses (a) through (i)
above guaranteed, directly or indirectly, in any manner by such Person, or in effect guaranteed,
directly or indirectly, by such Person through an agreement (A) to pay or purchase such Debt or to
advance or supply funds for the payment or purchase of such Debt, (B) to purchase, sell or lease
(as lessee or lessor) property, or to purchase or sell services, primarily for the purpose of
enabling the debtor to make payment of such Debt or to assure the holder of such Debt against loss,
(C) to supply funds to or in any other manner invest in the debtor (including any agreement to pay
for property or services irrespective of whether such property is received or such services are
rendered) or (D) otherwise to assure a creditor against loss, and

          (k) all Debt of the type described in clauses (a) through (i) above secured by (or for which
the holder of such Debt has an existing right, contingent or otherwise, to be secured by) any
Encumbrance on property (including accounts and contract rights) owned or held or used under lease
or license by such Person, even though such Person has not assumed or become liable for payment of
such Debt.

          “Development Budget” means the budget (comprised of the Program Specific Budget
Component and the Cross Program Budget Component) for the implementation of the Development Plan
(the initial form of which was agreed upon by Lexicon and Symphony Icon as of the Closing Date and
attached to the Amended and Restated Research and Development Agreement as Annex C thereto), as may
be further developed and revised from time to time in accordance with the Development Committee
Charter and the Amended and Restated Research and Development Agreement.

          “Development Committee” has the meaning set forth in Article 3 of the Amended and
Restated Research and Development Agreement.

          “Development Committee Charter” has the meaning set forth in Article 3 of the Amended
and Restated Research and Development Agreement.

          “Development Committee Member” has the meaning set forth in Paragraph 1 of Annex B to
the Amended and Restated Research and Development Agreement.

 

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

          “Development Plan” means the development plan covering all the Programs (the initial
form of which was agreed upon by Lexicon and Symphony Icon as of the Closing Date and attached to
the Amended and Restated Research and Development Agreement as Annex C thereto), as may be further
developed and revised from time to time in accordance with the Development Committee Charter and
the Amended and Restated Research and Development Agreement.

          “Development Product” means a LG617 Product or a LG103 Product that is administered in
a clinical trial performed pursuant to the Development Plan.

          “Development Services” has the meaning set forth in Section 1(b) of the RRD
Services Agreement.

          “Development Subcontracting Agreement” means a Subcontracting Agreement that is
directly related to one or both of the Programs and is not a Manufacturing Subcontracting
Agreement.

          “Director(s)” means the Persons identified as such in the Preliminary Statement of the
Indemnification Agreement (including such Persons as may become parties thereto after the date
hereof).

          “Disclosing Party” has the meaning set forth in Section 4 of the
Confidentiality Agreement.

          “Discontinuation Option” has the meaning set forth in Section 11(a) of the
Amended and Restated Research and Development Agreement.

          “Discontinuation Option Closing Date” means the date of expiration of the
Discontinuation Option pursuant to Section 11(a) of the Amended and Restated Research and
Development Agreement.

          “Discontinuation Price” has the meaning set forth in Section 11(a) of the
Amended and Restated Research and Development Agreement.

          “Discontinued Program” has the meaning set forth in Section 2.10 of the
Novated and Restated Technology License Agreement.

          “Disinterested Directors” has the meaning set forth in Article IX of the
Symphony Icon Charter.

          “Distribution” has the meaning set forth in Section 1.01 of the Holdings LLC
Agreement.

          “Early Purchase Option Exercise” has the meaning set forth in Section 1(c)(v)
of the Purchase Option Agreement.

 

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

          “Effective Registration Date” has the meaning set forth in Section 1(b) of the
Registration Rights Agreement.

          “Encumbrance” means (i) any security interest, pledge, mortgage, lien (statutory or
other), charge or option to purchase, lease or otherwise acquire any interest, (ii) any adverse
claim, restriction, covenant, title defect, hypothecation, assignment, deposit arrangement, license
or other encumbrance of any kind, preference or priority, or (iii) any other security agreement or
preferential arrangement of any kind or nature whatsoever (including, without limitation, any
conditional sale or other title retention agreement).

          “Equity Securities” means, with respect to any Person, shares of capital stock of (or
other ownership or profit interests in) such Person, warrants, options or other rights for the
purchase or other acquisition from such Person of shares of capital stock of (or other ownership or
profit interests in) such Person, securities convertible into or exchangeable for shares of capital
stock of (or other ownership or profit interests in) such Person or warrants, rights or options for
the purchase or other acquisition from such Person of such shares (or such other interests), and
other ownership or profit interests in such Person (including, without limitation, partnership,
member or trust interests therein), whether voting or nonvoting, and whether or not such shares,
warrants, options, rights or other interests are authorized or otherwise existing on any date of
determination.

          “ERISA” means the United States Employee Retirement Income Security Act of 1974, as
amended.

          “Excepted Debt” has the meaning set forth in Section 5(c)(iii) of the Purchase
Option Agreement.

          “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules
and regulations promulgated thereunder.

          “Existing Confidentiality Agreement” has the meaning set forth in Section 2(a)
of the Confidentiality Agreement.

          “Extension Funding” has the meaning set forth in Section 2 of the Research
Cost Sharing, Payment and Extension Agreement.

          “External Directors” means, at any time, up to two (2) Persons elected to the Symphony
Icon Board after the Closing Date (who shall be neither employees of Symphony Capital nor of
Lexicon) in accordance with the Symphony Icon Charter, the Symphony Icon By-laws and Section
4(b)(v) of the Purchase Option Agreement.

          “FDA” means the United States Food and Drug Administration or its successor agency in
the United States.

 

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

          “FDA Sponsor” has the meaning set forth in Section 5.1 of the Amended and
Restated Research and Development Agreement.

          “Final Termination Date” has the meaning set forth in Section 1(c)(iii) of the
Purchase Option Agreement.

          “Financial Audits” has the meaning set forth in Section 6.7 of the Amended and
Restated Research and Development Agreement.

          “Financing” has the meaning set forth in the Preliminary Statement of the Purchase
Option Agreement.

          “Fiscal Year” has the meaning set forth in each Operative Document in which it
appears.

          “Form S-3” means the Registration Statement on Form S-3 as defined under the
Securities Act.

          “FTE” means the time and effort of one or more qualified scientists, technicians,
project managers, preclinical or clinical research personnel, regulatory personnel, or patent
professionals that is equivalent to [**]. The percentage of a FTE billable by Lexicon to the
Programs for one individual shall be determined by dividing the number of hours worked directly by
said individual on one or more of the Programs, [**], by [**], with the further limitation that one
individual cannot account for more than one FTE over any annual period.

          “Funds Termination Date” has the meaning set forth in Section 1(c)(iii) of the
Purchase Option Agreement.

          “Funds Termination Notice” has the meaning set forth in Section 1(c)(iii) of
the Purchase Option Agreement.

          “GAAP” means generally accepted accounting principles in effect in the United States
of America from time to time.

          “Governmental Approvals” means authorizations, consents, orders, declarations or
approvals of, or filings with, or terminations or expirations of waiting periods imposed by any
Governmental Authority.

          “Governmental Authority” means any United States or non-United States federal,
national, supranational, state, provincial, local, or similar government, governmental, regulatory
or administrative authority, agency or commission or any court, tribunal, or judicial or arbitral
body.

 

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

          “Governmental Order” means any order, writ, judgment, injunction, decree, stipulation,
determination or award entered by or with any Governmental Authority.

          “Hedge Agreement” means any interest rate swap, cap or collar agreement, interest rate
future or option contract, currency swap agreement, currency future or option contract or other
similar hedging agreement.

          “Holdings” means Symphony Icon Holdings LLC, a Delaware limited liability company.

          “Holdings Claims” has the meaning set forth in Section 5.01 of the Share
Purchase Agreement.

          “Holdings LLC Agreement” means the Amended and Restated Limited Liability Company
Agreement of Holdings dated as of the Closing Date.

          “HSR Filings” means the pre-merger notification and report forms required under the
Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.

          “Icon Relevant Infringement” means an infringement, misappropriation, illegal use or
misuse of the Licensed Patent Rights or other Licensed Intellectual Property due to the
manufacture, use, sale or importation of a LG103 Product or a LG617 Product.

          “IND” means an Investigational New Drug Application, as described in 21 U.S.C. §
355(i)(1) and 21 C.F.R. § 312 in the regulations promulgated by the United States Food and Drug
Administration, or any foreign equivalent thereof.

          “Indemnification Agreement” means the Indemnification Agreement among Symphony Icon
and the Directors named therein, dated as of the Closing Date, as such agreement may be amended or
amended and restated from time to time.

          “Indemnified Party” has the meaning set forth in each Operative Document in which it
appears.

          “Indemnified Proceeding” has the meaning set forth in each Operative Document in which
it appears.

          “Indemnifying Party” has the meaning set forth in each Operative Document in which it
appears.

          “Initial Development Budget” means the initial development budget prepared by
representatives of Symphony Icon and Lexicon prior to the Closing Date, and attached to the Amended
and Restated Research and Development Agreement as Annex C thereto.

 

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

          “Initial Development Plan” means the initial development plan prepared by
representatives of Symphony Icon and Lexicon prior to the Closing Date, and attached to the Amended
and Restated Research and Development Agreement as Annex C thereto.

          “Initial Holdings LLC Agreement” means the Agreement of Limited Liability Company of
Holdings, dated April 30, 2007.

          “Initial Investors LLC Agreement” means the Agreement of Limited Liability Company of
Investors, dated April 30, 2007.

          “Initial LLC Member” has the meaning set forth in Section 1.01 of the Holdings
LLC Agreement.

          “Interest Certificate” has the meaning set forth in Section 1.01 of the
Holdings LLC Agreement.

          “Investment Company Act” means the Investment Company Act of 1940, as amended.

          “Investment Overview” means the investment overview describing the transactions
entered into pursuant to the Operative Documents.

          “Investment Policy” has the meaning set forth in Section 1(a)(vi) of the RRD
Services Agreement.

          “Investors” means Symphony Icon Investors LLC.

          “Investors LLC Agreement” means the Amended and Restated Agreement of Limited
Liability Company of Investors dated as of the Closing Date.

          “IRS” means the U.S. Internal Revenue Service.

          “Key Personnel” means those Lexicon Personnel listed on Schedule 6.5 to the
Amended and Restated Research and Development Agreement, as such schedule may be updated from time
to time by mutual agreement of the parties to the Amended and Restated Research and Development
Agreement.

          “Know-How” means any and all proprietary technology, including without limitation,
manufacturing processes or protocols, know-how, writings, documentation, data, technical
information, techniques, results of experimentation and testing, diagnostic and prognostic assays,
specifications, databases, any and all laboratory, research, pharmacological, toxicological,
analytical, quality control pre-clinical and clinical data, and other information and materials,
whether or not patentable.

 

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

          “Knowledge” of Lexicon, Symphony Icon or Holdings, as the case may be, means the
actual (and not imputed) knowledge of the executive officers or managing member of such Person
without the duty of inquiry or investigation.

          “Law” means any law, statute, treaty, constitution, regulation, rule, ordinance, order
or Governmental Approval, or other governmental restriction, requirement or determination, of or by
any Governmental Authority.

          “Lexicon” means Lexicon Pharmaceuticals, Inc., a Delaware corporation (f/k/a Lexicon
Genetics Incorporated).

          “Lexicon Accounting Advisor” means Ernst & Young LLP.

          “Lexicon Common Stock” means the common stock, par value $0.001 per share, of Lexicon.

          “Lexicon Common Stock Valuation” has the meaning set forth in Section 2(e) of
the Purchase Option Agreement.

          “Lexicon Funding Notice” has the meaning set forth in Section 2(b) of the
Research Cost Sharing, Payment and Extension Agreement.

          “Lexicon Obligations” has the meaning set forth in Section 6.1(a) of the
Amended and Restated Research and Development Agreement.

          “Lexicon Payment Amount” has the meaning set forth in Paragraph 14 of the
Development Committee Charter.

          “Lexicon Personnel” has the meaning set forth in Section 8.4 of the Amended
and Restated Research and Development Agreement.

          “Lexicon Public Filings” means all publicly available filings made by Lexicon with the
SEC.

          “Lexicon Subcontractor” means a third party that has entered into a Subcontracting
Agreement with Lexicon.

          “LG103” means [**].

          “LG103 Product” means pharmaceutical compositions that Target LG103, including
pharmaceutical compositions comprising LX1031, LX1032 and/or backups.

          “LG103 Program” means the development, manufacture and/or use of any LG103 Product.

          “LG617” means [**].

 

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

          “LG617 Product” means pharmaceutical compositions that Target LG617, including
pharmaceutical compositions comprising LX6171 and/or backups.

          “LG617 Program” means the development, manufacture and/or use of any LG617 Product.

          “License” has the meaning set forth in the Preliminary Statement of the Purchase
Option Agreement.

          “Licensed Intellectual Property” means the Licensed Patent Rights and the Licensed
Know-How.

          “Licensed Know-How” means any and all Know-How that is [**].

          “Licensed Patent Rights” means:

          (a) [**];

          (b) [**]; and

          (c) [**].

          “Licensed Patent Rights” include [**].

          “Licensor” means Lexicon.

          “Lien” has the meaning set forth in Section 1.01 of the Holdings LLC
Agreement.

          “Liquidating Event” has the meaning set forth in Section 8.01 of the Holdings
LLC Agreement.

          “LLC Agreements” means the Initial Holdings LLC Agreement, the Holdings LLC Agreement,
the Initial Investors LLC Agreement and the Investors LLC Agreement.

          “Loss” has the meaning set forth in each Operative Document in which it appears.

          “LX1031” means [**].

          “LX1032” means [**].

          “LX6171” means [**].

          “Management Fee” has the meaning set forth in Section 6(a) of the RRD Services
Agreement.

 

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

          “Management Services” has the meaning set forth in Section 1(a) of the RRD
Services Agreement.

          “Manager” means (i) for each LLC Agreement in which it appears, the meaning set forth
in such LLC Agreement, and (ii) for each other Operative Document in which it appears, RRD in its
capacity as the provider of Management Services on behalf of Symphony Icon pursuant to the RRD
Services Agreement.

          “Manager Event” has the meaning set forth in Section 3.01(g) of the Holdings
LLC Agreement.

          “Manufacturing Subcontracting Agreement” means a Subcontracting Agreement that is
directly related to the manufacture of Product (including procurement of components and development
of improved manufacturing methods).

          “Material Adverse Effect” means, with respect to any Person, a material adverse effect
on (i) the business, assets, property or condition (financial or otherwise) of such Person or, (ii)
its ability to comply with and satisfy its respective agreements and obligations under the
Operative Documents or, (iii) the enforceability of the obligations of such Person under any of the
Operative Documents to which it is a party.

          “Medical Discontinuation Event” means [**].

          “Membership Interest” means (i) for each LLC Agreement in which it appears, the
meaning set forth in such LLC Agreement, and (ii) for each other Operative Document in which it
appears, the meaning set forth in the Holdings LLC Agreement.

          “NASDAQ” means the Nasdaq Stock Market, Inc.

          “NDA” means a New Drug Application, as defined in the regulations promulgated by the
United States Food and Drug Administration, or any foreign equivalent thereof.

          “Non-Lexicon Capital Transaction” means any (i) sale or other disposition of all or
part of the Symphony Icon Shares or all or substantially all of the operating assets of Symphony
Icon, to a Person other than Lexicon or an Affiliate of Lexicon or (ii) distribution in kind of the
Symphony Icon Shares following the unexercised expiration or termination of the Purchase Option.

          “Novated and Restated Technology License Agreement” means the Novated and Restated
Technology License Agreement, dated as of the Closing Date, among Lexicon, Symphony Icon and
Holdings.

          “Operative Documents” means, collectively, the Indemnification Agreement, the Holdings
LLC Agreement, the Purchase Option Agreement, the Share Purchase Agreement, the Registration Rights
Agreement, the Subscription Agreement,

 

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

the Technology License Agreement, the Novated and Restated Technology License Agreement, the
RRD Services Agreement, the Research and Development Agreement, the Research Cost Sharing, Payment
and Extension Agreement, the Amended and Restated Research and Development Agreement, the
Confidentiality Agreement, and each other certificate and agreement executed in connection with any
of the foregoing documents.

          “Organizational Documents” means any certificates or articles of incorporation or
formation, partnership agreements, trust instruments, bylaws or other governing documents.

          “Partial Stock Payment” has the meaning set forth in Section 3(a)(iii) of the
Purchase Option Agreement.

          “Party(ies)” means, for each Operative Document or other agreement in which it
appears, the parties to such Operative Document or other agreement, as set forth therein. With
respect to any agreement in which a provision is included therein by reference to a provision in
another agreement, the term “Party” shall be read to refer to the parties to the document
at hand, not the agreement that is referenced.

          “Payment Terms” has the meaning set forth in Section 8.2 of the Amended and
Restated Research and Development Agreement.

          “Percentage” has the meaning set forth in Section 1.01 of the Holdings LLC
Agreement.

          “Permitted Investments” has the meaning set forth in Section 1.01 of the
Holdings LLC Agreement.

          “Permitted Lien” has the meaning set forth in Section 1.01 of the Holdings LLC
Agreement.

          “Person” means any individual, partnership (whether general or limited), limited
liability company, corporation, trust, estate, association, nominee or other entity.

          “Personnel” of a Party means such Party, its employees, subcontractors, consultants,
representatives and agents.

          “Prime Rate” means the quoted “Prime Rate” at JPMorgan Chase Bank or, if such
bank ceases to exist or is not quoting a base rate, prime rate reference rate or similar rate for
United States dollar loans, such other major money center commercial bank in New York City selected
by the Manager.

          “Product” means a LG617 Product and/or a LG103 Product.

 

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

          “Profit” has the meaning set forth in Section 1.01 of the Holdings LLC
Agreement.

          “Programs” means the LG617 Program and/or the LG103 Program.

          “Program Specific Budget Component” has the meaning set forth in Section 4.1
of the Amended and Restated Research and Development Agreement.

          “Program-Specific Claim” means any claim in a patent or patent application in the
Licensed Patent Rights that is directed exclusively to (i) the composition of matter, formulations
or use of any Product or (ii) methods of treating humans by inhibiting, agonizing, or otherwise
modulating (i.e., acting through) LG103 or LG617.

          “Program-Specific Patents” means any and all Licensed Patent Rights that contain at
least one Program-Specific Claim.

          “Protocol” means a written protocol that meets the substantive requirements of
Section 6 of the ICH Guideline for Good Clinical Practice as adopted by the FDA, effective
May 9, 1997, and is included within the Development Plan or later modified or added to the
Development Plan pursuant to the Amended and Restated Research and Development Agreement.

          “Public Companies” has the meaning set forth in Section 5(e) of the Purchase
Option Agreement.

          “Purchase Option” has the meaning set forth in Section 1(a) of the Purchase
Option Agreement.

          “Purchase Option Agreement” means the Purchase Option Agreement dated as of the
Closing Date, among Lexicon, Holdings and Symphony Icon.

          “Purchase Option Closing” has the meaning set forth in Section 2(a) of the
Purchase Option Agreement.

          “Purchase Option Closing Date” has the meaning set forth in Section 2(a) of
the Purchase Option Agreement.

          “Purchase Option Commencement Date” has the meaning set forth in Section
1(c)(iii) of the Purchase Option Agreement.

          “Purchase Option Exercise Date” has the meaning set forth in Section 2(a) of
the Purchase Option Agreement.

          “Purchase Option Exercise Notice” has the meaning set forth in Section 2(a) of
the Purchase Option Agreement.

 

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

          “Purchase Option Period” has the meaning set forth in Section 1(c)(iii) of the
Purchase Option Agreement.

          “Purchase Price” has the meaning set forth in Section 2(b) of the Purchase
Option Agreement.

          “QA Audits” has the meaning set forth in Section 6.6 of the Amended and
Restated Research and Development Agreement.

          “Registration Rights Agreement” means the Registration Rights Agreement dated as of
the Closing Date, between Lexicon and Holdings.

          “Registration Statement” has the meaning set forth in Section 1(b) of the
Registration Rights Agreement.

          “Regulatory Allocation” has the meaning set forth in Section 3.06 of the
Holdings LLC Agreement.

          “Regulatory Authority” means the United States Food and Drug Administration, or any
successor agency in the United States, or any health regulatory authority(ies) in any other country
that is a counterpart to the FDA and has responsibility for granting registrations or other
regulatory approval for the marketing, manufacture, storage, sale or use of drugs in such other
country.

          “Regulatory Files” means any IND, NDA or any other filings filed with any Regulatory
Authority with respect to the Programs.

          “Representative” of any Person means such Person’s shareholders, principals,
directors, officers, employees, members, managers and/or partners.

          “Research Cost Sharing, Payment and Extension Agreement” means the Research Cost
Sharing, Payment and Extension Agreement dated as of the Closing Date, among Lexicon, Holdings and
Symphony Icon.

          “Research and Development Agreement” means the Research and Development Agreement
dated as of the Closing Date, between Lexicon and Holdings.

          “RRD” means RRD International, LLC, a Delaware limited liability company.

          “RRD Indemnified Party” has the meaning set forth in Section 10(a) of the RRD
Services Agreement.

          “RRD Loss” has the meaning set forth in Section 10(a) of the RRD Services
Agreement.

 

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

          “RRD Personnel” has the meaning set forth in Section 1(a)(ii) of the RRD
Services Agreement.

          “RRD Services Agreement” means the RRD Services Agreement between Symphony Icon and
RRD, dated as of the Closing Date.

          “Schedule K-1” has the meaning set forth in Section 9.02(a) of the Holdings
LLC Agreement.

          “Scheduled Meeting” has the meaning set forth in Paragraph 6 of Annex B of the Amended
and Restated Research and Development Agreement.

          “Scientific Discontinuation Event” has the meaning set forth in Section 4.2(c)
of the Amended and Restated Research and Development Agreement.

          “SCP” means Symphony Capital Partners, L.P., a Delaware limited partnership.

          “SEC” means the United States Securities and Exchange Commission.

          “Securities Act” means the Securities Act of 1933, as amended.

          “Selling Stockholder Questionnaire” has the meaning set forth in Section 4(a)
of the Registration Rights Agreement.

          “Share Closing” has the meaning set forth in Section 2.04 of the Share
Purchase Agreement.

          “Share Date” has the meaning set forth in Section 2.02 of the Share Purchase
Agreement.

          “Share Purchase Agreement” means the Share Purchase Agreement, dated as of the Closing
Date, between Lexicon and Holdings.

          “Shares” has the meaning set forth in Section 2.01 of the Share Purchase
Agreement.

          “Solvent” has the meaning set forth in Section 1.01 of the Holdings LLC
Agreement.

          “SSP” means Symphony Strategic Partners, LLC, a Delaware limited liability company.

          “Stock Payment Date” has the meaning set forth in Section 2 of the
Subscription Agreement.

 

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

          “Stock Purchase Price” has the meaning set forth in Section 2 of the
Subscription Agreement.

          “Subcontracting Agreement” means (a) any written agreement between Lexicon and a third
party pursuant to which the third party performs any Lexicon Obligations or (b) any work order,
change order, purchase order or the like entered into pursuant to Section 6.2(b) of the
Amended and Restated Research and Development Agreement.

          “Sublicense Obligations” has the meaning set forth in Section 3.2 of the
Novated and Restated Technology License Agreement.

          “Sublicensed Intellectual Property” has the meaning set forth in Section 3.2
of the Novated and Restated Technology License Agreement.

          “Subscription Agreement” means the Subscription Agreement between Symphony Icon and
Holdings, dated as the Closing Date.

          “Subsidiary” of any Person means any corporation, partnership, joint venture, limited
liability company, trust or estate of which (or in which) more than 50% of (a) the issued and
outstanding capital stock having ordinary voting power to elect a majority of the board of
directors of such corporation (irrespective of whether at the time capital stock of any other class
or classes of such corporation shall or might have voting power upon the occurrence of any
contingency); (b) the interest in the capital or profits of such partnership, joint venture or
limited liability company; or (c) the beneficial interest in such trust or estate is at the time
directly or indirectly owned or controlled by such Person, by such Person and one or more of its
other Subsidiaries or by one or more of such Person’s other Subsidiaries.

          “Surviving Entity” means the surviving legal entity which is surviving entity to
Lexicon after giving effect to a Change of Control.

          “Symphony Capital” means Symphony Capital LLC, a Delaware limited liability company.

          “Symphony Fund(s)” means Symphony Capital Partners, L.P., a Delaware limited
partnership, and Symphony Strategic Partners, LLC, a Delaware limited liability company.

          “Symphony Icon” means Symphony Icon, Inc., a Delaware corporation.

          “Symphony Icon Auditors” has the meaning set forth in Section 5(b) of the RRD
Services Agreement.

          “Symphony Icon Board” means the board of directors of Symphony Icon.

 

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

          “Symphony Icon By-laws” means the By-laws of Symphony Icon, as adopted by resolution
of the Symphony Icon Board on the Closing Date.

          “Symphony Icon Charter” means the Amended and Restated Certificate of Incorporation of
Symphony Icon, dated as of the Closing Date.

          “Symphony Icon Director Event” has the meaning set forth in Section 3.01(h)(i)
of the Holdings LLC Agreement.

          “Symphony Icon Enhancements” means [**].

          “Symphony Icon Equity Securities” means the Common Stock and any other stock or shares
issued by Symphony Icon.

          “Symphony Icon Loss” has the meaning set forth in Section 10(b) of the RRD
Services Agreement.

          “Symphony Icon Shareholder” means any Person who owns any Symphony Icon Shares.

          “Symphony Icon Shares” has the meaning set forth in Section 2.02 of the
Holdings LLC Agreement.

          “Tangible Materials” means [**].

          “Target” when used as a noun, means a human gene and the products encoded by such
gene, including, without limitation, (a) any partial or full-length DNA sequence from such gene
(including any mutant or polymorphic forms thereof), (b) any RNA sequence (including any
post-transcriptionally modified variants thereof) encoded by any such gene, and/or (c) any peptide,
polypeptide or protein (including any post-translationally modified variants thereof) encoded by
any such gene; and when used as a verb, means to inhibit, agonize, or otherwise modulate (i.e., act
through) any of the foregoing, as applicable.

          “Tax Amount” has the meaning set forth in Section 4.02 of the Holdings LLC
Agreement.

          “Technology License Agreement” means the Technology License Agreement, dated as of the
Closing Date, between Lexicon and Holdings.

          “Term” has the meaning set forth in Section 4(b)(iv) of the Purchase Option
Agreement, unless otherwise stated in the applicable Operative Document.

          “Territory” means the world.

 

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

          “Third Party IP” has the meaning set forth in Section 2.9 of the Novated and
Restated Technology License Agreement.

          “Third Party Licensor” means a third party from which Lexicon has received a license
or sublicense to Licensed Intellectual Property.

          “Transfer” has for each Operative Document in which it appears the meaning set forth
in such Operative Document.

          “Transferee” has, for each Operative Document in which it appears, the meaning set
forth in such Operative Document.

          “Treasury Regulations” means the rules, regulations and orders, and interpretations
thereof, adopted by the IRS under the Code, as in effect from time to time.

          “Voluntary Bankruptcy” has the meaning set forth in Section 1.01 of the
Holdings LLC Agreement.

 

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

ANNEX B

CERTAIN ROYALTY AND MILESTONE PAYMENTS

NONE

B-1

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

ANNEX C

CERTAIN LICENSED PATENTS

[**]

C-1exv10w2

 

Exhibit 10.2

Confidential materials omitted and filed separately with
the Securities and Exchange Commission. Asterisks denote omissions.

 

AMENDED AND RESTATED

RESEARCH AND DEVELOPMENT AGREEMENT

among

LEXICON PHARMACEUTICALS, INC.

SYMPHONY ICON HOLDINGS LLC

and

SYMPHONY ICON, INC.

 

Dated as of June 15, 2007

 

 

1

 

Confidential materials omitted and filed separately with
the Securities and Exchange Commission. Asterisks denote omissions.

TABLE OF CONTENTS

	 	 	 	 	 
	 	 	Page
	1. Assignment
	 	 	1	 
	 
	 	 	 	 
	2. Overview of Development
	 	 	1	 
	 
	 	 	 	 
	3. Development Committee
	 	 	2	 
	 
	 	 	 	 
	4. Development Plan and Development Budget
	 	 	3	 
	4.1 Generally
	 	 	3	 
	4.2 Amendments
	 	 	3	 
	4.3 Lexicon Funded Research
	 	 	4	 
	 
	 	 	 	 
	5. Regulatory Matters
	 	 	5	 
	5.1 FDA Sponsor
	 	 	5	 
	5.2 Correspondence
	 	 	5	 
	5.3 Inspections and Meetings
	 	 	6	 
	5.4 Transfer of FDA Sponsorship
	 	 	6	 
	 
	 	 	 	 
	6. Lexicon’s Obligations
	 	 	7	 
	6.1 Generally
	 	 	7	 
	6.2 Subcontracting
	 	 	8	 
	6.3 Reports and Correspondence
	 	 	8	 
	6.4 Staffing
	 	 	9	 
	6.5 QA Audit
	 	 	9	 
	6.6 Financial Audit
	 	 	10	 
	6.7 Insurance
	 	 	10	 
	 
	 	 	 	 
	7. Symphony Icon’s Obligations
	 	 	11	 
	7.1 Generally
	 	 	11	 
	7.2 Subcontracting
	 	 	11	 
	7.3 Insurance
	 	 	11	 
	7.4 Staffing
	 	 	11	 
	7.5 Inspection and Audit
	 	 	11	 
	 
	 	 	 	 
	8. Funding and Payments
	 	 	12	 
	8.1 Use of Proceeds
	 	 	12	 
	8.2 Reimbursement
	 	 	13	 
	8.3 Budget Allocation and Deviations
	 	 	13	 
	8.4 Employee Benefits
	 	 	13	 
	 
	 	 	 	 
	9. Covenants
	 	 	14	 
	9.1 Mutual Covenants
	 	 	14	 

 

	 	 	 	 	 
	 	 	Page
	10. Confidentiality
	 	 	15	 
	 
	 	 	 	 
	11. Discontinuation Option
	 	 	15	 
	 
	 	 	 	 
	12. Representations and Warranties
	 	 	16	 
	12.1 Lexicon Representations and Warranties
	 	 	16	 
	12.2 Symphony Icon Representations and Warranties
	 	 	18	 
	 
	 	 	 	 
	13. Relationship Between Lexicon and Symphony Icon
	 	 	19	 
	 
	 	 	 	 
	14. Change of Control
	 	 	20	 
	 
	 	 	 	 
	15. No Restrictions; Indemnification
	 	 	20	 
	15.1 No Restrictions
	 	 	20	 
	15.2 Indemnification
	 	 	20	 
	 
	 	 	 	 
	16. Limitation of Liabilities
	 	 	23	 
	16.1 Between the Parties
	 	 	23	 
	16.2 Pursuant to the RRD Services Agreement
	 	 	24	 
	 
	 	 	 	 
	17. Term and Termination
	 	 	24	 
	17.1 Term
	 	 	24	 
	17.2 Termination for Lexicon’s Breach
	 	 	24	 
	17.3 Termination for Symphony Icon’s or Holdings’ Breach
	 	 	25	 
	17.4 Termination of License Agreement
	 	 	25	 
	17.5 Survival
	 	 	25	 
	 
	 	 	 	 
	18. Miscellaneous
	 	 	26	 
	18.1 No Petition
	 	 	26	 
	18.2 Notices
	 	 	26	 
	18.3 Governing Law; Consent to Jurisdiction and Service of Process
	 	 	27	 
	18.4 Waiver of Jury Trial
	 	 	28	 
	18.5 Entire Agreement
	 	 	28	 
	18.6 Amendment; Successors; Assignment; Counterparts
	 	 	28	 
	18.7 Severability
	 	 	29	 
	18.8 Third Party Beneficiary
	 	 	29	 

Annex A — Certain Definitions

Annex B — Development Committee Charter

Annex C — Initial Development Plan and Initial Development Budget

Annex D — [Intentionally Omitted.]

Annex E — Payment Terms

Schedule 6.2 — Subcontracting Agreements

Schedule 6.4 — Lexicon Key Personnel

Schedule 12.1(f) — Material Disclosed Contracts

ii

 

Confidential materials omitted and filed separately with
the Securities and Exchange Commission. Asterisks denote omissions.

AMENDED AND RESTATED

RESEARCH AND DEVELOPMENT AGREEMENT

     This AMENDED AND RESTATED RESEARCH AND DEVELOPMENT AGREEMENT (this “Agreement”) is
entered into as of June 15, 2007 (the “Closing Date”) by and among LEXICON PHARMACEUTICALS,
INC., a Delaware corporation (“Lexicon”), SYMPHONY ICON, INC., a Delaware corporation
(“Symphony Icon”) (each of Lexicon and Symphony Icon being a “Party,” and
collectively, the “Parties”), and SYMPHONY ICON HOLDINGS LLC, a Delaware limited liability
company (“Holdings”). Capitalized terms used herein and not defined herein shall have the
meanings assigned to such terms in Annex A attached hereto.

PRELIMINARY STATEMENT

     Lexicon and Holdings have entered into that certain Research and Development Agreement, dated
as of June 15, 2007 (the “Research and Development Agreement”). Pursuant to this
Agreement, Holdings desires to assign all of its rights and delegate its obligations under the
Research and Development Agreement to Symphony Icon, and Lexicon and Symphony Icon desire to amend
and restate the terms and conditions of the Research and Development Agreement.

     In the Novated and Restated Technology License Agreement, Lexicon grants Symphony Icon an
exclusive license to develop and commercialize the Products. Symphony Icon wishes for Lexicon to
continue to develop such Products. Symphony Icon and Lexicon desire to establish, and agree on the
responsibilities of, a Development Committee to oversee such development. Lexicon and Symphony
Icon further desire to comply with and perform certain agreements and obligations related thereto.

     The Parties hereto agree as follows:

     1. Assignment. The Parties agree that from and after the Closing Date, all of the
rights and obligations of Holdings under the Research and Development Agreement will be assigned
and transferred to, and assumed by, Symphony Icon.

     2. Overview of Development.

                         (a) The Parties shall develop the Programs in a collaborative and efficient manner as set
forth in this Article 2. Representatives of the Parties shall engage in joint
decision-making for the Programs as set forth in Articles 3 and 4 hereof. Symphony
Icon shall have overall responsibility for all matters set forth in the Development Plan (pursuant
to Article 7 hereof), and shall engage Lexicon (pursuant to Article 6 hereof), RRD
(pursuant to the RRD Services Agreement), and such independent contractors and agents as Lexicon
may retain on Symphony Icon’s behalf or as it may retain with RRD’s assistance (which contractors
include entities retained by Lexicon prior to the Closing Date pursuant to the Subcontracting
Agreements set forth on

 

Confidential materials omitted and filed separately with
the Securities and Exchange Commission. Asterisks denote omissions.

Schedule 6.2), to act on behalf of Symphony Icon and carry out the duties set forth
therein and herein.

                         (b) With respect to the LG617 Program and the LG103 Program, Lexicon shall be responsible for
the execution of all pre-clinical and clinical development, all scientific and technical services
associated with such development, and all patent work, including all related matters set forth in
the Development Plan for such Programs.

                         (c) Nothing in Section 2(b) shall in any way limit the authority of the Development
Committee (as defined below) or the Symphony Icon Board hereunder, and the engagements and
delegations set forth therein shall be subject to the terms and conditions of this Agreement and
the RRD Services Agreement, and the satisfactory performance by RRD and Lexicon of their
obligations pursuant hereto and thereto. The allocations of responsibility described in this
Article 2 shall remain subject to further modification in accordance with the terms and
conditions of this Agreement and the RRD Services Agreement.

                         (d) Lexicon hereby acknowledges and agrees to Symphony Icon’s engagement of RRD to act on its
behalf and to carry out the duties assigned to RRD herein and in the RRD Services Agreement,
including, but not limited to (i) providing personnel and support to the Development Committee and
the Symphony Icon Board, (ii) the management and administration of Symphony Icon, (iii) monitoring
Lexicon’s implementation of the Programs, and (iv) subject to Section 6.1(a) and without
limiting Lexicon’s role thereunder, such other development-related work as Symphony Icon may
reasonably delegate to RRD in accordance with the Development Plan.

                         (e) The Parties acknowledge that, subject to the rights of Symphony Icon under the Operative
Documents, Lexicon may enter into arrangements with one or more third parties with respect to the
development and commercialization of one or more Programs or Products; provided that such
arrangements are consistent with Lexicon’s potential reversionary interest in the Programs and/or
Products. In the event Lexicon enters into any such arrangement, subject to the rights of Symphony
Icon under the Operative Documents, Symphony Icon will use reasonable efforts to accommodate
requests by Lexicon with respect to the participation of such third party in development activities
hereunder relating to such Program or Product, including without limitation, participation or
observation rights for Development Committee meetings and activities; provided such participation
shall be limited to the applicable Programs or Products.

     3. Development Committee. The Parties shall establish and maintain a committee (the
“Development Committee”) to oversee the development of the Programs (including the
continued development and refinement of the Development Plan and the Development Budget). The
Development Committee shall be established, operated and governed in accordance with the policies
and procedures set forth in Annex B hereto (the “Development Committee Charter”).
The Development Committee Charter may be amended only with the unanimous approval of the
Development

2

 

Confidential materials omitted and filed separately with
the Securities and Exchange Commission. Asterisks denote omissions.

Committee Members and the consent of the Symphony Icon Board, Holdings and Lexicon. In no
event shall the Development Committee have the power to amend the terms of any Operative Document.

     4. Development Plan and Development Budget.

          4.1 Generally. The Parties have agreed, as of the Closing Date, to an Initial
Development Plan and an Initial Development Budget, which are attached hereto and incorporated
herein as Annex C, and which shall be further developed and refined from time to time in
accordance herewith. The Initial Development Plan consists (and the Development Plan shall
consist) of detailed provisions governing all research, pre-clinical, clinical, development,
manufacturing, scientific, technical, regulatory and patent work to be performed under the
Operative Documents. Following the Closing Date, the Development Committee shall, on an ongoing
basis, further develop the Development Plan to include, without limitation, (i) an outline of the
plan for the clinical development of each Program; and (ii) outlines of non-clinical activities,
key regulatory and quality activities, and CMC activities for each Program. The Initial
Development Budget consists (and the Development Budget shall consist) of two (2) components: (x)
a development budget for each Program covered by the Development Plan (the “Program Specific
Budget Component”), and (y) a budget for the cross program management and administrative
functions of Symphony Icon, as set forth in Section 1(a) of the RRD Services Agreement (the
“Cross Program Budget Component”). The development budgets for each Program in the Program
Specific Budget Component covered by the Development Plan shall be further divided into budget
spreadsheets summarizing (1) anticipated costs of engaging third party service providers and the
scope of work to be performed by such third parties; and (2) the number of FTEs to be dedicated to
the Programs (by function and work responsibilities, on a Program-by-Program basis). All presently
anticipated or actual expenditures of Symphony Icon, [**] , are included in the Initial Development
Budget attached hereto, and will continue to be included in any amendments thereof. The
Development Committee shall, at the request of the Symphony Icon Board, submit the Development Plan
and the Development Budget (as each shall have been developed and refined up to such point) to the
Symphony Icon Board for its review at the first meeting of the Symphony Icon Board. Following the
Symphony Icon Board’s review, the Development Committee shall work diligently to incorporate any
comments generated by the Symphony Icon Board’s review and update the Development Plan and the
Development Budget as soon as practicable, and submit the updated Development Plan and the updated
Development Budget to the Symphony Icon Board for further review.

          4.2 Amendments.

                         (a) All amendments of, and all material deviations from, the Development Plan and Development
Budget (including amendments or deviations made at the request of Lexicon or RRD, in accordance
with Section 8.3 hereof or Section 2(b) of the RRD Services Agreement,
respectively) shall be made in

3

 

Confidential materials omitted and filed separately with
the Securities and Exchange Commission. Asterisks denote omissions.

accordance with the procedures described in this Article 4 and in the Development
Committee Charter, including obtaining the approval of the Symphony Icon Board, as may be required
by the Development Committee Charter.

                         (b) The Development Committee shall review the Development Plan and Development Budget [**] to
determine whether any changes are required, and shall comply with all procedures required to amend
the Development Plan or Development Budget to implement such changes. Furthermore, following the
Closing Date, the Development Committee shall, on an ongoing basis, continue to develop the
Development Plan, including, without limitation, as set forth in Section 4.1 and in
response to requests, proposals or reports from Lexicon and RRD to the Development Committee.

                         (c) A Program, or a Product within a Program, may only be discontinued in the event that
either (i) the Parties mutually agree to discontinue such Program or Product based on (A) a Medical
Discontinuation Event, or (B) scientific evidence (regardless of whether such evidence is generated
by a Party or a third party) that [**] (a “Scientific Discontinuation Event”) that arises
in the course of developing such Program or Product; or (ii) upon recommendation of the Development
Committee, the Symphony Icon Board resolves to discontinue such Program or Product by (A) [**], or
(B) [**] ; provided, that notwithstanding the foregoing, the Symphony Icon Board may at any
time, by the applicable vote described in this clause (ii), discontinue a Program or
Product upon a Medical Discontinuation Event without a prior recommendation of the Development
Committee. The Development Committee shall promptly thereafter amend the Development Plan to
reflect such discontinuation and amend the Development Budget to reallocate to any or all of the
remaining Programs some or all of the funds previously allocated to the discontinued Program or
Product (with any funds not then allocated to be held for reallocation by the Development
Committee).

                         (d) The Development Plan shall never be amended in any manner that would require Lexicon or
Symphony Icon (or any Person acting on behalf of Lexicon or Symphony Icon (including RRD and its
RRD Personnel)) to perform any assignments or tasks in a manner that would violate any applicable
law or regulation. In the event of a change in any applicable law or regulation, the Development
Committee shall consider amending the Development Plan to enable Lexicon or Symphony Icon (or any
Person acting on behalf of Lexicon or Symphony Icon (including RRD and its RRD Personnel)), as the
case may be, to comply fully with such law or regulation. If such amendment is not approved, the
affected Party shall be excused from performing any activity specified herein or in the Development
Plan that would violate or result in a violation of any applicable law or regulation.

          4.3 Lexicon Funded Research. Lexicon and Symphony Icon hereby agree that, until the
end of the Term, Lexicon, upon request to the Development Committee, using commercially reasonable
methods, may expend its own funds to extend, increase, or otherwise modify, outside the scope of
the Development Plan, the trials and development activities run by Lexicon, subject to the prior
approval of the

4

 

Confidential materials omitted and filed separately with
the Securities and Exchange Commission. Asterisks denote omissions.

Development Committee. The Development Committee shall consider any such request in good
faith taking into account the fact that Symphony Icon will receive the benefits, if any, of such
additional activities, without any cost to Symphony Icon as well as taking into account the risks,
if any, of such activities to the relevant Program. Such additional Lexicon-supplied funds shall
not be included in the calculations used to determine the Discontinuation Price (pursuant to
Section 11(a) hereof) or the Purchase Price (pursuant to Section 2(b) of the Purchase
Option Agreement). Lexicon agrees that the results of such research and development shall
immediately become part of the Licensed Intellectual Property and shall thereafter be subject to
the terms of the Operative Documents. Lexicon’s rights pursuant to this Section 4.3 are in
addition to, and separate from, its rights pursuant to Section 8.3 hereof.

     5. Regulatory Matters.

          5.1 FDA Sponsor. Notwithstanding any governance provision contained herein or in any
Operative Document, the Parties agree that, until the termination or unexercised expiration of the
Purchase Option, Lexicon shall be the FDA sponsor, and shall serve the equivalent role with respect
to any corresponding recognized regulatory authority outside of the United States, for the
Programs, except any Programs which were the subject of a Discontinuation Option that was not
exercised by Lexicon (the “FDA Sponsor”). As the FDA Sponsor, Lexicon shall have the
responsibility and the authority to act as the sponsor and make those decisions and take all
actions necessary to assure compliance with all regulatory requirements. Lexicon agrees to be
bound by, and perform all obligations set forth in, 21 C.F.R. § 312 and any and all similar
obligations imposed by a recognized foreign regulatory authority related to Lexicon’s role as the
FDA Sponsor. Notwithstanding anything to the contrary in Article 4 or the Development
Committee Charter, Lexicon, in its capacity as FDA Sponsor, may discontinue or modify any Program
without the approval of the Development Committee or the Symphony Icon Board in the event such
actions are: (a) attributable to an event that is reportable to the FDA or corresponding recognized
regulatory authority outside of the United States; and (b) reasonably necessary to avoid the
imposition of criminal or civil liability; provided, however, that to the extent
commercially reasonable, Lexicon shall (i) pursuant to Section 5.2, advise and consult with
the Development Committee prior to taking such action and (ii) forward a copy of all regulatory
correspondence relevant to such discontinuation or modification to the members of the Symphony Icon
Board.

          5.2 Correspondence. Each Party hereto acknowledges that Lexicon, in its capacity as
FDA Sponsor, shall be the Party responding to any regulatory correspondence or inquiry regarding
one or both Programs. Lexicon shall: (a) notify at least one (1) Development Committee Member
designated by Holdings within [**] of any FDA or other governmental or regulatory inspection or
inquiry concerning any study or project under the Programs, including, but not limited to,
inspections of investigational sites or laboratories; and (b) forward to the Development Committee
copies of any correspondence from any regulatory or governmental agency relating to such a study or
project, including, but not limited to, Form FD-483 notices and FDA refusal to file,

5

 

Confidential materials omitted and filed separately with
the Securities and Exchange Commission. Asterisks denote omissions.

action or warning letters, even if they do not specifically mention Symphony Icon. Subject to
the following sentence, Symphony Icon shall not have any right to initiate any regulatory
correspondence with respect to the Programs. In the event that Symphony Icon receives a request or
notification from a Governmental Authority with respect to the Programs, Symphony Icon shall: (i)
notify Lexicon within [**] of receipt of such request or communication and (ii) to the extent
practicable, submit any proposed response to Lexicon for review and approval; provided,
that such approval shall not be unreasonably withheld and shall not prevent Symphony Icon from
complying with any legal requirements. Furthermore, Lexicon shall be the Party responsible for
responding to or handling any FDA or regulatory inspection with respect to one or both Programs;
provided, that Lexicon shall notify at least one (1) of the Development Committee Members
designated by Holdings (i) within [**] of receiving notice of the commencement of a clinical hold
for any Protocol, and (ii) concurrently with its submission to the FDA of any IND safety reports
for the Programs.

          5.3 Inspections and Meetings. Each Party agrees that, during an inspection by the FDA
or other Regulatory Authority concerning any study or project under the Programs, it will not
disclose to such agency any information and materials (including but not limited to (x) financial
data and pricing data including, but not limited to, budget and payment schedules, (y) sales data
(other than shipment data), and (z) personnel data (other than data as to qualification of
technical and professional persons performing functions subject to regulatory requirements)) that
are not required to be disclosed to such agency without first obtaining the consent of the other
Party, which consent shall not be unreasonably withheld or delayed, except to the extent
that such Party may be required by law to disclose such information and materials. Lexicon shall
be the Party responsible for arranging and participating in any meetings with any Regulatory
Authority concerning one or both Programs. To the extent practicable, Lexicon shall consult with
the Development Committee prior to any such meetings and provide to the Development Committee for
review all relevant correspondence to date. During Lexicon’s consultation with the Development
Committee, Lexicon and the Development Committee shall discuss and agree upon issues including but
not limited to overall regulatory strategy, proposed agendas, goals and objectives, preparation and
attendees. Following any meeting that pertains to a Program, but that was not attended by at least
one (1) of the Development Committee Members designated by Holdings, Lexicon shall provide at least
one (1) of the Development Committee Members designated by Holdings with an oral summary of that
meeting within [**] of such meeting and a written summary of that meeting within [**] of such
meeting.

          5.4 Transfer of FDA Sponsorship.

                         (a) On or prior to the thirtieth (30th) day after the unexercised expiration or termination of
the Purchase Option, Lexicon shall cease to act as the FDA Sponsor for the Programs for which
Lexicon has not exercised a Discontinuation Option, and Lexicon and Symphony Icon shall, at
Symphony Icon’s expense, take all actions necessary to effect the transfer of (x) the Regulatory
Files

6

 

Confidential materials omitted and filed separately with
the Securities and Exchange Commission. Asterisks denote omissions.

(subject to Symphony Icon’s rights under Section 2.7 of the Novated and Restated
Technology License Agreement) related to such Programs to Symphony Icon or its designee in
accordance with Section 2.7 of the Novated and Restated Technology License Agreement, and
(y) any and all materials necessary for Symphony Icon to practice or exploit the license granted to
it under the Novated and Restated Technology License Agreement, by such date. In conjunction with
such transfer, Lexicon shall assign to Symphony Icon or its designee, at Symphony Icon’s expense
and as of the date specified in the first sentence of this Section 5.4(a), all of the
material Development Subcontracting Agreements to which Lexicon is a party and that are assignable
to Symphony Icon or its designee without consent from the other party to the agreement. Lexicon
shall use commercially reasonable efforts to cause the assignment of any non-assignable material
Development Subcontracting Agreement or portion thereof relating to the Programs. If it is not
successful in causing such assignment, Lexicon shall act as Symphony Icon’s agent, at Symphony
Icon’s reasonable request and expense, in procuring all goods and services under such agreements
until such time as Symphony Icon enters into alternative arrangements to procure such services,
provided that Symphony Icon uses commercially reasonable efforts to enter into such
alternative arrangements as soon as possible. Lexicon agrees to take such commercially reasonable
actions as Symphony Icon may request in furtherance of the foregoing, at the expense of Symphony
Icon. Such efforts shall not include any obligation for Lexicon to incur any out-of-pocket costs.
Lexicon shall provide copies of all such Development Subcontracting Agreements to Symphony Icon, at
Symphony Icon’s expense, in connection with such transfer.

                         (b) Except as provided in the Amended and Restated Technology License Agreement, upon the
discontinuation of any of the Programs pursuant to Section 4.2(c), Lexicon shall have no
further obligations with respect to such Programs under the Operative Documents. If such Program
is transferred or licensed to a third party in accordance with Section 11 (such third
party, the “Transferee”), then Lexicon shall cooperate with Symphony Icon and the
Transferee to effect the assignment to the Transferee of the sponsorship to the Regulatory Files
(subject to Symphony Icon’s rights under Section 2.7 of the Novated and Restated Technology
License Agreement) that are related to such Program; provided, however, that
Lexicon shall not be obligated to take any action pursuant to this Section 5.4(b) for which
it will not receive full reimbursement from Symphony Icon or another party. The assignment of such
Regulatory Files to the Transferee does not include an assignment of any Licensed Intellectual
Property.

     6. Lexicon’s Obligations.

          6.1 Generally.

                         (a) Lexicon shall have primary responsibility for the implementation of the Programs. Without
limiting the foregoing, Lexicon shall specifically be responsible for (i) performing all
pre-clinical and clinical development for the LG617 Program and the LG103 Program in accordance
with the Development Plan,

7

 

Confidential materials omitted and filed separately with
the Securities and Exchange Commission. Asterisks denote omissions.

(ii) manufacturing of, or arranging for third parties to manufacture, Clinical Trial Materials
for the Programs, and carrying out the quality assurance therefor, in each case in accordance with
the Development Plan, and (iii) executing all other matters set forth in the Development Plan that
are delegated to Lexicon by Symphony Icon pursuant to the Development Plan (collectively, the
“Lexicon Obligations”).

                         (b) Lexicon agrees that it will work diligently and use commercially reasonable efforts to
discharge the Lexicon Obligations in a good scientific manner and in accordance with the
Development Plan, the Development Budget, and the terms of this Agreement.

          6.2 Subcontracting. All agreements between Lexicon and third parties (including
without limitation clinical research organizations and contract manufacturers) for such third
parties to perform any Lexicon Obligations (each such third party, a “Lexicon
Subcontractor” and each such agreement, a “Subcontracting Agreement”) entered into by
Lexicon prior to the Closing Date (except for those master service agreements executed prior to the
Closing Date that, only through the subsequent addition of a new work order, change order, project
or the like after the Closing Date, become Subcontracting Agreements) and listed on Schedule 6.2
hereto, shall be deemed to be acceptable to the Parties in all respects. Following the Closing
Date, Lexicon shall obtain approval of the Development Committee prior to entering into any
Subcontracting Agreement, issuing new work orders against existing Subcontracting Agreements, or
amending or terminating any Subcontracting Agreement, which approval shall not unreasonably be
withheld. Lexicon shall provide the Development Committee with a copy of each draft Subcontracting
Agreement. The Development Committee, or its designee(s), shall have [**] to approve or reject the
terms of such draft Subcontracting Agreement; provided that during such [**] period Lexicon
shall make appropriate representatives available to the Development Committee to discuss such
Subcontracting Agreement in good faith and reasonable detail and shall provide any information as
may be reasonably requested by the Development Committee or any member thereof. Only approval of
the terms of such draft Subcontracting Agreement will entitle Lexicon to reimbursement by Symphony
Icon for such Subcontracting Agreement. The terms of such draft Subcontracting Agreement shall be
deemed to have been approved if not objected to by any Development Committee Member within the [**]
period. The terms of any such Subcontracting Agreements shall be deemed the Confidential
Information of Lexicon and be subject to the rights and obligations set forth in the
Confidentiality Agreement. Lexicon shall monitor the performance of its Lexicon Subcontractors and
shall promptly notify the Development Committee with respect to any Lexicon Subcontractor
performance issues that may have a material adverse effect on the Programs. The Development
Committee shall have the authority to direct Lexicon to terminate any Subcontracting Agreement
pursuant to the terms thereof.

          6.3 Reports and Correspondence. Lexicon shall keep the Development Committee informed
of its activities under the Development Plan through regular reports, as set forth in this
Section 6.3. At each Scheduled Meeting of the

8

 

Confidential materials omitted and filed separately with
the Securities and Exchange Commission. Asterisks denote omissions.

          Development Committee, or according to a schedule agreed to by the Development Committee,
Lexicon shall, to the extent reasonably required by the Development Committee, provide a summary of
Lexicon’s activities and developments with respect to the Programs for the period following the
most recent preceding scheduled summary report. Such summary report shall include the following
types of information in a format and frequency as determined by the Development Committee: (i)
updates regarding (A) [**]; and (B) [**]; (ii) a copy of each standard clinical study progress
report for the Programs received by Lexicon during the preceding period from any of the clinical
research organizations engaged by Lexicon pursuant to any Subcontracting Agreements and a copy of
any final preclinical study reports for such Programs; (iii) a financial report, in a format agreed
upon by the Development Committee, itemizing actual spending under the Development Plan as well as
any variation from planned spending; (iv) if the portion of the Development Budget related to a
particular Program is altered to the extent that available funding for such Program no longer
appears to be adequate to complete the Program, an updated budget forecast; (v) copies of all
Subcontracting Agreements executed since the previous Development Committee Meeting; and (vi) such
other information as the Development Committee may reasonably request. Lexicon shall notify at
least one (1) of the Development Committee Members designated by Holdings as soon as possible, but
no later than within [**] of the occurrence of any event that has, or could reasonably be expected
to have, in Lexicon’s judgment in light of the circumstances existing at the time, a material
adverse effect on the Development Plan or the Development Budget and shall keep the Development
Committee regularly updated and informed with respect to any such event.

          6.4 Staffing. Lexicon shall use commercially reasonable efforts to provide such
sufficient and competent staff and Personnel (including, without limitation, such employees or
agents of, or independent contractors retained by, Lexicon) that have the skill and expertise
necessary to perform the Lexicon Obligations. Lexicon shall notify Symphony Icon in advance, if
practicable, and in any event promptly thereafter, of any change in Key Personnel involved in the
Programs.

          6.5 QA Audit. During the Term, Lexicon will permit Symphony Icon’s representatives
(such representatives to be identified by Symphony Icon in advance and reasonably acceptable to
Lexicon and to enter into a confidentiality agreement with Lexicon) to examine and audit, during
regular business hours, the work performed by Lexicon hereunder and the Lexicon facilities at which
such work is conducted to determine that Lexicon Obligations are being conducted in accordance with
the terms of the Agreement, the Development Plan and the Development Budget (“QA Audits”).
Symphony Icon shall give Lexicon reasonable advance notice of such QA Audits specifying the scope
of the audit. Symphony Icon shall reimburse Lexicon for its time associated with QA Audits;
provided, however, that should a particular QA Audit reveal a material deficiency
in Lexicon’s quality assurance procedures, then Lexicon will be responsible for all costs of such
QA Audit, including Symphony Icon’s reasonable costs associated with such QA Audit, the work to be
re-performed and the costs or expenses associated with curing such material deficiencies. Symphony
Icon and Lexicon

9

 

Confidential materials omitted and filed separately with
the Securities and Exchange Commission. Asterisks denote omissions.

shall meet to discuss the results of the QA Audit and, if required, jointly agree upon any
actions that will be required as a result of such QA Audit including defining material deficiencies
to be addressed. Lexicon shall make commercially reasonable efforts to reconcile all such
deficiencies found by Symphony Icon during such QA Audit.

          6.6 Financial Audit. During the Term, Lexicon will permit Symphony Icon’s
representatives (such representatives (i) to be identified by Symphony Icon in advance and
reasonably acceptable to Lexicon and (ii) to enter into a confidentiality agreement with Lexicon),
to verify Lexicon’s invoices, other receipts, and FTE records that are related to Lexicon’s
performance of the work under the Programs (“Financial Audits”), which review shall be
conducted during regular business hours and will take place no more than once per year, unless
otherwise agreed to by the Parties. Symphony Icon shall give Lexicon reasonable advance notice of
such Financial Audits specifying the scope of the audit, which shall not include work that has
previously undergone Financial Audits. Symphony Icon shall reimburse Lexicon for its time
associated with Financial Audits; provided, however, that should a particular
Financial Audit reveal an overstatement of costs and expenses in the reports submitted by Lexicon
to Symphony Icon for reimbursement purposes during the period covered by such Financial Audit that
exceeds [**] in the aggregate, then Lexicon will be responsible for all costs of such Financial
Audit, including Symphony Icon’s reasonable costs associated therewith. Symphony Icon and Lexicon
shall meet to discuss the results of the Financial Audit and, if required, jointly agree upon any
actions that will be required as a result of such Financial Audit including defining material
discrepancies to be addressed. Lexicon shall make commercially reasonable efforts to reconcile all
such discrepancies found by Symphony Icon during such Financial Audit. In addition, Lexicon shall,
during regular business hours, cooperate with, and promptly respond to, inquiries from the Symphony
Icon Auditors, if the Symphony Icon Auditors shall reasonably conclude that they require additional
information or clarification regarding any invoices, other receipts or FTE records submitted by
Lexicon.

          6.7 Insurance. Lexicon shall carry and maintain throughout the Term (i) clinical
trial liability insurance (including errors and omissions coverage and product coverage), at
Lexicon’s sole expense, with limits of at least [**], and (ii) property and casualty insurance
covering Products and other Lexicon assets used in executing the Development Plan in amounts
customarily carried by business entities with a size and risk profile similar to Lexicon, at
Lexicon’s sole expense, with limits of at least [**]. Symphony Icon and RRD shall be named as
additional insureds on all clinical trial liability insurance. Upon Symphony Icon’s request,
Lexicon shall instruct its insurance carrier(s) to promptly furnish to Symphony Icon certificates
reflecting such coverage and a representation indicating that such coverage shall not be canceled
or otherwise terminated during the Term without [**] prior written notice to Symphony Icon.
Notwithstanding anything to the contrary herein, this Section 6.7 shall survive for a
period of [**] following termination or expiration of this Agreement.

10

 

Confidential materials omitted and filed separately with
the Securities and Exchange Commission. Asterisks denote omissions.

     7. Symphony Icon’s Obligations.

          7.1 Generally. Symphony Icon shall have overall responsibility for all matters set
forth in the Development Plan, and shall be responsible for (i) executing or delegating its
management and administration responsibilities; and (ii) executing or delegating the development
activities set forth in the Development Plan. Symphony Icon shall, and shall instruct all Persons
whom it engages pursuant to Article 2 hereof to, perform its obligations hereunder and
under the Development Plan in good faith and in accordance with the applicable provisions of the
Development Plan and the Development Budget, and the terms of this Agreement.

          7.2 Subcontracting. Symphony Icon is subcontracting, and will in the future
subcontract, certain of its responsibilities under the Development Plan to Lexicon (pursuant
hereto), to RRD (pursuant to the RRD Services Agreement) and to other vendors and service providers
(pursuant to subcontracting agreements to be approved by the Development Committee);
provided, that Symphony Icon shall remain responsible for the performance of its
obligations hereunder notwithstanding any such arrangement. Each subcontracting agreement entered
into by Symphony Icon (except for the RRD Services Agreement) shall include a provision permitting
assignment at any time of the subcontracting agreement from Symphony Icon to Lexicon without the
subcontractor’s consent; provided that Symphony Icon may not assign its obligations under
any such subcontracting agreement to Lexicon without Lexicon’s prior written consent.

          7.3 Insurance. Symphony Icon shall maintain insurance with creditworthy insurance
companies against such risks and in such amounts as are usually maintained or insured against by
other companies of established repute engaged in the same or a similar business.

          7.4 Staffing. Symphony Icon shall use commercially reasonable efforts to provide, or
cause to be provided on its behalf (including Personnel retained by RRD), sufficient and competent
staff and Personnel that have the skill and expertise necessary to perform Symphony Icon’s
obligations under this Agreement, the RRD Services Agreement, the Development Plan and the
Development Budget, including, but not limited to, (i) carrying out its management and
administrative functions pursuant to the RRD Services Agreement, and (ii) carrying out its clinical
development duties in accordance with the RRD Services Agreement, this Agreement, the Development
Plan and the Development Budget. Symphony Icon shall notify Lexicon in advance, if practicable,
and in any event promptly thereafter, of any change in the key RRD Personnel involved in the
Programs.

          7.5 Inspection and Audit. Symphony Icon shall permit each of Lexicon, Holdings,
Investors and each Symphony Fund and their duly authorized representatives at all reasonable
business hours to inspect and audit (1) Symphony Icon’s books, records and other reasonably
requested materials and (2) any and all properties of

11

 

Confidential materials omitted and filed separately with
the Securities and Exchange Commission. Asterisks denote omissions.

Symphony Icon, and it shall provide to each of Lexicon, Holdings, Investors and each Symphony
Fund all books, records and other materials related to any meeting of the Symphony Icon Board or
Symphony Icon Shareholders and to permit Holdings, Investors and each Symphony Fund to make copies
or extracts therefrom; provided, that each aforementioned party may conduct one such
inspection or audit in each calendar year without cost to such party, and that any party conducting
additional inspections or audits shall reimburse the Manager for its reasonable costs and expenses
in facilitating such additional inspections or audits unless such additional inspections or audits
were performed to determine whether previously identified material deficiencies have been
addressed. Symphony Icon and the party conducting such inspection or audit, or such party’s
representative, shall meet to discuss the results of such inspection or audit and, if required,
jointly agree upon any actions that will be required as a result of such inspection or audit
including defining material discrepancies to be addressed. Symphony Icon shall make commercially
reasonable efforts to reconcile all such discrepancies found by Lexicon, Holdings, Investors or any
Symphony Fund during such inspection or audit.

     8. Funding and Payments.

          8.1 Use of Proceeds.

                         (a) Symphony Icon shall use any and all (i) proceeds received by Symphony Icon as a result of
the Financing (including proceeds of the Lexicon Payment Amount), (ii) indemnity payments received
by Symphony Icon, and (iii) payments received by Symphony Icon pursuant to first and third party
covered insurance claims, for the development of the Programs and general corporate purposes of
Symphony Icon, including the payment of all fees and expenses in accordance with the Development
Plan and the Development Budget, as may be modified from time to time pursuant to Section 4.2, and
the payment of any indemnification obligations of Symphony Icon under the Operative Documents and
agreements with third party contractors. Notwithstanding the foregoing, Symphony Icon agrees that
any agreement under which Symphony Icon indemnifies any Person shall contain appropriate provisions
to cause such Person who receives payments from Symphony Icon as a result of Symphony Icon’s
indemnification obligations under the Operative Documents, and who is subsequently reimbursed from
insurance proceeds with respect to such losses, costs, interest, awards, judgments, fees,
liabilities, damages and expenses for which such Person received the indemnity payments from
Symphony Icon, to then reimburse Symphony Icon the amounts paid to such Person by Symphony Icon to
the extent of the insurance proceeds. Symphony Icon further agrees to use all commercially
reasonable means to enforce such provisions.

                         (b) Symphony Icon shall use any and all payments received by Symphony Icon from Lexicon
following the exercise of a Discontinuation Option or from a third party for the transfer or
license of rights to a Program following the unexercised expiration of a Discontinuation Option, in
the manner as determined by the Development Committee in its sole discretion. If the Development
Committee

12

 

Confidential materials omitted and filed separately with
the Securities and Exchange Commission. Asterisks denote omissions.

determines such payments from Lexicon or a third party are not necessary for the development
of the Programs, general corporate purposes of Symphony Icon, or payment of any indemnification
obligations of Symphony Icon, the Development Committee shall so notify the Symphony Icon Board the
amount thereof and that such amount is released to Symphony Icon for application as determined by
the Symphony Icon Board. The Symphony Icon Board may, in its sole discretion, declare a dividend
or otherwise distribute such amount to Holdings, and the Purchase Price shall be reduced by the
aggregate amount of such dividends or other distributions.

          8.2 Reimbursement. Symphony Icon shall compensate Lexicon for its Development
Plan-associated activities and services, including, without limitation, its research, clinical and
manufacturing services and any other activities delegated to and by Lexicon in accordance with this
Agreement. Such compensation shall be made in accordance with the provisions of this Article
8 and the payment terms attached hereto as Annex E (the “Payment Terms”), the
terms of which are hereby adopted and incorporated herein; provided that Lexicon shall be
directly responsible for compensation and reimbursement of Lexicon Subcontractors, it being
understood that the cost shall be passed through to Symphony Icon. With respect to costs for
travel, unless the Development Committee provides Lexicon with prior approval, all Lexicon
personnel shall adhere to Lexicon’s travel policy.

          8.3 Budget Allocation and Deviations. Lexicon shall have the discretion to incur
out-of-pocket fees, expenses and costs and allocate its resources in a manner consistent with the
Development Plan and the Development Budget. If Lexicon reasonably anticipates that the actual
cost for any particular Activity will exceed that portion of the Development Budget allocated for
such Activity by the greater of (a) [**] or more or (b) [**] or more (or such greater amount as the
Symphony Icon Board may subsequently determine), then Lexicon may request that the Development
Committee amend the Development Budget, either at its next Scheduled Meeting or at an Ad Hoc
Meeting, to reflect such cost increase. Lexicon shall be fully reimbursed, pursuant to Section
8.2, for all out-of-pocket amounts incurred with respect to an Activity performed pursuant to
the Development Plan, as such Development Plan may be modified upon approval of the Development
Committee, provided that, without the approval of the Development Committee, Lexicon shall not be
reimbursed for expenditures that exceed the amounts set forth in the Development Budget by the
criteria set forth in the second sentence of this Section 8.3. If the Development
Committee denies a request made by Lexicon pursuant to this Section 8.3 to amend the
Development Budget, then Lexicon shall no longer be obligated to perform such incremental activity
that is expected to give rise to such additional expenditures.

          8.4 Employee Benefits. Symphony Icon shall not be responsible for providing or paying
any benefits (including, but not limited to, unemployment, disability, insurance, or medical, and
any pension or profit sharing plans) to Lexicon or to any employees of Lexicon or any persons
retained or used by Lexicon to perform activities pursuant to the Development Plan, including
independent contractors,

13

 

Confidential materials omitted and filed separately with
the Securities and Exchange Commission. Asterisks denote omissions.

Subcontractors and agents (collectively, “Lexicon Personnel”). As to Lexicon or any
Lexicon Personnel, Symphony Icon shall not be responsible for: (a) any federal, state or local
income tax withholding; (b) Federal Insurance Contributions Act contributions; (c) contributions to
state disability funds or liability funds or similar withholdings; (d) payment of any overtime
wages; (e) workers’ compensation; or (f) compliance with any laws, rules or regulations governing
employees. Lexicon agrees that, as between Symphony Icon and Lexicon, Lexicon is and will continue
to be responsible for: (i) all matters relating to the payment of compensation and provision of
benefits to Lexicon Personnel; and (ii) compliance with all applicable laws, rules and regulations
governing Lexicon’s employees. Lexicon acknowledges that Lexicon is not entitled to reimbursement
with respect to any amounts related to the services of Lexicon Personnel in excess of the fully
burdened FTE rates in accordance with Annex E attached hereto and Symphony Icon
acknowledges that the FTE rates used as the basis for reimbursing Lexicon for the services of
Lexicon Personnel include Lexicon’s costs associated with providing such benefits and fulfilling
such responsibilities. Such FTE rates also cover all direct and indirect, cash and non-cash
compensation paid to or on behalf of said employee or other individual performing duties
customarily performed by an employee; all payroll related taxes and costs; all fringe benefits and
perquisites; all overhead and support provided by Lexicon for said employee, including but not
limited to facility, office, laboratory and equipment costs, training and education, and general
corporate management, supervision, executive and administrative functions and activities; and
quality assurance and other functions and activities benefiting Lexicon or multiple departments,
projects or employees within Lexicon.

     9. Covenants.

          9.1 Mutual Covenants. Each of Lexicon and Symphony Icon covenants and agrees that,
with respect to the Programs and any other rights and obligations set forth in the Operative
Documents, it shall:

                         (a) perform all of its obligations pursuant to this Agreement in material compliance with:
(i) all applicable federal and state laws, statutes, rules, regulations and orders (including all
applicable approval and qualification requirements thereunder), including, without limitation, the
Federal Food, Drug and Cosmetic Act and the regulations promulgated pursuant thereto; (ii) all
applicable good clinical practices and guidelines; (iii) all applicable standard operating
procedures; (iv) all applicable Protocols; and (v) the provisions of this Agreement;

                         (b) keep complete, proper and separate books of record and account, including a record of all
costs and expenses incurred, all charges made, all credits made and received, and all income
derived in connection with the operation of its business, all in accordance with GAAP;

                         (c) not employ (or, to the best of its Knowledge, shall not use any contractor or consultant
who is or that employs) any individual or entity

14

 

Confidential materials omitted and filed separately with
the Securities and Exchange Commission. Asterisks denote omissions.

debarred by the FDA (or subject to a similar sanction of any other Regulatory Authority), or,
to the best of its Knowledge, any individual who or entity which is the subject of an FDA debarment
investigation or proceeding (or similar proceeding of any other Regulatory Authority), in the
conduct of the Programs;

                         (d) promptly deliver to the other, upon receipt thereof, notice of all actions, suits,
investigations, litigation and proceedings before any Governmental Authority, which would
reasonably be expected to affect such Party’s ability to perform its obligations under this
Agreement;

                         (e) upon its acquiring Knowledge of (i) any breach by it of any representation, warranty,
covenant or any other term or condition of this Agreement or (ii) any other event or development,
in each case that is, or is reasonably expected to be, materially adverse to the other Party with
respect to any Program, such Party shall promptly notify the other Party in writing within [**] of
acquiring such Knowledge; provided, that the failure to provide such notice shall not
impair or otherwise be deemed a waiver of any rights any Party may have arising from such breach,
event or development and that notice under this Section 9.1(e) shall not be deemed an
admission by the Party providing such notice of any breach of any of the Operative Documents; and

                         (f) with reasonable promptness, deliver to the other Party such data and information relating
to the ability of such Party to perform its obligations hereunder as from time to time may be
reasonably requested by the other Party (subject to the maintenance of the confidentiality of any
such information by the receiving Party). For the avoidance of doubt, this Section 9.1(f)
includes Lexicon’s obligations to provide financial and other necessary information in respect of
such Programs to Symphony Icon and RRD to enable Symphony Icon to fulfill its obligations to
Lexicon under Section 5(d) of the Purchase Option Agreement, and to enable RRD to fulfill
its obligations to Symphony Icon and Lexicon under Sections 5(a) and 5(b) of the
RRD Services Agreement.

     10. Confidentiality. It is understood that during the course of this Agreement each
of the Parties shall be bound by the terms of the Confidentiality Agreement.

     11. Discontinuation Option.

                         (a) A Program may only be discontinued in accordance with Section 4.2(c). In the
event of such a Program discontinuation during the Term, (i) Symphony Icon shall so notify Lexicon
promptly and in writing of such discontinuation, and (ii) Lexicon shall have the right and option
(a “Discontinuation Option”), exercisable for [**] after receipt of such written notice
from Symphony Icon of such discontinuation, to buy back the Licensed Intellectual Property related
to such discontinued Program for a price (payable by wire transfer to Symphony Icon) that is [**]
(such sum, the “Discontinuation Price”), to be reasonably determined between the Parties,
or, if the Parties are unable to come to a resolution within [**] after receipt of

15

 

Confidential materials omitted and filed separately with
the Securities and Exchange Commission. Asterisks denote omissions.

such written notice from Symphony Icon of such discontinuation, to be determined in accordance
with Section 11(b) hereof. If the Discontinuation Price is determined in accordance with
Section 11(b), then the [**] period for Lexicon’s exercise of a Discontinuation Option
shall be extended by the time needed for such determination so that Lexicon has at least [**] after
such determination to decide whether it wishes to exercise a Discontinuation Option. Following the
unexercised expiration of a Discontinuation Option, Symphony Icon may transfer or license its
rights to such Program to a third party at any time prior to the expiration of the Term. Under no
circumstances may Symphony Icon or Lexicon (unless Lexicon has exercised its Discontinuation Option
for such Program) reinitiate work on a discontinued Program prior to the expiration or termination
of the Purchase Option. Any Discontinuation Price paid to Symphony Icon by Lexicon and
subsequently dividended or otherwise distributed to Holdings shall reduce the Purchase Price in the
amount of such dividends or other distributions.

                         (b) If Lexicon and Symphony Icon cannot agree on the Discontinuation Price within [**] after
receipt of such written notice from Symphony Icon of such discontinuation, then at Lexicon’s
request, the Chief Executive Officer of Lexicon and Chairman of the Symphony Icon Board shall make
good faith efforts to resolve the disagreement(s) regarding the calculation of the Discontinuation
Price. If the Chief Executive Officer of Lexicon and Chairman of the Symphony Icon Board do not
agree on the Discontinuation Price within [**] after Lexicon’s request, then the Parties shall
jointly select a nationally recognized expert to resolve any remaining disagreements regarding
calculation of the Discontinuation Price. The Parties shall use their respective commercially
reasonable efforts to cause such expert to make its determination of the Discontinuation Price
within [**] of accepting its selection. The expert’s determination of the Discontinuation Price
shall, absent manifest error, be (i) binding and conclusive and (ii) the Discontinuation Price at
which a Discontinuation Option shall be exercised by Lexicon. All costs and expenses of the expert
shall be shared equally between Lexicon and Symphony Icon. Notwithstanding the foregoing, in any
case, each Party shall be responsible for the payment of its respective costs and expenses,
including any attorneys’ fees.

     12. Representations and Warranties.

          12.1 Lexicon Representations and Warranties. Lexicon hereby represents and warrants
to Symphony Icon and Holdings that, as of the Closing Date:

                         (a) Organization. Lexicon is a corporation, duly organized, validly existing and in
good standing under the laws of the State of Delaware.

                         (b) Authority and Validity. Lexicon has all requisite corporate power and authority
to execute, deliver and perform its obligations under this Agreement and the Novated and Restated
Technology License Agreement and to consummate the transactions contemplated thereby. The
execution, delivery and performance by Lexicon of this Agreement and the Novated and Restated
Technology

16

 

Confidential materials omitted and filed separately with
the Securities and Exchange Commission. Asterisks denote omissions.

License Agreement and the consummation of the transactions contemplated thereby have been duly
and validly authorized by all necessary action required on the part of Lexicon, and no other
proceedings on the part of Lexicon are necessary to authorize this Agreement or the Novated and
Restated Technology License Agreement or for Lexicon to perform its obligations under this
Agreement or the Novated and Restated Technology License Agreement. This Agreement and the Novated
and Restated Technology License Agreement constitute the lawful, valid and legally binding
obligations of Lexicon, enforceable in accordance with their terms, except as the same may be
limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting
the enforcement of creditors’ rights generally and general equitable principles regardless of
whether such enforceability is considered in a proceeding at law or in equity.

                         (c) No Violation or Conflict. The execution, delivery and performance of this
Agreement and the Novated and Restated Technology License Agreement and the transactions
contemplated thereby do not and will not (i) violate, conflict with or result in the breach of any
provision of the Organizational Documents of Lexicon, (ii) conflict with or violate any law or
Governmental Order applicable to Lexicon or any of its assets, properties or businesses, or (iii)
conflict with, result in any breach of, constitute a default (or event that with the giving of
notice or lapse of time, or both, would become a default) under, require any consent under, or give
to others any rights of termination, amendment, acceleration, suspension, revocation or
cancellation of, or result in the creation of any Encumbrance on any of the assets or properties of
Lexicon, pursuant to, any note, bond, mortgage or indenture, contract, agreement, lease, sublease,
license, permit, franchise or other instrument or arrangement to which Lexicon is a party except,
in the case of clauses (ii) and (iii), to the extent that such conflicts, breaches,
defaults or other matters would not, individually or in the aggregate, reasonably be expected to
have a Material Adverse Effect on Lexicon or a material adverse effect on the Programs.

                         (d) Governmental Consents and Approvals. The execution, delivery and performance of
this Agreement and the Novated and Restated Technology License Agreement by Lexicon do not, and the
consummation of the transactions contemplated thereby do not and will not, require any Governmental
Approval which has not already been obtained, effected or provided, except with respect to which
the failure to so obtain, effect or provide would not, individually or in the aggregate, reasonably
be expected to have a Material Adverse Effect on Lexicon or a material adverse effect on the
Programs.

                         (e) Litigation. Except as disclosed on the most recently filed Form 10-K filing of
Lexicon, there are no actions by or against Lexicon pending before any Governmental Authority or,
to the Knowledge of Lexicon, threatened to be brought by or before any Governmental Authority, that
would, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect
on Lexicon. There are no pending or, to the Knowledge of Lexicon, threatened actions, to which
Lexicon is a party (or is threatened to be named as a party) to set aside, restrain, enjoin or
prevent

17

 

Confidential materials omitted and filed separately with
the Securities and Exchange Commission. Asterisks denote omissions.

the execution, delivery or performance of this Agreement or the Operative Documents or the
consummation of the transactions contemplated hereby or thereby by any party hereto or thereto.
Lexicon is not subject to any Governmental Order (nor, to the Knowledge of Lexicon, is there any
such Governmental Order threatened to be imposed by any Governmental Authority) that would,
individually or in the aggregate, reasonably be expected to have a Material Adverse Effect on
Lexicon or a material adverse effect on the Programs.

                         (f) No Contracts. Except as disclosed on Schedule 12.1(f) hereto, there are
no material contracts between Lexicon and any third party (other than licenses of intellectual
property that are in turn licensed to Symphony Icon under the Novated and Restated Technology
License Agreement), including contractors, manufacturers or suppliers, used with or otherwise
necessary for the Programs, and all such contracts are assignable to Symphony Icon. Except as
disclosed on Schedule 12.1(f) hereto, each such contract is assignable to Symphony Icon
without the prior consent of the applicable third party, or the absence of such contract (due to
the inability or impracticability of assigning such contract to Symphony Icon following a
termination of this Agreement without the exercise of the Purchase Option) would not have a
material adverse effect on any of the Programs or on Symphony Icon’s rights under the Novated and
Restated Technology License Agreement.

          12.2 Symphony Icon Representations and Warranties. Symphony Icon hereby represents
and warrants to Lexicon that, as of the Closing Date:

                         (a) Organization. Symphony Icon is a corporation, duly organized, validly existing
and in good standing under the laws of the State of Delaware.

                         (b) Authority and Validity. Symphony Icon has all requisite corporate power and
authority to execute, deliver and perform its obligations under this Agreement and the Novated and
Restated Technology License Agreement and to consummate the transactions contemplated thereby. The
execution, delivery and performance by Symphony Icon of this Agreement and the Novated and Restated
Technology License Agreement and the consummation of the transactions contemplated thereby have
been duly and validly authorized by all necessary action required on the part of Symphony Icon, and
no other proceedings on the part of Symphony Icon are necessary to authorize this Agreement or the
Novated and Restated Technology License Agreement or for Symphony Icon to perform its obligations
under this Agreement or the Novated and Restated Technology License Agreement. This Agreement and
the Novated and Restated Technology License Agreement constitute the lawful, valid and legally
binding obligations of Symphony Icon, enforceable in accordance with its terms, except as the same
may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws
affecting the enforcement of creditors’ rights generally and general equitable principles
regardless of whether such enforceability is considered in a proceeding at law or in equity.

18

 

Confidential materials omitted and filed separately with
the Securities and Exchange Commission. Asterisks denote omissions.

                         (c) No Violation or Conflict. The execution, delivery and performance of this
Agreement and the Novated and Restated Technology License Agreement and the transactions
contemplated thereby do not and will not (i) violate, conflict with or result in the breach of any
provision of the Organizational Documents of Symphony Icon, (ii) conflict with or violate any law
or Governmental Order applicable to Symphony Icon or any of its assets, properties or businesses,
or (iii) conflict with, result in any breach of, constitute a default (or event that with the
giving of notice or lapse of time, or both, would become a default) under, require any consent
under, or give to others any rights of termination, amendment, acceleration, suspension, revocation
or cancellation of, or result in the creation of any Encumbrance on any of the assets or properties
of Symphony Icon, pursuant to any note, bond, mortgage or indenture, contract, agreement, lease,
sublease, license, permit, franchise or other instrument or arrangement to which Symphony Icon is a
party except, in the case of clauses (ii) and (iii), to the extent that such
conflicts, breaches, defaults or other matters would not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect on Symphony Icon.

                         (d) Governmental Consents and Approvals. The execution, delivery and performance of
this Agreement and the Novated and Restated Technology License Agreement by Symphony Icon do not,
and the consummation of the transactions contemplated thereby do not and will not, require any
Governmental Approval which has not already been obtained, effected or provided, except with
respect to which the failure to so obtain, effect or provide would not, individually or in the
aggregate, reasonably be expected to have a Material Adverse Effect on Symphony Icon.

                         (e) Litigation. There are no actions by or against Symphony Icon pending before any
Governmental Authority or, to the Knowledge of Symphony Icon, threatened to be brought, by or
before any Governmental Authority that would, individually or in the aggregate, reasonably be
expected to have a Material Adverse Effect on Symphony Icon. There are no pending or, to the
Knowledge of Symphony Icon, threatened actions to which Symphony Icon is a party (or is threatened
to be named as a party) to set aside, restrain, enjoin or prevent the execution, delivery or
performance of this Agreement or the consummation of the transactions contemplated hereby by any
party hereto. Symphony Icon is not subject to any Governmental Order (nor, to the knowledge of
Symphony Icon, is there any such Governmental Order threatened to be imposed by any Governmental
Authority) that would, individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect on Symphony Icon or a material adverse effect on the Programs.

     13. Relationship Between Lexicon and Symphony Icon. Nothing contained in this
Agreement or any acts or omissions hereunder shall constitute or be construed so as to create any
joint venture or partnership relationship between Lexicon and Symphony Icon, and the Parties
acknowledge and agree that Lexicon is acting as an independent contractor in the performance of its
obligations under this Agreement.

19

 

Confidential materials omitted and filed separately with
the Securities and Exchange Commission. Asterisks denote omissions.

     14. Change of Control. Holdings has the Change of Control Put Option described in
Section 2A of the Purchase Option Agreement following a Change of Control with respect to
Lexicon.

     15. No Restrictions; Indemnification.

          15.1 No Restrictions. Nothing in this Agreement shall limit or restrict the right of
any director, officer or employee of Lexicon or any director, officer, or employee of any of its
subsidiaries or its Affiliates to engage in any other business or to devote his or her time and
attention to the management or other aspects of any other business, whether of a similar or
dissimilar nature, nor limit or restrict the right of Lexicon or any of its affiliates to engage in
any other business or to render services of any kind to any other Person.

          15.2 Indemnification.

                         (a) To the greatest extent permitted by applicable law, Lexicon shall indemnify and hold
harmless Symphony Icon, Holdings and RRD and each of their respective Affiliates, officers,
directors, employees, agents, members, managers, successors and assigns (each, a “Symphony
Indemnified Party”), and Symphony Icon shall indemnify and hold harmless Lexicon, and its
Affiliates and each of their respective officers, directors, employees, agents (other than Lexicon
Subcontractors), members, managers, successors and assigns (each, a “Lexicon Indemnified
Party”), from and against any and all claims, losses, costs, interest, awards, judgments, fees
(including reasonable fees for attorneys and other professionals), court costs, liabilities,
damages and expenses incurred by any Symphony Indemnified Party or Lexicon Indemnified Party
(irrespective of whether any such Indemnified Party is a party to the action for which
indemnification hereunder is sought) (hereinafter, a “Loss”) to the extent resulting from,
arising out of, or relating to any and all third party suits, claims, actions, proceedings or
demands based upon:

                              (i) in the case of Lexicon being the Indemnifying Party, (A) any breach of any
representation or warranty made by Lexicon herein or in any other Operative Document, (B)
any breach of any covenant, agreement or obligation of Lexicon contained herein or in any
other Operative Document, except to the extent such covenant, agreement or obligation
relates to Lexicon’s performance under the Development Plan, (C) any gross negligence or
willful misconduct of Lexicon (and not that of any Lexicon Subcontractors) in connection
with Lexicon’s performance of its obligations under this Agreement (including the
Development Plan), (D) any action undertaken or performed by or on behalf of Lexicon prior
to, and including, the Closing Date that relates to the Programs or the Products, or (E) in
the event Lexicon exercises a Discontinuation Option for a Program, any action undertaken
and/or performed by or on behalf of Lexicon after the Discontinuation Option Closing Date
and relating to the Product that was the subject of such Program (including the
development, manufacture, use, handling, storage, sale or other

20

 

Confidential materials omitted and filed separately with
the Securities and Exchange Commission. Asterisks denote omissions.

disposition of such Product); in each case, except (1) with respect to Losses for
which Lexicon is entitled to indemnification under this Article 15 or (2) to the
extent such Loss arises from the gross negligence or willful misconduct of a Symphony
Indemnified Party; and

                              (ii) in the case of Symphony Icon being the Indemnifying Party, (A) any breach of any
representation or warranty made by Symphony Icon herein or in any other Operative Document,
(B) any breach of any covenant, agreement or obligation of Symphony Icon contained herein
or in any other Operative Document, (C) any and all activities undertaken or performed by
or on behalf of the Parties under the Development Plan during the Term, (D) any gross
negligence or willful misconduct of Symphony Icon (and not that of its direct
subcontractors) in connection with Symphony Icon’s performance of its obligations under
this Agreement, or (E) the development, manufacture, use, handling, storage, sale or other
disposition of the Products (including in the course of conducting the Programs) during the
Term (except with respect to the development, manufacture, use, handling, storage, sale or
other disposition, after Lexicon’s exercise of a Discontinuation Option, of Products
covered under Section 15.2(a)(i)(E)); in each case, except (1) with respect to
Losses for which Symphony Icon is entitled to indemnification under this Article
15, or (2) Losses deemed to have arisen from the breach by Lexicon of any covenant,
agreement or obligation under this Agreement that relates to Lexicon’s performance under
the Development Plan, as determined by a court, arbitrator or pursuant to a settlement
agreement, or (3) to the extent such Loss arises from the gross negligence or willful
misconduct of a Lexicon Indemnified Party.

          To the extent that the foregoing undertaking by Lexicon or Symphony Icon may be unenforceable
for any reason, such Party shall make the maximum contribution to the payment and satisfaction of
any Loss that is permissible under applicable law.

                         (b) Notice of Claims. Any Indemnified Party that proposes to assert a right to be
indemnified under this Section 15.2 shall notify Lexicon or Symphony Icon, as applicable
(the “Indemnifying Party”), promptly after receipt of notice of commencement of any action,
suit or proceeding against such Indemnified Party (an “Indemnified Proceeding”) in respect
of which a claim is to be made under this Section 15.2, or the incurrence or realization of
any Loss in respect of which a claim is to be made under this Section 15.2, of the
commencement of such Indemnified Proceeding or of such incurrence or realization, enclosing a copy
of all relevant documents, including all papers served and claims made, but the omission so to
notify the applicable Indemnifying Party promptly of any such Indemnified Proceeding or incurrence
or realization shall not relieve (x) such Indemnifying Party from any liability that it may have to
such Indemnified Party under this Section 15.2 or otherwise, except, as to such
Indemnifying Party’s liability under this Section 15.2, to the extent, but only to the
extent, that such Indemnifying Party shall have been prejudiced by such omission, or

21

 

Confidential materials omitted and filed separately with
the Securities and Exchange Commission. Asterisks denote omissions.

(y) any other indemnitor from liability that it may have to any Indemnified Party under the
Operative Documents.

                         (c) Defense of Proceedings. In case any Indemnified Proceeding shall be brought
against any Indemnified Party, it shall notify the applicable Indemnifying Party of the
commencement thereof as provided in Section 15.2(b), and such Indemnifying Party shall be
entitled to participate in, and provided such Indemnified Proceeding involves a claim
solely for money damages and does not seek an injunction or other equitable relief against the
Indemnified Party and is not a criminal or regulatory action, to assume the defense of, such
Indemnified Proceeding with counsel reasonably satisfactory to such Indemnified Party. After
notice from such Indemnifying Party to such Indemnified Party of such Indemnifying Party’s election
so to assume the defense thereof and the failure by such Indemnified Party to object to such
counsel within ten (10) Business Days following its receipt of such notice, such Indemnifying Party
shall not be liable to such Indemnified Party for legal or other expenses related to such
Indemnified Proceedings incurred after such notice of election to assume such defense except as
provided below and except for the reasonable costs of investigating, monitoring or cooperating in
such defense subsequently incurred by such Indemnified Party reasonably necessary in connection
with the defense thereof. Such Indemnified Party shall have the right to employ its counsel in any
such Indemnified Proceeding, but the fees and expenses of such counsel shall be at the expense of
such Indemnified Party unless:

                              (i) the employment of counsel by such Indemnified Party at the expense of the
applicable Indemnifying Party has been authorized in writing by such Indemnifying Party;

                              (ii) such Indemnified Party shall have reasonably concluded in its good faith (which
conclusion shall be determinative unless a court determines that such conclusion was not
reached reasonably and in good faith) that there is or may be a conflict of interest
between the applicable Indemnifying Party and such Indemnified Party in the conduct of the
defense of such Indemnified Proceeding or that there are or may be one or more different or
additional defenses, claims, counterclaims, or causes of action available to such
Indemnified Party (it being agreed that in any case referred to in this clause (ii)
such Indemnifying Party shall not have the right to direct the defense of such Indemnified
Proceeding on behalf of the Indemnified Party);

                              (iii) the applicable Indemnifying Party shall not have employed counsel reasonably
acceptable to the Indemnified Party to assume the defense of such Indemnified Proceeding
within a reasonable time after notice of the commencement thereof; provided,
however, that (A) this clause (iii) shall not be deemed to constitute a
waiver of any conflict of interest that may arise with respect to any such counsel, and (B)
an Indemnified Party may not invoke this clause (iii) if such Indemnified Party
failed to timely object to such counsel pursuant to the first paragraph of this Section
15.2(c) above (it being agreed that

22

 

Confidential materials omitted and filed separately with
the Securities and Exchange Commission. Asterisks denote omissions.

in any case referred to in this clause (iii) such Indemnifying Party shall not
have the right to direct the defense of such Indemnified Proceeding on behalf of the
Indemnified Party); or

                              (iv) any counsel employed by the applicable Indemnifying Party shall fail to timely
commence or reasonably conduct the defense of such Indemnified Proceeding and such failure
has prejudiced (or is in immediate danger of prejudicing) the outcome of such Indemnified
Proceeding (it being agreed that in any case referred to in this clause (iv) such
Indemnifying Party shall not have the right to direct the defense of such Indemnified
Proceeding on behalf of the Indemnified Party);

in each of which cases the fees and expenses of counsel for such Indemnified Party shall be at the
expense of such Indemnifying Party. Only one counsel shall be retained by all Indemnified Parties
with respect to any Indemnified Proceeding, unless counsel for any Indemnified Party reasonably
concludes in good faith (which conclusion shall be determinative unless a court determines that
such conclusion was not reached reasonably and in good faith) that there is or may be a conflict of
interest between such Indemnified Party and one or more other Indemnified Parties in the conduct of
the defense of such Indemnified Proceeding or that there are or may be one or more different or
additional defenses, claims, counterclaims, or causes or action available to such Indemnified
Party.

                         (d) Settlement. Without the prior written consent of such Indemnified Party, such
Indemnifying Party shall not settle or compromise, or consent to the entry of any judgment in, any
pending or threatened Indemnified Proceeding, unless such settlement, compromise, consent or
related judgment (i) includes an unconditional release of such Indemnified Party from all liability
for Losses arising out of such claim, action, investigation, suit or other legal proceeding, (ii)
provides for the payment of money damages as the sole relief for the claimant (whether at law or in
equity), (iii) involves no admission of fact adverse to the Indemnified Party or finding or
admission of any violation of law or the rights of any Person by the Indemnified Party, and (iv) is
not in the nature of a criminal or regulatory action. No Indemnified Party shall settle or
compromise, or consent to the entry of any judgment in, any pending or threatened Indemnified
Proceeding (A) in respect of which any payment would result hereunder or under any other Operative
Document, (B) which includes an injunction that will adversely affect any Indemnifying Party, (C)
which involves an admission of fact adverse to the Indemnifying Party or a finding or admission of
any violation of law or the rights of any Person by the Indemnifying Party, or (D) which is in the
nature of a criminal or regulatory action, without the prior written consent of the Indemnifying
Party, such consent not to be unreasonably conditioned, withheld or delayed.

     16. Limitation of Liabilities.

          16.1 Between the Parties. TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, NEITHER
PARTY NOR ANY OF THEIR RESPECTIVE DIRECTORS, OFFICERS, MEMBERS, MANAGERS, EMPLOYEES,

23

 

Confidential materials omitted and filed separately with
the Securities and Exchange Commission. Asterisks denote omissions.

INDEPENDENT CONTRACTORS OR AGENTS (INCLUDING RRD AND ITS MEMBERS, MANAGERS, EMPLOYEES,
INDEPENDENT CONTRACTORS AND AGENTS) SHALL HAVE ANY LIABILITY OF ANY TYPE (INCLUDING, BUT NOT
LIMITED TO, CLAIMS IN CONTRACT, NEGLIGENCE AND TORT LIABILITY) FOR ANY SPECIAL, INCIDENTAL,
INDIRECT, PUNITIVE OR CONSEQUENTIAL DAMAGES, INCLUDING, BUT NOT LIMITED TO, THE LOSS OF
OPPORTUNITY, LOSS OF USE OR LOSS OF REVENUE OR PROFIT IN CONNECTION WITH OR ARISING OUT OF THIS
AGREEMENT OR THE SERVICES PERFORMED HEREUNDER, EVEN IF SUCH DAMAGES MAY HAVE BEEN FORESEEABLE. THE
FOREGOING SHALL NOT LIMIT EITHER PARTY’S INDEMNIFICATION OBLIGATIONS PURSUANT TO SECTION
15.2 AND SHALL NOT APPLY TO BREACHES OF ITS CONFIDENTIALITY OBLIGATIONS PURSUANT TO ARTICLE
10.

          16.2 Pursuant to the RRD Services Agreement. Each Party hereby acknowledges and
agrees that, pursuant to Sections 9(f) and (g) of the RRD Services Agreement, RRD
has expressly disclaimed all liability for (a) any claim arising out of, or allegedly arising out
of the activities carried out by (or within the authority of) Lexicon (and such Lexicon
Subcontractors and vendors it may retain) hereunder, or for any liability arising under the Novated
and Restated Technology License Agreement with respect to any license or sublicense thereunder in
relation to the activities carried out by (or within the authority of) Lexicon (and such Lexicon
Subcontractors and vendors it may retain) hereunder, and (b) supervising, compensating or
discharging, or any other liability to or with respect to, any vendor retained by Lexicon (or, in
the case of a vendor engaged by both RRD and Lexicon, to and for such vendor to the extent that
such vendor performs services for Lexicon), except that RRD shall make payments from Symphony
Icon’s funds to reimburse Lexicon, in accordance with Article 8 and Annex E of this
Agreement, for costs and expenses incurred by Lexicon in connection with the engagement of such
vendors by Lexicon for the performance of services contemplated under the Development Plan. Each
Party acknowledges that RRD has certain rights in respect of such disclaimers pursuant to the RRD
Services Agreement.

     17. Term and Termination.

          17.1 Term. This Agreement shall be effective as of the Closing Date and shall expire
on the last day of the Term, unless the Agreement is earlier terminated as specified in this
Article 17.

          17.2 Termination for Lexicon’s Breach.

                         (a) Symphony Icon may terminate this Agreement at any time upon written notice to Lexicon if
Lexicon is in material default or breach of this Agreement that has resulted in, or would
reasonably be expected to result in, a material adverse effect on the Programs or Symphony Icon’s
or Holdings’ rights under the Operative Agreements, and such material default or breach continues
unremedied for a

24

 

Confidential materials omitted and filed separately with
the Securities and Exchange Commission. Asterisks denote omissions.

period of [**] after written notice thereof is delivered to Lexicon. Such cure period may be
extended if (i) Lexicon reasonably believes such breach can be cured within [**] of Lexicon’s
receipt of Symphony Icon’s written notice of such breach (and notifies Symphony Icon in writing of
such belief and the basis for such belief), and (ii) Symphony Icon, acting reasonably, agrees. If
Lexicon fails to remedy the default or breach within the applicable cure period, Symphony Icon may
by final notice of termination to Lexicon terminate this Agreement.

                         (b) In the event that Symphony Icon terminates this Agreement pursuant to Section
17.2(a) above, Lexicon may exercise its Purchase Option (which shall include the costs
associated with Lexicon’s material default or breach), pursuant to Section 1(c)(v) of the
Purchase Option Agreement, within [**] of receiving such notice of termination from Symphony Icon;
provided, that if such termination occurs after a Change of Control with respect to Lexicon
due to the Surviving Entity’s material default or breach of this Agreement, and if the Surviving
Entity does not exercise such Purchase Option, then Holdings may exercise its Put Option pursuant
to Section 2A of the Purchase Option Agreement.

          17.3 Termination for Symphony Icon’s or Holdings’ Breach. Lexicon may terminate this
Agreement at any time upon written notice to Symphony Icon and Holdings if Symphony Icon or
Holdings is in material default or breach of this Agreement that has resulted in, or would
reasonably be expected to result in, a material adverse effect on the Programs or Lexicon’s rights
under the Operative Agreements, and such material default or breach continues unremedied for a
period of [**] after written notice thereof is delivered to Symphony Icon and Holdings. Such cure
period may be extended if (i) Symphony Icon or Holdings reasonably believes such breach can be
cured within [**] of Symphony Icon’s and Holdings’ receipt of Lexicon’s written notice of such
breach (and notifies Lexicon in writing of such belief and the basis for such belief), and (ii)
Lexicon, acting reasonably, agrees. If Symphony Icon or Holdings fails to remedy the default or
breach within the applicable cure period, Lexicon may by final notice of termination to Symphony
Icon and Holdings terminate this Agreement.

          17.4 Termination of License Agreement. This Agreement shall automatically terminate
upon the termination of the Novated and Restated Technology License Agreement.

          17.5 Survival.

                         (a) The agreements and covenants of the Parties set forth in Articles 10, 11,
15, 16 and 18, and Sections 6.7 and 17.5 shall survive the
expiration or termination of this Agreement. In addition, Section 8.2 shall, to the extent
that the costs and expenses reimbursable thereunder have been incurred or become uncancellable
prior to such termination, also survive such expiration.

25

 

Confidential materials omitted and filed separately with
the Securities and Exchange Commission. Asterisks denote omissions.

                         (b) If Lexicon does not exercise the Purchase Option, in addition to the provisions specified
in Section 17.5(a), Section 5.4 shall also survive such unexercised expiration.

     18. Miscellaneous.

          18.1 No Petition. Lexicon covenants and agrees that, prior to the date which is one
(1) year and one (1) day after the expiration of the Term, Lexicon will not institute or join in
the institution of any bankruptcy, insolvency, reorganization or similar proceeding against
Symphony Icon. The provisions of this Section 18.1 shall survive the termination of this
Agreement.

          18.2 Notices. Any notice, request, demand, waiver, consent, approval or other
communication which is required or permitted to be given to any party shall be in writing addressed
to the party at its address set forth below and shall be deemed given (i) when delivered to the
party personally, (ii) if sent to the party by facsimile transmission (promptly followed by a
hard-copy delivered in accordance with this Section 18.2), when the transmitting party
obtains written proof of transmission and receipt; provided, however, that
notwithstanding the foregoing, any communication sent by facsimile transmission after 5:00 PM
(receiving party’s time) or not on a Business Day shall not be deemed received until the next
Business Day, (iii) when delivered by next Business Day delivery by a nationally recognized courier
service, or (iv) if sent by registered or certified mail when received, provided postage
and registration or certification fees are prepaid and delivery is confirmed by a return receipt:

     Lexicon:

Lexicon Pharmaceuticals, Inc.

8800 Technology Forest Place

The Woodlands, TX 77381-1160

Attn: Arthur T. Sands, M.D., Ph.D.

Facsimile: (281) 863-8095

     with copies to:

Lexicon Pharmaceuticals, Inc.

8800 Technology Forest Place

The Woodlands, TX 77381-1160

Attn: Jeffrey L. Wade

Facsimile: (281) 863-8010

     and

Lexicon Pharmaceuticals, Inc.

8800 Technology Forest Place

The Woodlands, TX 77381-1160

26

 

Confidential materials omitted and filed separately with
the Securities and Exchange Commission. Asterisks denote omissions.

Attn: Julia P. Gregory

Facsimile: (281) 863-8095

     Symphony Icon:

Symphony Icon, Inc.

7361 Calhoun Place, Suite 325

Rockville, MD 20855

Attn: Charles W. Finn, Ph.D.

Facsimile: (301) 762-6154

     Holdings:

Symphony Icon Holdings LLC

7361 Calhoun Place, Suite 325

Rockville, MD 20855

Attn: Robert L. Smith, Jr.

Facsimile: (301) 762-6154

     with copies to:

Symphony Capital Partners, L.P.

875 Third Avenue, 18th Floor

New York, NY 10022

Attn: Mark Kessel

Facsimile: (212) 632-5401

     and

Symphony Strategic Partners, LLC

875 Third Avenue, 18th Floor

New York, NY 10022

Attn: Mark Kessel

Facsimile: (212) 632-5401

or to such other address as such party may from time to time specify by notice given in the manner
provided herein to each other party entitled to receive notice hereunder.

          18.3 Governing Law; Consent to Jurisdiction and Service of Process.

                         (a) This Agreement shall be governed by, and construed in accordance with, the laws of the
State of New York; except to the extent that this Agreement pertains to the internal governance of
Symphony Icon or Holdings, and to such extent this Agreement shall be governed and construed in
accordance with the laws of the State of Delaware.

27

 

Confidential materials omitted and filed separately with
the Securities and Exchange Commission. Asterisks denote omissions.

                         (b) Each of the Parties hereby irrevocably and unconditionally submits, for itself and its
property, to the nonexclusive jurisdiction of any New York State court or federal court of the
United States of America sitting in The City of New York, Borough of Manhattan, and any appellate
court from any jurisdiction thereof, in any action or proceeding arising out of or relating to this
Agreement, or for recognition or enforcement of any judgment, and each of the Parties hereby
irrevocably and unconditionally agrees that all claims in respect of any such action or proceeding
may be heard and determined in any such New York State court or, to the fullest extent permitted by
law, in such federal court. Each of the Parties agrees that a final judgment in any such action or
proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment
or in any other manner provided by law. Nothing in this Agreement shall affect any right that any
Party may otherwise have to bring any action or proceeding relating to this Agreement.

                         (c) Each of the Parties irrevocably and unconditionally waives, to the fullest extent it may
legally and effectively do so, any objection that it may now or hereafter have to the laying of
venue of any suit, action or proceeding arising out of or relating to this Agreement in any New
York State or federal court. Each of the Parties irrevocably waives, to the fullest extent
permitted by law, the defense of an inconvenient forum to the maintenance of such action or
proceeding in any such court.

          18.4 Waiver of Jury Trial. EACH OF THE PARTIES HERETO IRREVOCABLY WAIVES ALL RIGHT TO
TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR
OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT.

          18.5 Entire Agreement. This Agreement (including any Annexes, Schedules, Exhibits or
other attachments hereto) constitutes the entire agreement between the Parties with respect to the
matters covered hereby, and no oral or written statement may be used to interpret or vary the
meaning of the terms and conditions hereof. This Agreement supersedes all prior and
contemporaneous agreements, correspondence, discussion and understanding with respect to such
matters between the Parties, including the Research and Development Agreement, but excluding the
Operative Documents.

          18.6 Amendment; Successors; Assignment; Counterparts.

                         (a) The terms of this Agreement shall not be altered, modified, amended, waived or
supplemented in any manner whatsoever except by a written instrument signed by each of the Parties
and Holdings.

                         (b) Nothing expressed or implied herein is intended or shall be construed to confer upon or to
give to any Person, other than the Parties (and, to the extent of Section 18.8, RRD), any
right, remedy or claim under or by reason of this Agreement or of any term, covenant or condition
hereof, and all the terms, covenants,

28

 

Confidential materials omitted and filed separately with
the Securities and Exchange Commission. Asterisks denote omissions.

conditions, promises and agreements contained herein shall be for the sole and exclusive
benefit of the Parties (and, to the extent of Section 18.8, RRD) and their successors and
permitted assigns.

                         (c) This Agreement may not be assigned by either Party hereto without the prior written
consent of the other Party; provided that, in the event Lexicon undergoes a Change of
Control in compliance with Article 14 hereof, Lexicon may assign this Agreement to its
Successor Entity.

                         (d) This Agreement may be executed in one or more counterparts, each of which, when executed,
shall be deemed an original but all of which taken together shall constitute one and the same
Agreement.

          18.7 Severability. If any term or other provision of this Agreement is invalid,
illegal or incapable of being enforced by any rule of law or public policy, all other conditions
and provisions of this Agreement shall nevertheless remain in full force and effect so long as the
economic or legal substance of the transactions contemplated hereby is not affected in a manner
materially adverse to either party. Upon such determination that any term or other provision is
invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith
to modify this Agreement so as to effect the original intent of the parties as closely as possible
in an acceptable manner to the end that the transactions contemplated hereby are fulfilled to the
extent possible.

          18.8 Third Party Beneficiary. Each of the Parties agrees that RRD shall be a third
party beneficiary of Articles 2, 8 and 16, and Sections 4.1,
4.2(a), 4.2(b), 7.1, 7.3, 9.1(f), 15.2 and
18.6(b) of this Agreement.

[SIGNATURES FOLLOW ON NEXT PAGE]

29

 

Confidential materials omitted and filed separately with
the Securities and Exchange Commission. Asterisks denote omissions.

     IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the day
and year above written.

	 	 	 	 	 	 	 
	 	 	SYMPHONY ICON HOLDINGS LLC	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	Symphony
Capital Partners, L.P.,
its Manager	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	Symphony
Capital GP, L.P.,
its general partner	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	Symphony
GP, LLC,

its general partner	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	Name: Mark Kessel
	 	 
	 

	 	 	 	Title: Managing Member	 	 
	 
	 	 	 	 	 	 
	 	 	SYMPHONY ICON, INC.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	Name: Mark Kessel

Title: Chairman of the Board	 	 
	 
	 	 	 	 	 	 
	 	 	LEXICON PHARMACEUTICALS, INC.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	Name: Arthur T. Sands, M.D., Ph.D.

Title: President and Chief Executive Officer	 	 

Signature Page to Amended and Restated Research and Development Agreement

 

 

Confidential materials omitted and filed separately with
the Securities and Exchange Commission. Asterisks denote omissions.

ANNEX A

CERTAIN DEFINITIONS

See attached.

Annex A — 1

 

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

CERTAIN DEFINITIONS

          “$” means United States dollars.

          “Accredited Investor” has the meaning set forth in Rule 501(a) of Regulation D
promulgated under the Securities Act of 1933, as amended.

          “Act” means the Delaware Limited Liability Company Act, 6 Del. C. § 18-101 et seq.

          “Activity” means:

               (a) in the case of goods or services procured from third party vendors, the resources applied
(and the costs incurred therefor) on one clinical study or protocol under a single contract with a
vendor, said contract consisting of either a purchase order or a stand alone contract, if for a
one-time purchase, or a series of work orders under a master contract or master services agreement,
if for multiple purchases of similar goods or services from the same vendor; and

               (b) in the case of internally provided goods or services, the resources applied, allocated or
reallocated (and the costs associated therewith) under a single budgetary line item for any LG103
Program or any LG617 Program.

          “Ad Hoc Meeting” has the meaning set forth in Paragraph 6 of Annex B of the Amended
and Restated Research and Development Agreement.

          “Additional Party” has the meaning set forth in Section 14 of the
Confidentiality Agreement.

          “Additional Regulatory Filings” means such Governmental Approvals as required to be
made under any law applicable to the purchase of the Symphony Icon Equity Securities under the
Purchase Option Agreement.

          “Adjusted Capital Account Deficit” has the meaning set forth in Section 1.01
of the Holdings LLC Agreement.

          “Affected Member” has the meaning set forth in Section 26 of the Investors LLC
Agreement.

          “Affiliate” means, with respect to any Person (i) any Person directly or indirectly
controlling, controlled by or under common control with such Person, (ii) any officer, director,
general partner, member or trustee of such Person, or (iii) any Person who is an officer, director,
general partner, member or trustee of any Person described in clauses (i) or (ii)
of this sentence. For purposes of this definition, the terms “controlling,” “controlled by” or
“under common control with” shall mean the possession, direct or indirect, of the power to direct
or cause the direction of the management and policies of a

 

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

Person or entity, whether through the ownership of voting securities, by contract or
otherwise, or the power to elect at least 50% of the directors, managers, general partners, or
persons exercising similar authority with respect to such Person or entities.

          “Amended and Restated Research and Development Agreement” means the Amended and
Restated Research and Development Agreement dated as of the Closing Date, among Lexicon, Holdings
and Symphony Icon.

          “Annual Price” has the meaning set forth in Section 2(b) of the Purchase
Option Agreement.

          “Asset Value” has the meaning set forth in Section 1.01 of the Holdings LLC
Agreement.

          “Auditors” means an independent certified public accounting firm of recognized
national standing.

          “Balance
Sheet Deficiency” has the meaning set forth in Section 1(c)(iii) of
the Purchase Option Agreement.

          “Balance
Sheet Deficiency Date” has the meaning set forth in Section 1(c)(iii) of the Purchase Option Agreement.

          “Balance Sheet Deficiency Threshold” shall have the meaning set forth in Section 3(b)
of the Research Cost Sharing, Payment and Extension Agreement.

          “Bankruptcy Code” means the United States Bankruptcy Code.

          “Bankruptcy Event” means, with respect to a Person, the occurrence of either of the
following:

               (a) a case or other proceeding shall be commenced, without the application or consent of such
Person, in any court, seeking the liquidation, reorganization, debt arrangement, dissolution,
winding up, or composition or readjustment of debts of such Person, the appointment of a trustee,
receiver, custodian, liquidator, assignee, sequestrator or the like for such Person of all or
substantially all of its assets, or any similar action with respect to such Person under any Law
relating to bankruptcy, insolvency, reorganization, winding up or composition or adjustment of
debts, and such case or proceeding shall continue undismissed, or unstayed and in effect, for a
period of sixty (60) consecutive days; or an order for relief in respect of such Person shall be
entered in an involuntary case under the federal bankruptcy Laws or other similar Laws now or
hereafter in effect; or

               (b) such Person shall generally not pay its debts as such debts become due or shall admit in
writing its inability to pay its debts generally or such Person shall commence a voluntary case or
other proceeding under any applicable bankruptcy,

 

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

insolvency, reorganization, debt arrangement, dissolution or other similar Law now or
hereafter in effect, or shall consent to the appointment of or taking possession by a receiver,
liquidator, assignee, trustee (other than a trustee under a deed of trust, indenture or similar
instrument), custodian, sequestrator (or other similar official) for, such Person or for any
substantial part of its property, or shall make any general assignment for the benefit of
creditors, or shall be adjudicated insolvent, or admit in writing its inability to pay its debts
generally as they become due, or, if a corporation or similar entity, its board of directors shall
vote to implement any of the foregoing.

          “BMS” means Bristol-Myers Squibb Company, a Delaware corporation.

          “Business Day” means any day other than Saturday, Sunday or any other day on which
commercial banks in the City of New York are authorized or required by law to remain closed.

          “Capital Contributions” has the meaning set forth in Section 1.01 of the
Holdings LLC Agreement.

          “Capitalized Leases” means all leases that have been or should be, in accordance with
GAAP, recorded as capitalized leases.

          “Cash Available for Distribution” has the meaning set forth in Section 1.01 of
the Holdings LLC Agreement.

          “Chair” has the meaning set forth in Paragraph 4 of Annex B to the Amended and
Restated Research and Development Agreement.

          “Change of Control” means and includes the occurrence of any of the following events,
but specifically excludes (i) acquisitions of capital stock directly from Lexicon for cash, whether
in a public or private offering, (ii) sales of capital stock by stockholders of Lexicon, and (iii)
acquisitions of capital stock by or from any employee benefit plan or related trust:

          (a) the merger, reorganization or consolidation of Lexicon into or with another corporation or
legal entity in which Lexicon’s stockholders holding the right to vote with respect to matters
generally immediately preceding such merger, reorganization or consolidation, own less than fifty
percent (50%) of the voting securities of the surviving entity; or

          (b) the sale of all or substantially all of Lexicon’s assets or business.

          “Change of Control Put Option” has the meaning set forth in Section 2A of the
Purchase Option Agreement.

          “Change of Control Put Option Exercise Notice” has the meaning set forth in
Section 2A of the Purchase Option Agreement.

 

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

          “Class A Member” means a holder of a Class A Membership Interest.

          “Class A Membership Interest” means a Class A Membership Interest in Holdings.

          “Class B Member” means a holder of a Class B Membership Interest.

          “Class B Membership Interest” means a Class B Membership Interest in Holdings.

          “Class C Member” means a holder of a Class C Membership Interest.

          “Class C Membership Interest” means a Class C Membership Interest in Holdings.

          “Class D Member” means a holder of a Class D Membership Interest.

          “Class D Membership Interest” means a Class D Membership Interest in Holdings.

          “Client Schedules” has the meaning set forth in Section 5(b) of the RRD
Services Agreement.

          “Clinical Trial Material” means Product and placebo for administration to animals for
pre-clinical testing or to humans for clinical testing, and Product for non-clinical testing.

          “Closing Date” means June 15, 2007.

          “CMC” means the chemistry, manufacturing and controls documentation as required for
filings with a Regulatory Authority relating to the manufacturing, production and testing of drug
products.

          “CNS Field” means the field of prevention, palliation, control or treatment in humans
of (a) depression, schizophrenia, bipolar disease, dementia, anxiety, attention deficit
hyperactivity disorder, anorexia nervosa and other affective disorders, (b) Alzheimer’s disease and
other cognitive disorders, (c) Parkinson’s disease, amyotrophic lateral sclerosis and other
neurodegenerative disorders, (d) pain, (e) epilepsy, (f) insomnia, narcolepsy and other sleep
disorders, (g) substance abuse and (h) migraine.

          “Code” means the Internal Revenue Code of 1986, as amended from time to time.

          “Common Stock” means the common stock, par value $0.01 per share, of Symphony Icon.

 

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

          “Company Expenses” has the meaning set forth in Section 5.09 of the Holdings
LLC Agreement.

          “Company Property” has the meaning set forth in Section 1.01 of the Holdings
LLC Agreement.

          “Confidential Information” has the meaning set forth in Section 2 of the
Confidentiality Agreement.

          “Confidentiality Agreement” means the Confidentiality Agreement, dated as of the
Closing Date, among Symphony Icon, Holdings, Lexicon, SCP, SSP, Investors, Symphony Capital and
RRD, as such agreement may be amended or amended and restated from time to time.

          “Conflict Transaction” has the meaning set forth in Article X of the Symphony
Icon Charter.

          “Control” means, with respect to any material, information or intellectual property
right, that a Party owns or has a license to such item or right, and has the ability to grant the
other Party access, a license or a sublicense (as applicable) in or to such item or right as
provided in the Operative Documents without violating the terms of any agreement or other
arrangement with any third party.

          “Cross Program Budget Component” has the meaning set forth in Section 4.1 of
the Amended and Restated Research and Development Agreement.

          “Debt” of any Person means, without duplication:

          (a) all indebtedness of such Person for borrowed money,

          (b) all obligations of such Person for the deferred purchase price of property or services
(other than any portion of any trade payable obligation that shall not have remained unpaid for 91
days or more from the later of (A) the original due date of such portion and (B) the customary
payment date in the industry and relevant market for such portion),

          (c) all obligations of such Person evidenced by bonds, notes, debentures or other similar
instruments,

          (d) all obligations of such Person created or arising under any conditional sale or other
title retention agreement with respect to property acquired by such Person (whether or not the
rights and remedies of the seller or lender under such agreement in an event of default are limited
to repossession or sale of such property),

          (e) all Capitalized Leases to which such Person is a party,

 

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

          (f) all obligations, contingent or otherwise, of such Person under acceptance, letter of
credit or similar facilities,

          (g) all obligations of such Person to purchase, redeem, retire, defease or otherwise acquire
for value any Equity Securities of such Person,

          (h) the net amount of all financial obligations of such Person in respect of Hedge Agreements,

          (i) the net amount of all other financial obligations of such Person under any contract or
other agreement to which such Person is a party,

          (j) all
Debt of other Persons of the type described in clauses (a) through (i)
above guaranteed, directly or indirectly, in any manner by such Person, or in effect guaranteed,
directly or indirectly, by such Person through an agreement (A) to pay or purchase such Debt or to
advance or supply funds for the payment or purchase of such Debt, (B) to purchase, sell or lease
(as lessee or lessor) property, or to purchase or sell services, primarily for the purpose of
enabling the debtor to make payment of such Debt or to assure the holder of such Debt against loss,
(C) to supply funds to or in any other manner invest in the debtor (including any agreement to pay
for property or services irrespective of whether such property is received or such services are
rendered) or (D) otherwise to assure a creditor against loss, and

          (k) all Debt of the type described in clauses (a) through (i) above secured by (or for which
the holder of such Debt has an existing right, contingent or otherwise, to be secured by) any
Encumbrance on property (including accounts and contract rights) owned or held or used under lease
or license by such Person, even though such Person has not assumed or become liable for payment of
such Debt.

          “Development Budget” means the budget (comprised of the Program Specific Budget
Component and the Cross Program Budget Component) for the implementation of the Development Plan
(the initial form of which was agreed upon by Lexicon and Symphony Icon as of the Closing Date and
attached to the Amended and Restated Research and Development Agreement as Annex C thereto), as may
be further developed and revised from time to time in accordance with the Development Committee
Charter and the Amended and Restated Research and Development Agreement.

          “Development Committee” has the meaning set forth in Article 3 of the Amended and
Restated Research and Development Agreement.

          “Development Committee Charter” has the meaning set forth in Article 3 of the Amended
and Restated Research and Development Agreement.

          “Development Committee Member” has the meaning set forth in Paragraph 1 of Annex B to
the Amended and Restated Research and Development Agreement.

 

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

          “Development Plan” means the development plan covering all the Programs (the initial
form of which was agreed upon by Lexicon and Symphony Icon as of the Closing Date and attached to
the Amended and Restated Research and Development Agreement as Annex C thereto), as may be further
developed and revised from time to time in accordance with the Development Committee Charter and
the Amended and Restated Research and Development Agreement.

          “Development Product” means a LG617 Product or a LG103 Product that is administered in
a clinical trial performed pursuant to the Development Plan.

          “Development Services” has the meaning set forth in Section 1(b) of the RRD
Services Agreement.

          “Development Subcontracting Agreement” means a Subcontracting Agreement that is
directly related to one or both of the Programs and is not a Manufacturing Subcontracting
Agreement.

          “Director(s)” means the Persons identified as such in the Preliminary Statement of the
Indemnification Agreement (including such Persons as may become parties thereto after the date
hereof).

          “Disclosing Party” has the meaning set forth in Section 4 of the
Confidentiality Agreement.

          “Discontinuation Option” has the meaning set forth in Section 11(a) of the
Amended and Restated Research and Development Agreement.

          “Discontinuation Option Closing Date” means the date of expiration of the
Discontinuation Option pursuant to Section 11(a) of the Amended and Restated Research and
Development Agreement.

          “Discontinuation Price” has the meaning set forth in Section 11(a) of the
Amended and Restated Research and Development Agreement.

          “Discontinued Program” has the meaning set forth in Section 2.10 of the
Novated and Restated Technology License Agreement.

          “Disinterested Directors” has the meaning set forth in Article IX of the
Symphony Icon Charter.

          “Distribution” has the meaning set forth in Section 1.01 of the Holdings LLC
Agreement.

          “Early Purchase Option Exercise” has the meaning set forth in Section 1(c)(v)
of the Purchase Option Agreement.

 

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

          “Effective Registration Date” has the meaning set forth in Section 1(b) of the
Registration Rights Agreement.

          “Encumbrance” means (i) any security interest, pledge, mortgage, lien (statutory or
other), charge or option to purchase, lease or otherwise acquire any interest, (ii) any adverse
claim, restriction, covenant, title defect, hypothecation, assignment, deposit arrangement, license
or other encumbrance of any kind, preference or priority, or (iii) any other security agreement or
preferential arrangement of any kind or nature whatsoever (including, without limitation, any
conditional sale or other title retention agreement).

          “Equity Securities” means, with respect to any Person, shares of capital stock of (or
other ownership or profit interests in) such Person, warrants, options or other rights for the
purchase or other acquisition from such Person of shares of capital stock of (or other ownership or
profit interests in) such Person, securities convertible into or exchangeable for shares of capital
stock of (or other ownership or profit interests in) such Person or warrants, rights or options for
the purchase or other acquisition from such Person of such shares (or such other interests), and
other ownership or profit interests in such Person (including, without limitation, partnership,
member or trust interests therein), whether voting or nonvoting, and whether or not such shares,
warrants, options, rights or other interests are authorized or otherwise existing on any date of
determination.

          “ERISA” means the United States Employee Retirement Income Security Act of 1974, as
amended.

          “Excepted Debt” has the meaning set forth in Section 5(c)(iii) of the Purchase
Option Agreement.

          “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules
and regulations promulgated thereunder.

          “Existing Confidentiality Agreement” has the meaning set forth in Section 2(a)
of the Confidentiality Agreement.

          “Extension Funding” has the meaning set forth in Section 2 of the Research
Cost Sharing, Payment and Extension Agreement.

          “External Directors” means, at any time, up to two (2) Persons elected to the Symphony
Icon Board after the Closing Date (who shall be neither employees of Symphony Capital nor of
Lexicon) in accordance with the Symphony Icon Charter, the Symphony Icon By-laws and Section
4(b)(v) of the Purchase Option Agreement.

          “FDA” means the United States Food and Drug Administration or its successor agency in
the United States.

 

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

          “FDA Sponsor” has the meaning set forth in Section 5.1 of the Amended and
Restated Research and Development Agreement.

          “Final Termination Date” has the meaning set forth in Section 1(c)(iii) of the
Purchase Option Agreement.

          “Financial Audits” has the meaning set forth in Section 6.7 of the Amended and
Restated Research and Development Agreement.

          “Financing” has the meaning set forth in the Preliminary Statement of the Purchase
Option Agreement.

          “Fiscal Year” has the meaning set forth in each Operative Document in which it
appears.

          “Form S-3” means the Registration Statement on Form S-3 as defined under the
Securities Act.

          “FTE” means the time and effort of one or more qualified scientists, technicians,
project managers, preclinical or clinical research personnel, regulatory personnel, or patent
professionals that is equivalent to [**]. The percentage of a FTE billable by Lexicon to the
Programs for one individual shall be determined by dividing the number of hours worked directly by
said individual on one or more of the Programs, [**], by [**], with the further limitation that one
individual cannot account for more than one FTE over any annual period.

          “Funds Termination Date” has the meaning set forth in Section 1(c)(iii) of the
Purchase Option Agreement.

          “Funds Termination Notice” has the meaning set forth in Section 1(c)(iii) of
the Purchase Option Agreement.

          “GAAP” means generally accepted accounting principles in effect in the United States
of America from time to time.

          “Governmental Approvals” means authorizations, consents, orders, declarations or
approvals of, or filings with, or terminations or expirations of waiting periods imposed by any
Governmental Authority.

          “Governmental Authority” means any United States or non-United States federal,
national, supranational, state, provincial, local, or similar government, governmental, regulatory
or administrative authority, agency or commission or any court, tribunal, or judicial or arbitral
body.

 

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

          “Governmental Order” means any order, writ, judgment, injunction, decree, stipulation,
determination or award entered by or with any Governmental Authority.

          “Hedge Agreement” means any interest rate swap, cap or collar agreement, interest rate
future or option contract, currency swap agreement, currency future or option contract or other
similar hedging agreement.

          “Holdings” means Symphony Icon Holdings LLC, a Delaware limited liability company.

          “Holdings Claims” has the meaning set forth in Section 5.01 of the Share
Purchase Agreement.

          “Holdings LLC Agreement” means the Amended and Restated Limited Liability Company
Agreement of Holdings dated as of the Closing Date.

          “HSR Filings” means the pre-merger notification and report forms required under the
Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.

          “Icon Relevant Infringement” means an infringement, misappropriation, illegal use or
misuse of the Licensed Patent Rights or other Licensed Intellectual Property due to the
manufacture, use, sale or importation of a LG103 Product or a LG617 Product.

          “IND” means an Investigational New Drug Application, as described in 21 U.S.C. §
355(i)(1) and 21 C.F.R. § 312 in the regulations promulgated by the United States Food and Drug
Administration, or any foreign equivalent thereof.

          “Indemnification Agreement” means the Indemnification Agreement among Symphony Icon
and the Directors named therein, dated as of the Closing Date, as such agreement may be amended or
amended and restated from time to time.

          “Indemnified Party” has the meaning set forth in each Operative Document in which it
appears.

          “Indemnified Proceeding” has the meaning set forth in each Operative Document in which
it appears.

          “Indemnifying Party” has the meaning set forth in each Operative Document in which it
appears.

          “Initial Development Budget” means the initial development budget prepared by
representatives of Symphony Icon and Lexicon prior to the Closing Date, and attached to the Amended
and Restated Research and Development Agreement as Annex C thereto.

 

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

          “Initial Development Plan” means the initial development plan prepared by
representatives of Symphony Icon and Lexicon prior to the Closing Date, and attached to the Amended
and Restated Research and Development Agreement as Annex C thereto.

          “Initial Holdings LLC Agreement” means the Agreement of Limited Liability Company of
Holdings, dated April 30, 2007.

          “Initial Investors LLC Agreement” means the Agreement of Limited Liability Company of
Investors, dated April 30, 2007.

          “Initial LLC Member” has the meaning set forth in Section 1.01 of the Holdings
LLC Agreement.

          “Interest Certificate” has the meaning set forth in Section 1.01 of the
Holdings LLC Agreement.

          “Investment Company Act” means the Investment Company Act of 1940, as amended.

          “Investment Overview” means the investment overview describing the transactions
entered into pursuant to the Operative Documents.

          “Investment Policy” has the meaning set forth in Section 1(a)(vi) of the RRD
Services Agreement.

          “Investors” means Symphony Icon Investors LLC.

          “Investors LLC Agreement” means the Amended and Restated Agreement of Limited
Liability Company of Investors dated as of the Closing Date.

          “IRS” means the U.S. Internal Revenue Service.

          “Key Personnel” means those Lexicon Personnel listed on Schedule 6.5 to the
Amended and Restated Research and Development Agreement, as such schedule may be updated from time
to time by mutual agreement of the parties to the Amended and Restated Research and Development
Agreement.

          “Know-How” means any and all proprietary technology, including without limitation,
manufacturing processes or protocols, know-how, writings, documentation, data, technical
information, techniques, results of experimentation and testing, diagnostic and prognostic assays,
specifications, databases, any and all laboratory, research, pharmacological, toxicological,
analytical, quality control pre-clinical and clinical data, and other information and materials,
whether or not patentable.

 

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

          “Knowledge” of Lexicon, Symphony Icon or Holdings, as the case may be, means the
actual (and not imputed) knowledge of the executive officers or managing member of such Person
without the duty of inquiry or investigation.

          “Law” means any law, statute, treaty, constitution, regulation, rule, ordinance, order
or Governmental Approval, or other governmental restriction, requirement or determination, of or by
any Governmental Authority.

          “Lexicon” means Lexicon Pharmaceuticals, Inc., a Delaware corporation (f/k/a Lexicon
Genetics Incorporated).

          “Lexicon Accounting Advisor” means Ernst & Young LLP.

          “Lexicon Common Stock” means the common stock, par value $0.001 per share, of Lexicon.

          “Lexicon Common Stock Valuation” has the meaning set forth in Section 2(e) of
the Purchase Option Agreement.

          “Lexicon Funding Notice” has the meaning set forth in Section 2(b) of the
Research Cost Sharing, Payment and Extension Agreement.

          “Lexicon Obligations” has the meaning set forth in Section 6.1(a) of the
Amended and Restated Research and Development Agreement.

          “Lexicon Payment Amount” has the meaning set forth in Paragraph 14 of the
Development Committee Charter.

          “Lexicon Personnel” has the meaning set forth in Section 8.4 of the Amended
and Restated Research and Development Agreement.

          “Lexicon Public Filings” means all publicly available filings made by Lexicon with the
SEC.

          “Lexicon Subcontractor” means a third party that has entered into a Subcontracting
Agreement with Lexicon.

          “LG103” means [**].

          “LG103 Product” means pharmaceutical compositions that Target LG103, including
pharmaceutical compositions comprising LX1031, LX1032 and/or backups.

          “LG103 Program” means the development, manufacture and/or use of any LG103 Product.

          “LG617” means [**].

 

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

          “LG617 Product” means pharmaceutical compositions that Target LG617, including
pharmaceutical compositions comprising LX6171 and/or backups.

          “LG617 Program” means the development, manufacture and/or use of any LG617 Product.

          “License” has the meaning set forth in the Preliminary Statement of the Purchase
Option Agreement.

          “Licensed Intellectual Property” means the Licensed Patent Rights and the Licensed
Know-How.

          “Licensed Know-How” means any and all Know-How that is [**].

          “Licensed Patent Rights” means:

          (a) [**];

          (b) [**]; and

          (c) [**].

          “Licensed Patent Rights” include [**].

          “Licensor” means Lexicon.

          “Lien” has the meaning set forth in Section 1.01 of the Holdings LLC
Agreement.

          “Liquidating Event” has the meaning set forth in Section 8.01 of the Holdings
LLC Agreement.

          “LLC Agreements” means the Initial Holdings LLC Agreement, the Holdings LLC Agreement,
the Initial Investors LLC Agreement and the Investors LLC Agreement.

          “Loss” has the meaning set forth in each Operative Document in which it appears.

          “LX1031” means [**].

          “LX1032” means [**].

          “LX6171” means [**].

          “Management Fee” has the meaning set forth in Section 6(a) of the RRD Services
Agreement.

 

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

          “Management Services” has the meaning set forth in Section 1(a) of the RRD
Services Agreement.

          “Manager” means (i) for each LLC Agreement in which it appears, the meaning set forth
in such LLC Agreement, and (ii) for each other Operative Document in which it appears, RRD in its
capacity as the provider of Management Services on behalf of Symphony Icon pursuant to the RRD
Services Agreement.

          “Manager Event” has the meaning set forth in Section 3.01(g) of the Holdings
LLC Agreement.

          “Manufacturing Subcontracting Agreement” means a Subcontracting Agreement that is
directly related to the manufacture of Product (including procurement of components and development
of improved manufacturing methods).

          “Material Adverse Effect” means, with respect to any Person, a material adverse effect
on (i) the business, assets, property or condition (financial or otherwise) of such Person or, (ii)
its ability to comply with and satisfy its respective agreements and obligations under the
Operative Documents or, (iii) the enforceability of the obligations of such Person under any of the
Operative Documents to which it is a party.

          “Medical Discontinuation Event” means [**].

          “Membership Interest” means (i) for each LLC Agreement in which it appears, the
meaning set forth in such LLC Agreement, and (ii) for each other Operative Document in which it
appears, the meaning set forth in the Holdings LLC Agreement.

          “NASDAQ” means the Nasdaq Stock Market, Inc.

          “NDA” means a New Drug Application, as defined in the regulations promulgated by the
United States Food and Drug Administration, or any foreign equivalent thereof.

          “Non-Lexicon Capital Transaction” means any (i) sale or other disposition of all or
part of the Symphony Icon Shares or all or substantially all of the operating assets of Symphony
Icon, to a Person other than Lexicon or an Affiliate of Lexicon or (ii) distribution in kind of the
Symphony Icon Shares following the unexercised expiration or termination of the Purchase Option.

          “Novated and Restated Technology License Agreement” means the Novated and Restated
Technology License Agreement, dated as of the Closing Date, among Lexicon, Symphony Icon and
Holdings.

          “Operative Documents” means, collectively, the Indemnification Agreement, the Holdings
LLC Agreement, the Purchase Option Agreement, the Share Purchase Agreement, the Registration Rights
Agreement, the Subscription Agreement,

 

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

the Technology License Agreement, the Novated and Restated Technology License Agreement, the
RRD Services Agreement, the Research and Development Agreement, the Research Cost Sharing, Payment
and Extension Agreement, the Amended and Restated Research and Development Agreement, the
Confidentiality Agreement, and each other certificate and agreement executed in connection with any
of the foregoing documents.

          “Organizational Documents” means any certificates or articles of incorporation or
formation, partnership agreements, trust instruments, bylaws or other governing documents.

          “Partial Stock Payment” has the meaning set forth in Section 3(a)(iii) of the
Purchase Option Agreement.

          “Party(ies)” means, for each Operative Document or other agreement in which it
appears, the parties to such Operative Document or other agreement, as set forth therein. With
respect to any agreement in which a provision is included therein by reference to a provision in
another agreement, the term “Party” shall be read to refer to the parties to the document
at hand, not the agreement that is referenced.

          “Payment Terms” has the meaning set forth in Section 8.2 of the Amended and
Restated Research and Development Agreement.

          “Percentage” has the meaning set forth in Section 1.01 of the Holdings LLC
Agreement.

          “Permitted Investments” has the meaning set forth in Section 1.01 of the
Holdings LLC Agreement.

          “Permitted Lien” has the meaning set forth in Section 1.01 of the Holdings LLC
Agreement.

          “Person” means any individual, partnership (whether general or limited), limited
liability company, corporation, trust, estate, association, nominee or other entity.

          “Personnel” of a Party means such Party, its employees, subcontractors, consultants,
representatives and agents.

          “Prime Rate” means the quoted “Prime Rate” at JPMorgan Chase Bank or, if such
bank ceases to exist or is not quoting a base rate, prime rate reference rate or similar rate for
United States dollar loans, such other major money center commercial bank in New York City selected
by the Manager.

          “Product” means a LG617 Product and/or a LG103 Product.

 

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

          “Profit” has the meaning set forth in Section 1.01 of the Holdings LLC
Agreement.

          “Programs” means the LG617 Program and/or the LG103 Program.

          “Program Specific Budget Component” has the meaning set forth in Section 4.1
of the Amended and Restated Research and Development Agreement.

          “Program-Specific Claim” means any claim in a patent or patent application in the
Licensed Patent Rights that is directed exclusively to (i) the composition of matter, formulations
or use of any Product or (ii) methods of treating humans by inhibiting, agonizing, or otherwise
modulating (i.e., acting through) LG103 or LG617.

          “Program-Specific Patents” means any and all Licensed Patent Rights that contain at
least one Program-Specific Claim.

          “Protocol” means a written protocol that meets the substantive requirements of
Section 6 of the ICH Guideline for Good Clinical Practice as adopted by the FDA, effective
May 9, 1997, and is included within the Development Plan or later modified or added to the
Development Plan pursuant to the Amended and Restated Research and Development Agreement.

          “Public Companies” has the meaning set forth in Section 5(e) of the Purchase
Option Agreement.

          “Purchase Option” has the meaning set forth in Section 1(a) of the Purchase
Option Agreement.

          “Purchase Option Agreement” means the Purchase Option Agreement dated as of the
Closing Date, among Lexicon, Holdings and Symphony Icon.

          “Purchase Option Closing” has the meaning set forth in Section 2(a) of the
Purchase Option Agreement.

          “Purchase Option Closing Date” has the meaning set forth in Section 2(a) of
the Purchase Option Agreement.

          “Purchase Option Commencement Date” has the meaning set forth in Section
1(c)(iii) of the Purchase Option Agreement.

          “Purchase Option Exercise Date” has the meaning set forth in Section 2(a) of
the Purchase Option Agreement.

          “Purchase Option Exercise Notice” has the meaning set forth in Section 2(a) of
the Purchase Option Agreement.

 

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

          “Purchase Option Period” has the meaning set forth in Section 1(c)(iii) of the
Purchase Option Agreement.

          “Purchase Price” has the meaning set forth in Section 2(b) of the Purchase
Option Agreement.

          “QA Audits” has the meaning set forth in Section 6.6 of the Amended and
Restated Research and Development Agreement.

          “Registration Rights Agreement” means the Registration Rights Agreement dated as of
the Closing Date, between Lexicon and Holdings.

          “Registration Statement” has the meaning set forth in Section 1(b) of the
Registration Rights Agreement.

          “Regulatory Allocation” has the meaning set forth in Section 3.06 of the
Holdings LLC Agreement.

          “Regulatory Authority” means the United States Food and Drug Administration, or any
successor agency in the United States, or any health regulatory authority(ies) in any other country
that is a counterpart to the FDA and has responsibility for granting registrations or other
regulatory approval for the marketing, manufacture, storage, sale or use of drugs in such other
country.

          “Regulatory Files” means any IND, NDA or any other filings filed with any Regulatory
Authority with respect to the Programs.

          “Representative” of any Person means such Person’s shareholders, principals,
directors, officers, employees, members, managers and/or partners.

          “Research Cost Sharing, Payment and Extension Agreement” means the Research Cost
Sharing, Payment and Extension Agreement dated as of the Closing Date, among Lexicon, Holdings and
Symphony Icon.

          “Research and Development Agreement” means the Research and Development Agreement
dated as of the Closing Date, between Lexicon and Holdings.

          “RRD” means RRD International, LLC, a Delaware limited liability company.

          “RRD Indemnified Party” has the meaning set forth in Section 10(a) of the RRD
Services Agreement.

          “RRD Loss” has the meaning set forth in Section 10(a) of the RRD Services
Agreement.

 

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

          “RRD Personnel” has the meaning set forth in Section 1(a)(ii) of the RRD
Services Agreement.

          “RRD Services Agreement” means the RRD Services Agreement between Symphony Icon and
RRD, dated as of the Closing Date.

          “Schedule K-1” has the meaning set forth in Section 9.02(a) of the Holdings
LLC Agreement.

          “Scheduled Meeting” has the meaning set forth in Paragraph 6 of Annex B of the Amended
and Restated Research and Development Agreement.

          “Scientific Discontinuation Event” has the meaning set forth in Section 4.2(c)
of the Amended and Restated Research and Development Agreement.

          “SCP” means Symphony Capital Partners, L.P., a Delaware limited partnership.

          “SEC” means the United States Securities and Exchange Commission.

          “Securities Act” means the Securities Act of 1933, as amended.

          “Selling Stockholder Questionnaire” has the meaning set forth in Section 4(a)
of the Registration Rights Agreement.

          “Share Closing” has the meaning set forth in Section 2.04 of the Share
Purchase Agreement.

          “Share Date” has the meaning set forth in Section 2.02 of the Share Purchase
Agreement.

          “Share Purchase Agreement” means the Share Purchase Agreement, dated as of the Closing
Date, between Lexicon and Holdings.

          “Shares” has the meaning set forth in Section 2.01 of the Share Purchase
Agreement.

          “Solvent” has the meaning set forth in Section 1.01 of the Holdings LLC
Agreement.

          “SSP” means Symphony Strategic Partners, LLC, a Delaware limited liability company.

          “Stock Payment Date” has the meaning set forth in Section 2 of the
Subscription Agreement.

 

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

          “Stock Purchase Price” has the meaning set forth in Section 2 of the
Subscription Agreement.

          “Subcontracting Agreement” means (a) any written agreement between Lexicon and a third
party pursuant to which the third party performs any Lexicon Obligations or (b) any work order,
change order, purchase order or the like entered into pursuant to Section 6.2(b) of the
Amended and Restated Research and Development Agreement.

          “Sublicense Obligations” has the meaning set forth in Section 3.2 of the
Novated and Restated Technology License Agreement.

          “Sublicensed Intellectual Property” has the meaning set forth in Section 3.2
of the Novated and Restated Technology License Agreement.

          “Subscription Agreement” means the Subscription Agreement between Symphony Icon and
Holdings, dated as the Closing Date.

          “Subsidiary” of any Person means any corporation, partnership, joint venture, limited
liability company, trust or estate of which (or in which) more than 50% of (a) the issued and
outstanding capital stock having ordinary voting power to elect a majority of the board of
directors of such corporation (irrespective of whether at the time capital stock of any other class
or classes of such corporation shall or might have voting power upon the occurrence of any
contingency); (b) the interest in the capital or profits of such partnership, joint venture or
limited liability company; or (c) the beneficial interest in such trust or estate is at the time
directly or indirectly owned or controlled by such Person, by such Person and one or more of its
other Subsidiaries or by one or more of such Person’s other Subsidiaries.

          “Surviving Entity” means the surviving legal entity which is surviving entity to
Lexicon after giving effect to a Change of Control.

          “Symphony Capital” means Symphony Capital LLC, a Delaware limited liability company.

          “Symphony Fund(s)” means Symphony Capital Partners, L.P., a Delaware limited
partnership, and Symphony Strategic Partners, LLC, a Delaware limited liability company.

          “Symphony Icon” means Symphony Icon, Inc., a Delaware corporation.

          “Symphony Icon Auditors” has the meaning set forth in Section 5(b) of the RRD
Services Agreement.

          “Symphony Icon Board” means the board of directors of Symphony Icon.

 

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

          “Symphony Icon By-laws” means the By-laws of Symphony Icon, as adopted by resolution
of the Symphony Icon Board on the Closing Date.

          “Symphony Icon Charter” means the Amended and Restated Certificate of Incorporation of
Symphony Icon, dated as of the Closing Date.

          “Symphony Icon Director Event” has the meaning set forth in Section 3.01(h)(i)
of the Holdings LLC Agreement.

          “Symphony Icon Enhancements” means [**].

          “Symphony Icon Equity Securities” means the Common Stock and any other stock or shares
issued by Symphony Icon.

          “Symphony Icon Loss” has the meaning set forth in Section 10(b) of the RRD
Services Agreement.

          “Symphony Icon Shareholder” means any Person who owns any Symphony Icon Shares.

          “Symphony Icon Shares” has the meaning set forth in Section 2.02 of the
Holdings LLC Agreement.

          “Tangible Materials” means [**].

          “Target” when used as a noun, means a human gene and the products encoded by such
gene, including, without limitation, (a) any partial or full-length DNA sequence from such gene
(including any mutant or polymorphic forms thereof), (b) any RNA sequence (including any
post-transcriptionally modified variants thereof) encoded by any such gene, and/or (c) any peptide,
polypeptide or protein (including any post-translationally modified variants thereof) encoded by
any such gene; and when used as a verb, means to inhibit, agonize, or otherwise modulate (i.e., act
through) any of the foregoing, as applicable.

          “Tax Amount” has the meaning set forth in Section 4.02 of the Holdings LLC
Agreement.

          “Technology License Agreement” means the Technology License Agreement, dated as of the
Closing Date, between Lexicon and Holdings.

          “Term” has the meaning set forth in Section 4(b)(iv) of the Purchase Option
Agreement, unless otherwise stated in the applicable Operative Document.

          “Territory” means the world.

 

 

Confidential materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.

          “Third Party IP” has the meaning set forth in Section 2.9 of the Novated and
Restated Technology License Agreement.

          “Third Party Licensor” means a third party from which Lexicon has received a license
or sublicense to Licensed Intellectual Property.

          “Transfer” has for each Operative Document in which it appears the meaning set forth
in such Operative Document.

          “Transferee” has, for each Operative Document in which it appears, the meaning set
forth in such Operative Document.

          “Treasury Regulations” means the rules, regulations and orders, and interpretations
thereof, adopted by the IRS under the Code, as in effect from time to time.

          “Voluntary Bankruptcy” has the meaning set forth in Section 1.01 of the
Holdings LLC Agreement.

 

 

Confidential materials omitted and filed separately with
the Securities and Exchange Commission. Asterisks denote omissions.

ANNEX B

SYMPHONY ICON, INC.

DEVELOPMENT COMMITTEE CHARTER

     Purpose

     The Development Committee (the “Development Committee”) is established by Symphony
Icon, Inc. (“Symphony Icon”) to oversee a clinical development plan (the “Development
Plan”) and a development budget (the “Development Budget”) for the Programs (each as
defined in that certain Novated and Restated Technology License Agreement (“TLA”), dated as
of June 15, 2007, among Symphony Icon, Lexicon Pharmaceuticals, Inc. (“Lexicon”) and
Symphony Icon Holdings LLC (“Holdings”, and together with Lexicon, the “Parties”
and each a “Party”), and to develop and commercialize the LG617 Program and the LG103
Program (each as defined in the TLA). Capitalized terms used herein and not defined herein shall
have the meanings assigned to such terms in Annex A to the Amended and Restated Research
and Development Agreement, dated as of June 15, 2007, among Symphony Icon, Holdings and Lexicon.

     Composition

     1. The Development Committee shall initially have six (6) members, and shall at all times have
an even number of members and consist of an equal number of members designated by each Party (the
“Development Committee Members”). Each Party may bring additional employees or
representatives to each meeting as non-voting observers, but only if such employees or
representatives are bound by confidentiality obligations at least as stringent as those described
in the Confidentiality Agreement. The size and composition of the Development Committee provided
herein may not be changed without the consent of both Holdings and Lexicon.

     2. One-half (1/2) of the Development Committee Members shall be designated by Lexicon and
one-half (1/2) shall be designated by Holdings.

     3. Each Development Committee Member shall have the requisite background, experience and
training to carry out the duties and obligations of the Development Committee. Development
Committee Members need not be directors of Symphony Icon, Holdings or Lexicon.

     4. The chair of the Development Committee shall be, initially, Philip M. Brown, M.D., J.D.,
the Vice President of Clinical Development of Lexicon, and any succeeding chair shall be such
person as may be appointed to the position of Vice President of Clinical Development of Lexicon (or
an equivalent successor position) (the “Chair”). If Lexicon wishes to appoint a Chair
other than the then-current Vice President of Clinical Development of Lexicon (or the holder of an
equivalent successor position),

Annex B-1

 

Confidential materials omitted and filed separately with
the Securities and Exchange Commission. Asterisks denote omissions.

then such appointment shall require the consent of the Symphony Icon Board; provided,
that (x) [**], or (y) [**].

     5. By written notice to Lexicon, Holdings may remove or replace one or more Development
Committee Members designated by Holdings. By written notice to Holdings, Lexicon may remove or
replace one or more Development Committee Members designated by Lexicon.

     Operations

     6. The Development Committee shall meet once per month during the Term, unless and until the
Development Committee determines that such meetings should occur once per quarter (in either case,
each a “Scheduled Meeting”). Scheduled Meetings may be held in person or by teleconference
when appropriate; provided that each Scheduled Meeting during the first six months of the
term shall be held in person unless otherwise unanimously agreed by the members of the Development
Committee. In-person Scheduled Meetings shall be held at Lexicon’s headquarters (presently its
facilities in The Woodlands, Texas) unless otherwise unanimously agreed by the members of the
Development Committee. Each of Symphony Icon and Lexicon shall be solely responsible for the costs
associated with its employees and/or representatives attending and participating in such Scheduled
Meetings. In addition, any Development Committee Member may call for an ad hoc meeting of the
Development Committee to be held by teleconference at any time during regular business hours, by
giving the other members of the Development Committee advance written notice of at least [**]
(each, an “Ad Hoc Meeting”). An Ad Hoc Meeting may be called to address any time-sensitive
matter, including additional expenditure requests pursuant to Section 8.3 of the Amended
and Restated Research and Development Agreement or Section 2 of the RRD Services Agreement.

     7. The Chair shall, in consultation with other Development Committee Members and the
management of Symphony Icon, develop and set the Development Committee’s agenda for each Scheduled
Meeting. The Chair shall include on such agenda each item requested by a Development Committee
member at least [**] before the applicable Scheduled Meeting. The agenda and information
concerning the business to be conducted at each Scheduled Meeting shall be communicated in writing
to the Development Committee Members at least [**] in advance of such Scheduled Meeting to permit
meaningful review. Such an agenda shall not be required for an Ad Hoc Meeting.

     8. Each Party’s Development Committee Members shall collectively have three (3) votes,
regardless of the number of its Development Committee Members participating in any Scheduled
Meeting or Ad Hoc Meeting. No votes shall be taken unless there is at least one (1) Development
Committee Member representing each of Lexicon and Holdings participating in such Scheduled Meeting
or Ad Hoc Meeting, as the case may be. Each Party may allocate its three (3) votes among its
attending Development Committee Members in any manner, at such Party’s discretion. If only one

Annex B-2

 

Confidential materials omitted and filed separately with
the Securities and Exchange Commission. Asterisks denote omissions.

(1) Development Committee Member is attending on behalf of a given Party, such Development
Committee Member may cast all the votes allocated to such Party. Unless otherwise specified
herein, all actions taken by the Development Committee as a committee shall be by majority vote.
If the Development Committee Members reach a deadlock on any vote, then such deadlock shall be
resolved in accordance with Paragraph 11 of this Development Committee Charter.

     9. Notwithstanding anything herein to the contrary, during the Term, this Development
Committee Charter may be amended only with the unanimous approval of the Development Committee
Members and the consent of the Symphony Icon Board, Holdings and Lexicon.

     10. The Chair, or such person as the Chair may designate, shall prepare, and distribute to all
Development Committee Members, draft committee minutes within a reasonable period of time following
each Scheduled Meeting or Ad Hoc Meeting, but in any case, in sufficient time to be included as
part of the agenda for the next Scheduled Meeting. As part of the agenda of the first Scheduled
Meeting, the Development Committee Members shall agree upon a standard procedure for review and
approval of such draft committee minutes by the Development Committee Members.

     11. If the Development Committee is unable to decide by a majority vote on any issue within
the scope of its authority and duties, then the Development Committee shall promptly raise such
issue to the chief executive officer (or equivalent officer) of Lexicon and the chairman of the
Symphony Icon Board. The chief executive officer and chairman shall have [**] to mutually agree on
how to resolve such issue. If such parties are unable to resolve such issue within the [**]
period, then [**].

     Authority and Duties

     12. The Development Committee shall, using the Initial Development Plan and the Initial
Development Budget as a basis, continue to develop and refine the Development Plan and Development
Budget, and shall, at the request of the Symphony Icon Board, submit each to the Symphony Icon
Board at the first meeting of the Symphony Icon Board, as provided in Section 4.1 of the
Amended and Restated Research and Development Agreement. Following the Symphony Icon Board’s
review, the Development Committee shall work diligently to incorporate the comments generated by
such review in order to update the Development Plan and Development Budget as soon as practicable
and shall then submit the updated Development Plan and Development Budget to the Symphony Icon
Board for review. The Development Committee shall thereafter continue to develop and refine the
Development Plan and the Development Budget as needed, and shall conduct a comprehensive review of
each on a semi-annual basis. In addition, the Development Committee shall decide on any other
matters relating to the Development Plan and the Development Budget that may arise, including (i)
responding to requests from RRD or Lexicon for amendments to the Development Plan and/or the
Development Budget, and (ii) addressing all other matters that are identified in the Operative
Documents or the Symphony Icon Charter as requiring the

Annex B-3

 

Confidential materials omitted and filed separately with
the Securities and Exchange Commission. Asterisks denote omissions.

approval of the Development Committee (including, but not limited to, the approval of any new,
or the amendment or termination of any existing, Development Subcontracting Agreement). Unless
otherwise approved pursuant to Paragraph 11 hereof, or discontinued or modified pursuant to
Sections 4.2(c) or 5.1 of the Amended and Restated Research and Development
Agreement, no material change to the Development Plan or Development Budget will be adopted by
Symphony Icon unless and until the Development Committee approves such change.

     13. The Development Committee shall report at least quarterly to the Symphony Icon Board
regarding progress relative to the Development Plan and the Development Budget, and any changes in
the Development Plan and/or Development Budget, and shall respond promptly to any reasonable
requests for additional information made by the Symphony Icon Board. The Development Committee
shall also submit its material decisions regarding the Development Plan and Development Budget to
the Symphony Icon Board, including regulatory strategies and discontinuation or modification of the
Programs.

     14. The Development Committee shall continuously evaluate the funding requirements of the
Programs, and may, in the event of a shortfall in the funds allocated to one or more Programs, and
subject to the approval of the Symphony Icon Board, reallocate funds within the Development Budget
to compensate for such shortfall. In the event that such reallocation is insufficient to
compensate fully for such shortfall and such shortfall has or will create a Balance Sheet
Deficiency within [**], then the Development Committee may, pursuant to Section 2 of the
Research Cost Sharing, Payment and Extension Agreement, recommend that the Symphony Icon Board
submit to Lexicon a Lexicon Funding Notice requiring Lexicon to either contribute funds to Symphony
Icon in an amount to be determined by the Development Committee (the “Lexicon Payment
Amount”), or, if the Purchase Option Period has not expired, exercise the Purchase Option, in
each case within [**] of receipt of the Lexicon Funding Notice; provided, however,
that (A) any decision by the Development Committee to submit a Lexicon Funding Notice shall be made
in accordance with this Development Committee Charter, the Research Cost Sharing, Payment and
Extension Agreement, the Development Budget and Development Plan (for purposes of which, in the
case of a Lexicon Payment Amount determined after the expiration of the Purchase Option, shall be
the Development Plan in effect immediately prior to such expiration), (B) in no event shall the
aggregate total of all Lexicon Payment Amounts exceed $15,000,000 less the aggregate amount of all
dividends and distributions, if any, under Section 8.1 of the Amended and Restated Research
and Development Agreement, and (C) the Development Committee’s right to recommend that the Symphony
Icon Board submit a Lexicon Funding Notice shall be subject to termination pursuant to Section
2(d) of the Research Cost Sharing, Payment and Extension Agreement. For the avoidance of doubt,
and subject to the foregoing conditions and restrictions, the Development Committee’s right to
recommend that the Symphony Icon Board submit a Lexicon Funding Notice shall survive the expiration
of the Purchase Option Period and the termination of the Purchase Option Agreement pursuant to its
terms.

Annex B-4

 

Confidential materials omitted and filed separately with
the Securities and Exchange Commission. Asterisks denote omissions.

     15. The foregoing list of duties is not exhaustive, and the Development Committee may, in
addition, perform such other functions as may be necessary or appropriate for the performance of
its duties and the furtherance of the development of Programs, including as may be required under
any Operative Document. In no event shall the Development Committee have the power to amend any of
the Operative Documents. The Development Committee shall have the power to delegate its authority
and duties to sub-committees as it deems appropriate; provided, however, that each
such sub-committee shall have at least one (1) Development Committee Member who is designated by
Holdings and at least one (1) Development Committee Member who is designated by Lexicon.

Annex B-5

 

Confidential materials omitted and filed separately with
the Securities and Exchange Commission. Asterisks denote omissions.

ANNEX C

INITIAL DEVELOPMENT PLAN AND INITIAL DEVELOPMENT BUDGET

[**]

Annex C-1

 

Confidential materials omitted and filed separately with
the Securities and Exchange Commission. Asterisks denote omissions.

ANNEX E

PAYMENT TERMS

	1.	 	With respect to the development activities and services provided by Lexicon pursuant to this
Agreement, and in accordance with the terms of this Agreement, the Development Plan and the
Development Budget, Lexicon will invoice Symphony Icon, and Symphony Icon will pay Lexicon, in
accordance with this Annex E.
	 
	2.	 	[**].
	 
	3.	 	[**].
	 
	4.	 	All fees, personnel costs, expenses and pass-through costs will be payable in US Dollars. If
Symphony Icon disputes in good faith any portion of an invoice, then Symphony Icon shall pay
the undisputed amounts as set forth in the preceding sentence and the parties shall use good
faith efforts to reconcile the disputed amount as soon as practicable.
	 
	5.	 	Lexicon will transmit invoices to Symphony Icon at the following address:

Symphony Icon, Inc.

7361 Calhoun Place, Suite 325

Rockville, MD 20855

Attn: Accounts Payable

	6.	 	All payments to Lexicon shall be sent to Lexicon, as follows:

	 	 	 	 	 
	If mailed:

	 	Lexicon Pharmaceuticals, Inc.	 	 
	 

	 	P.O. Box 132167	 	 
	 

	 	The Woodlands, TX 77393-2167	 	 
	 

	 	Attn: Accounts Receivable	 	 
	 
	 	 	 	 
	If wired:

	 	Name of bank:
	 	[**]
	 

	 	Routing number:
	 	[**]
	 

	 	Lexicon account number:
	 	[**]
	 

	 	Bank address:
	 	[**]
	 

	 	 	 	[**]

Annex E-1

 

Confidential materials omitted and filed separately with
the Securities and Exchange Commission. Asterisks denote omissions.

SCHEDULE 6.2

SUBCONTRACTING AGREEMENTS

     Each of the following references to Subcontracting Agreements include all exhibits,
protocols, study plans, client authorization letters, statements of work, task orders, change
orders and other similar subordinate or ancillary documents executed on or prior to the Closing
Date in connection with such Subcontracting Agreements.

     [**]

 

Confidential materials omitted and filed separately with
the Securities and Exchange Commission. Asterisks denote omissions.

SCHEDULE 6.4

LEXICON KEY PERSONNEL

     [**]

 

Confidential materials omitted and filed separately with
the Securities and Exchange Commission. Asterisks denote omissions.

SCHEDULE 12.1(f)

MATERIAL DISCLOSED CONTRACTS

     Each of the following references include all exhibits, protocols, study plans, client
authorization letters, statements of work, task orders, change orders and other similar subordinate
or ancillary documents executed on or prior to the Closing Date in connection with each such
agreement. Lexicon may not assign its rights or obligations under any agreement listed below to
Symphony Icon without the prior written consent of the applicable third party.

     [**]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00127-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00127-of-00352.parquet"}]]